Use of tenecteplase for treating late-window stroke patients
The administration of tenecteplase to late-window acute ischemic stroke patients with salvageable brain tissue or patterns addresses the lack of effective treatments for this condition, improving clinical outcomes and recanalization rates when combined with mechanical thrombectomy.
Patent Information
- Application Number
- PCT/US2024/027846
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-11
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-07
AI Technical Summary
There is an unmet need for effective treatment methods for late-window acute ischemic stroke patients, as current therapies are ineffective for those who do not receive medical attention within the initial 4.5-hour time frame, and there are no FDA-approved medicines for this condition.
Administering tenecteplase, a tissue plasminogen activator variant, to patients with salvageable brain tissue or patterns, between 4.5 and 24 hours after stroke onset, at a dose of 0.25 mg/kg up to a maximum of 25 mg, particularly for those with internal carotid artery, middle cerebral artery M1, or M2 occlusions, potentially combined with mechanical thrombectomy.
This approach improves clinical outcomes by enhancing the ordinal modified Rankin scale scores, increasing functional independence, and achieving recanalization of occluded vessels, compared to placebo-treated patients, with improved results at 90 days post-treatment.
Smart Images

Figure IMGF000010_0001 
Figure IMGF000038_0001 
Figure IMGF000039_0001
Abstract
Description
[0001] PATENT Genentech Docket No: P38439-WO METHODS OF TREATING LATE-WINDOW STROKE PATIENTS CROSS-REFERENCE TO RELATED APPLICATIONS This application claims benefit of priority to U.S. Provisional Application No.63 / 500,192, filed May 4, 2023, U.S. Provisional Application No.63 / 503,950, filed May 23, 2020, and U.S. Provisional Application No.63 / 589,610, filed October 11, 2023, the contents of each of which are incorporated herein by reference in their entireties. SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 30, 2024, is named 50474-328WO4_Sequence_Listing_4_30_24 and is 3,990 bytes in size. FIELD The present disclosure relates to methods for the treatment of late-window acute ischemic stroke (AIS) patients using the tissue plasminogen activator variant tenecteplase. BACKGROUND Acute ischemic stroke (AIS) is the fifth leading cause of death in the United States. Approximately 795,000 people suffer a stroke annually, with 23% due to recurrent stroke. Projections estimate that by the year 2030, an additional 3.4 million U.S. adults 18 years and older, representing 3.88% of the adult population, will experience a stroke, which is a 20.5% increase in prevalence from 2012. Stroke is also the leading cause of serious, long-term disability. Approximately 2% of females and 3% of males are disabled from stroke. From 2017 to 2018, the direct and indirect costs of stroke in the U.S. totaled nearly $53 billion. It is projected that total direct medical costs will more than double, from $36.7 billion to $94.3 billion, between 2015 and 2035. More than 15 million people worldwide suffer a stroke annually -- and of these, 5 million die and another 5 million are left permanently disabled. Seventy percent of stroke patients do not arrive at a hospital until 4.5-24 hours after symptom onset, but there are no FDA-approved medicines for the late time window. SUMMARY In one aspect, provided herein is a method for treating acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern, the method comprising administering to the subject at a time between 4.5 and 24 hours after onset of said AIS a therapeutically effective amount of tenecteplase, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg, and wherein the subject has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA) M1 occlusion, and / or an MCA M2 occlusion. In some embodiments, the subject has an MCA M1 occlusion. In some embodiments, the subject has an MCA M2 occlusion. PATENT Genentech Docket No: P38439-WO In some embodiments, the subject is a member of a population of subjects, wherein each member of the population (i) has AIS and salvageable brain tissue or a salvageable brain pattern, (ii) has an ICA occlusion, an MCA M1 occlusion, and / or an MCA M2 occlusion; and (iii) is administered a therapeutically effective amount of tenecteplase at a time between 4.5 and 24 hours after onset of the AIS, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg; and wherein the method improves clinical outcome in the population of subjects relative to a reference population of subjects, wherein each member of the reference population (iv) has AIS and salvageable brain tissue or a salvageable brain pattern, (v) has an ICA occlusion, an MCA M1 occlusion, and / or an MCA M2 occlusion; and (vi) is administered placebo at a time between 4.5 and 24 hours after onset of AIS. In some embodiments, the clinical outcome is ordinal modified Rankin scale (mRS) score, and the distribution of mRS scores in the population of subjects is improved relative to the distribution of mRS scores in the reference population. In some embodiments, the clinical outcome is the proportion of subjects with functional independence, wherein functional independence is an mRS score of 0-2. In some embodiments, the clinical outcome is assessed 90 days after the tenecteplase is administered. In some embodiments, the clinical outcome is the proportion of subjects having recanalization of one or more occluded vessels. In some embodiments, recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA), and / or recanalization is assessed 24 hours after the tenecteplase is administered. In some embodiments, the subject has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the subject is a member of a population of subjects in which each member of the population of subjects has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the method improves clinical outcome in the population of subjects relative to the reference population of subjects, wherein each member of the reference population has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the clinical outcome is final infarct volume. In some embodiments, the clinical outcome is infarct growth. In some embodiments, the clinical outcome is assessed between 72 hours and 96 hours after a baseline measurement of infarct volume. In some embodiments, the method further comprises conducting a mechanical thrombectomy to the subject, wherein the mechanical thrombectomy is conducted prior to, concurrently with, or after the administration of tenecteplase or placebo. In some embodiments, the mechanical thrombectomy is conducted after the administration of tenecteplase or placebo. In some embodiments, the time between the administration of tenecteplase or placebo and the mechanical thrombectomy is six minutes or less. In some embodiments, the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile, wherein the target mismatch profile is defined by one or more of (a) a mismatch ratio; (b) a mismatch volume; and (c) an ischemic core volume. In some embodiments, (a) the mismatch ratio is determined by comparing the total volume of ischemic tissue to the ischemic core volume, and the target mismatch profile is defined by a mismatch ratio of at least PATENT Genentech Docket No: P38439-WO 1.8; (b) the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue, and the target mismatch profile is defined by a mismatch volume of at least 15 mL; and / or (c) the target mismatch profile is defined by an ischemic core volume of less than 70 mL. In some embodiments, the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging technology, and (a) the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan; and / or (b) the advanced imaging comprises use of RAPID software. In another aspect, provided herein is a method for treating acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern, which includes administering to the subject at a time between 4.5 and 24 hours after onset of said AIS a therapeutically effective amount of tenecteplase, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg. In some embodiments, the therapeutically effective amount of tenecteplase is administered intravenously. In some embodiments, the tenecteplase is administered as a single bolus injection over 5 seconds. In some embodiments, the subject is a member of a population of subjects, wherein each member of the population (i) has AIS and salvageable brain tissue or a salvageable brain pattern, and (ii) is administered a therapeutically effective amount of tenecteplase at a time between 4.5 and 24 hours after onset of the AIS, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg; and wherein the method improves clinical outcome in the population of subjects relative to a reference population of subjects, wherein each member of the reference population (iii) has AIS and salvageable brain tissue or a salvageable brain pattern, and (iv) is administered placebo at a time between 4.5 and 24 hours after onset of AIS. In some embodiments, the clinical outcome is ordinal modified Rankin scale (mRS) score. In some embodiments, the distribution of mRS scores in the population of subjects is improved relative to the distribution of mRS scores in the reference population. In some embodiments, the distribution of mRS scores in the population of subjects is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the distribution of mRS scores in the reference population. In some embodiments, a proportion of subjects having mRS score of 0 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to a proportion of subjects having mRS score of 0 in the reference population. In some embodiments, a proportion of subjects having mRS score of 0 in the population is improved by about 2% relative to a proportion of subjects having mRS score of 0 in the reference population. In some embodiments, a proportion of subjects having mRS score of 1 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.1%, 3.5%, 4%, 4.5%, or 5% relative to a proportion of subjects having mRS score of 1 in the reference population. In some embodiments, a proportion of subjects having mRS score of 1 in the population is improved by about 3.7% relative to a proportion of subjects having mRS score of 1 in the reference population. In some embodiments, a proportion of subjects having mRS score of 0 or 1 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% relative to a proportion of subjects having mRS score of 0 or PATENT Genentech Docket No: P38439-WO 1 in the reference population. In some embodiments, a proportion of subjects having mRS score of 0 or 1 in the population is improved by about 5.7% relative to a proportion of subjects having mRS score of 0 or 1 in the reference population. In some embodiments, a proportion of subjects having mRS score of 0, 1, or 2 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to a proportion of subjects having mRS score of 0, 1, or 2 in the reference population. In some embodiments, a proportion of subjects having mRS score of 0, 1, or 2 in the population is improved by about 3.7% relative to a proportion of subjects having mRS score of 0, 1, or 2 in the reference population. In some embodiments, the mRS score is assessed 90 days after the tenecteplase is administered. In some embodiments, each member of the population of subjects and each member of the reference population has an MCA M1 occlusion before administration of tenecteplase or placebo and the distribution of mRS scores at Day 90 in the population of subjects is improved relative to the distribution of mRS scores at Day 90 in the reference population. In some embodiments, the distribution of mRS scores at Day 90 in the population of subjects is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the distribution of mRS scores at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 at Day 90 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to the proportion of subjects having mRS score of 0 at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 at Day 90 in the population is improved by about 2.8% relative to the proportion of subjects having mRS score of 0 at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 1 at Day 90 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 1 at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 1 at Day 90 in the population is improved by about 11.7% relative to the proportion of subjects having mRS score of 1 at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 or 1 at Day 90 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 0 or 1 at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 or 1 at Day 90 in the population is improved by about 14.5% relative to the proportion of subjects having mRS score of 0 or 1 at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the population is improved by about 14.5% relative to the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the reference population. PATENT Genentech Docket No: P38439-WO In some embodiments, the clinical outcome is the proportion of subjects with functional independence. In some embodiments, functional independence is an mRS score of 0-2. In some embodiments, the proportion of subjects with functional independence in the population of subjects is at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% higher than the proportion of subjects with functional independence in the reference population. In some embodiments, the proportion of subjects with functional independence in the population of subjects is about 3.6% higher than the proportion of subjects with functional independence in the reference population. In some embodiments, functional independence is assessed 90 days after the tenecteplase is administered. In some embodiments, the clinical outcome is the proportion of subjects having recanalization of one or more occluded vessels. In some embodiments, recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). In some embodiments, the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30%, higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels. In some embodiments, the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is about 13% higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels. In some embodiments, recanalization is assessed 24 hours after the tenecteplase is administered. In some embodiments, each member of the population of subjects has an MCA M1 occlusion. In some embodiments, the subject has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the subject is a member of a population of subjects in which each member of the population of subjects has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the method improves clinical outcome in the population of subjects relative to the reference population of subjects, wherein each member of the reference population has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the clinical outcome is final infarct volume. In some embodiments, the mean final infarct volume in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% lower than the mean final infarct volume of subjects in the reference population. In some embodiments, final infarct volume is assessed between 72 hours and 96 hours after a baseline measurement of infarct volume. In some embodiments, the clinical outcome is infarct growth. In some embodiments, the mean infarct growth in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% lower than the mean infarct growth of subjects in the reference population. In some embodiments, infarct growth is assessed between 72 hours and 96 hours after a baseline measurement of infarct volume. In some embodiments, the method further includes conducting a mechanical thrombectomy to the subject. In some embodiments, the mechanical thrombectomy is conducted prior to, concurrently with, or after the administration of tenecteplase or placebo. In some embodiments, the mechanical thrombectomy is conducted after the administration of tenecteplase or placebo. In some embodiments, the mechanical thrombectomy comprises groin puncture. In some embodiments, the time between the administration of tenecteplase or placebo and the mechanical thrombectomy is six PATENT Genentech Docket No: P38439-WO minutes or less. In some embodiments, tenecteplase or placebo is administered 6 minutes or less before the mechanical thrombectomy is conducted. In some embodiments, the incidence of symptomatic intracranial hemorrhage (sICH) is not increased in the population of subjects relative to the reference population. In some embodiments, the incidence of sICH is an incidence within 36 hours of administration of tenecteplase. In some embodiments, the incidence or severity of adverse events is not increased in the population of subjects relative to the reference population. In some embodiments, the mortality rate is not increased in the population of subjects relative to the reference population. In some embodiments, the mortality rate is a mortality rate up to 30 days after the tenecteplase is administered or a mortality rate up to 90 days after the tenecteplase is administered. In some embodiments, the proportion of subjects with parenchymal hematoma type 2 (PH2) is not increased in the population of subjects relative to the reference population. In some embodiments, each member of the population of subjects has a baseline infarct volume that is less than 20 mL prior to the administration. In some embodiments, each member of the population of subjects has a large vessel occlusion. In some embodiments, each member of the population of subjects has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA)M1 occlusion, and / or an MCA M2 occlusion. In some embodiments, one or more members of the population of subjects has an ICA occlusion or an MCA M1 occlusion. In some embodiments, one or more members of the population of subjects has an MCA M1 occlusion. In some embodiments, one or more members of the population of subjects has an MCA M2 occlusion. In some embodiments, each member of the reference population has an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion. In some embodiments, no member of the population of subjects has active internal bleeding or hemorrhagic stroke. In some embodiments, no member of the reference population has active internal bleeding or hemorrhagic stroke. In some embodiments, no member of the population of subjects has acute symptomatic arterial occlusions in more than one vascular territory. In some embodiments, no member of the population of subjects has bilateral MCA occlusions or an MCA and a basilar artery occlusion. In some embodiments, each member of the population of subjects has a NIHSS score of at least 5 before the administration. In some embodiments, one or more members of the population of subjects is identified for treatment at an ECC. In some embodiments, each member of the population of subjects is identified for treatment at an ECC. In some embodiments, one or more members of the population of subjects is identified for treatment at a nECC. In some embodiments, each member of the population of subjects is identified for treatment at an nECC. In some embodiments, one or more members of the population of subjects receives an endovascular therapy subsequent to the administration of tenecteplase. In some embodiments, the endovascular therapy is a thrombectomy. In some embodiments, the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile. In some embodiments, the target mismatch profile is defined by one or more of: a mismatch ratio; a mismatch volume; and an ischemic core volume. In some embodiments, the mismatch ratio is determined by comparing the total volume of ischemic PATENT Genentech Docket No: P38439-WO tissue to the ischemic core volume. In some embodiments, the target mismatch profile is defined by a mismatch ratio of at least 1.8. In some embodiments, the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue. In some embodiments, the target mismatch profile is defined by a mismatch volume of at least 15 mL. In some embodiments, the target mismatch profile is defined by an ischemic core volume of less than 70 mL. In some embodiments, the total volume of ischemic tissue is the Tmax >6s lesion volume. In some embodiments, the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging technology. In some embodiments, the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan. In some embodiments, the advanced imaging comprises use of RAPID software. In some embodiments, the target mismatch profile is defined by: a mismatch ratio of at least 1.8; a mismatch volume of at least 15 mL; and an ischemic core volume of less than 70 mL. In some embodiments, one or more members of the population of subjects has: (a) an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion, wherein the occlusion is identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA); and (b) a target mismatch profile defined by: a mismatch ratio of at least 1.8; a mismatch volume of at least 15 mL; and an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of a CTP scan or a MRP scan. In some embodiments, one or more members of the population of subjects has: (a) a Tmax>6s perfusion deficit consistent with an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion; and (b) a target mismatch profile defined by: a mismatch ratio of at least 1.8; a mismatch volume of at least 15 mL; and an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of RAPID software. In some embodiments, one or more members of the population of subjects has an ICA or M1 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a diffusion-weighted imaging (DWI) lesion volume 25 mL or less; or one or more members of the population of subjects has an M2 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume 15 mL or less. In some embodiments, the population of subjects is a population of human subjects. In another aspect, mRS score of the subject is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 is increased by about 2% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 1 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 1 is increased by about 3.7% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 is increased by about 5.7% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0, 1, or 2 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration. In PATENT Genentech Docket No: P38439-WO some embodiments, the likelihood of the subject’s mRS score being 0, 1, or 2 is increased by about 3.7% after the administration. In some embodiments, mRS score of the subject is less than 3 after the administration. In some embodiments, the mRS score is assessed 90 days after the tenecteplase is administered. In some embodiments, the subject has an MCA M1 occlusion before administration of tenecteplase and the mRS score of the subject at Day 90 is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 at Day 90 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 at Day 90 is increased by about 2.8% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 1 at Day 90 is increased by at least 1%, 5%, 10%, 15%, or 20% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 1 at Day 90 is increased by about 11.7% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 at Day 90 is increased by at least 1%, 5%, 10%, 15%, or 20% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 at Day 90 is increased by about 14.5% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0, 1, or 2 at Day 90 is increased by at least 1%, 5%, 10%, 15%, or 20% after the administration. In some embodiments, the likelihood of the subject’s mRS score being 0, 1, or 2 at Day 90 is increased by about 14.5% after the administration. In some embodiments, functional independence of the subject is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration. In some embodiments, functional independence of the subject is improved by about 3.6% after the administration. In some embodiments, the functional independence is an mRS score of 0-2. In some embodiments, functional independence is assessed 90 days after the tenecteplase is administered. In some embodiments, recanalization of one or more occluded vessels of the subject is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% after the administration, wherein the recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). In some embodiments, the recanalization of one or more occluded vessels of the subject is improved by about 13% after the administration. In some embodiments, the recanalization is assessed 24 hours after the tenecteplase is administered. In some embodiments, the subject has an MCA M1 occlusion before administration. In some embodiments, each member of the population of subjects has an MCA M2 occlusion. In some embodiments, the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is about 21% higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels. In some embodiments, each member of the population of subjects has an MCA M2 occlusion. PATENT Genentech Docket No: P38439-WO In some embodiments, the method further includes conducting a mechanical thrombectomy on the subject. In some embodiments, the mechanical thrombectomy is conducted prior to, concurrently with, or after the administration of tenecteplase. In some embodiments, the mechanical thrombectomy is conducted after the administration of tenecteplase. In some embodiments, the mechanical thrombectomy comprises groin puncture. In some embodiments, a time between the administration of tenecteplase and the mechanical thrombectomy is six minutes or less. In some embodiments, tenecteplase is administered 6 minutes or less before the mechanical thrombectomy is conducted. In some embodiments, the incidence of symptomatic intracranial hemorrhage (sICH) is not increased in the subject after the administration. In some embodiments, the incidence of sICH is an incidence within 36 hours of administration of tenecteplase. In some embodiments, the incidence or severity of adverse events is not increased in the subject after the administration. In some embodiments, the mortality rate is not increased in the subject after the administration. In some embodiments, the mortality rate is a mortality rate up to 30 days after the tenecteplase is administered or a mortality rate up to 90 days after the tenecteplase is administered. In some embodiments, if the subject has parenchymal hematoma type 2 (PH2), pH2 is not increased after the administration. In some embodiments, the subject has a baseline infarct volume that is less than 20 mL prior to the administration. In some embodiments, the subject has a large vessel occlusion. In some embodiments, the subject has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA) M1 occlusion, and / or an MCA M2 occlusion. In some embodiments, the subject has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the subject has an MCA M1 occlusion. In some embodiments, the subject does not have active internal bleeding or hemorrhagic stroke. In some embodiments, the subject does not have acute symptomatic arterial occlusions in more than one vascular territory. In some embodiments, the subject does not have bilateral MCA occlusions or an MCA and a basilar artery occlusion. In some embodiments, the subject has a NIHSS score of at least 5 before the administration. In some embodiments, the subject is identified for treatment at an ECC. In some embodiments, the subject is identified for treatment at a nECC. In some embodiments, the subject receives an endovascular therapy subsequent to the administration of tenecteplase. In some embodiments, the endovascular therapy is a thrombectomy. In some embodiments, the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile. In some embodiments, the target mismatch profile is defined by one or more of: a. a mismatch ratio; b. a mismatch volume; and c. an ischemic core volume. In some embodiments, the mismatch ratio is determined by comparing the total volume of ischemic tissue to the ischemic core volume. In some embodiments, the target mismatch profile is defined by a mismatch ratio of at least 1.8. In some embodiments, the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue. In some embodiments, the target mismatch profile is defined by a mismatch volume of at least 15 mL. In some embodiments, the target mismatch profile is defined by an ischemic core volume of less than 70 mL. In some embodiments, the total volume of ischemic tissue is the >6s lesion volume. In some embodiments, the salvageable brain tissue or salvageable brain pattern is identified by advanced PATENT Genentech Docket No: P38439-WO imaging technology. In some embodiments, the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan. In some embodiments, the advanced imaging comprises use of RAPID software. In some embodiments, the target mismatch profile is defined by: a. a mismatch ratio of at least 1.8; b. a mismatch volume of at least 15 mL; and c. an ischemic core volume of less than 70 mL. In some embodiments, the subject has: (a) an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion, wherein the occlusion is identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA); and (b) a target mismatch profile defined by: i. a mismatch ratio of at least 1.8; ii. a mismatch volume of at least 15 mL; and iii. an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of a CTP scan or a MRP scan. In some embodiments, the subject has: (a) a Tmax>6s perfusion deficit consistent with an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion; and (b) a target mismatch profile defined by: i. a mismatch ratio of at least 1.8; ii. a mismatch volume of at least 15 mL; and iii. an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of RAPID software. In some embodiments, the subject has an ICA or M1 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a diffusion-weighted imaging (DWI) lesion volume 25 mL or less; or the subject has an M2 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume 15 mL or less. In another aspect, provided herein is a method for treating AIS in a subject having an MCA M2 occlusion, the method comprising administering tenecteplase to the subject, wherein the subject has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject at a time between 4.5 and 24 hours after the onset of AIS; and wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg. In some embodiments, the subject is a member of a population of subjects, wherein each member of the population (i) has AIS and salvageable brain tissue or a salvageable brain pattern, and (ii) is administered a therapeutically effective amount of tenecteplase at a time between 4.5 and 24 hours after onset of the AIS, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg; and the method increases the proportion of subjects having complete recanalization of one or more occluded vessels relative to a reference population of subjects, wherein each member of the reference population (iii) has AIS and salvageable brain tissue or a salvageable brain pattern, and (iv) is administered placebo at a time between 4.5 and 24 hours after onset of AIS. In some embodiments, the subject is a human subject. BRIEF DESCRIPTION OF THE DRAWINGS FIGs.1 and 2 are schematic diagrams showing the design of the ML40787 Phase III clinical trial. Eligible patients are randomized (R) on Day 1 into a tenecteplase (TNK) treatment group or a placebo (PBO) group. Eligible patients from each group receive mechanical thrombectomy (MT). Treatment assessments are performed at 24 hours (hr) and 72-96 hours post-randomization. Follow- PATENT Genentech Docket No: P38439-WO up occurs on Days 30 and 90. The primary endpoint is assessed at the Day 90 visit. AIS = acute ischemic stroke. FIG.3 is a schematic diagram showing the patient disposition from the study. N=458 excludes randomized patients who did not provide informed consent; total number of evaluable patients was 455 (excluding 3 patients with no post-baseline primary outcome data). Mechanical thrombectomy (MT) is defined as successful clot contact. For the two patients who discontinued the study early by physician decision, death occurred after discontinuation for both patients. Percentages are based on N in each treatment arm. FU = Follow-up FIG.4 shows a readout of a primary efficacy endpoint in the intent-to-treat (ITT) population, which is ordinal modified Rankin scale (mRS) score at Day 90. CI = confidence interval, OR = odds ratio. FIGs.5 and 6 provide subgroup analyses of the primary endpoint. ITT = intent-to-treat, IV = intravenous, CI = confidence interval, NIHSS = National Institutes of Health Stroke Scale, OR = odds ratio, ICA = internal carotid artery, MT = mechanical thrombectomy, ECC = endovascular capable center, nECC = non-endovascular capable center, FIG.7 shows a readout of a secondary efficacy endpoint in the intent-to-treat (ITT) population, which is functional independence (mRS 0-2) at Day 90. CI = confidence interval, mRS = modified Rankin Scale, OR = odds ratio. FIG.8 shows a readout of a secondary efficacy endpoint in the intent-to-treat (ITT) population, which is complete recanalization at 24 hours post-randomization. CI = confidence interval, mRS = modified Rankin Scale, OR = odds ratio. FIG.9 shows a readout of a secondary efficacy endpoint in the intent-to-treat (ITT) population, which is reperfusion at 24 hours post-randomization. CI = confidence interval, OR = odds ratio. FIG.10 provides ordinal modified Rankin scale scores at Day 90 for the subgroup having M1 occlusion (n= 227). CI = confidence interval, cOR = common odds ratio, mRS = modified Rankin scale. cOR and corresponding P value are adjusted for protocol version (1-^^YV^^^^^^DJH^^^^^^\HDUV^ vs. >70 years, and baseline National Institutes of Health Stroke Scale (NIHSS^^^^^^^YV^^!^^^^^ FIG.11 is a Consolidated Standards of Reporting Trials (CONSORT) diagram showing progress of subjects through the TIMELESS trial. *: Intent-to-treat population. FIG.12 is a stacked bar graph showing the distribution of modified Rankin Scale scores at the 90-day follow-up in the per-protocol populations of the ML40787 trial. cOR: common odds ratio; CI: confidence interval. The per-protocol population was defined as all patients from the intent-to-treat population who did not have any key major protocol deviations. cOR was adjusted for protocol version (1-4 vs. ^^^^DJH^^^^^^YV. >70 years) and type of occlusion (ICA / M1 vs. M2), with OR >1 corresponding to values favoring tenecteplase. P value is for the Wald test of the null hypothesis cOR=1. FIG.13 is a set of Kaplan–Meier curves showing overall survival in patients treated with tenecteplase or placebo according to the ML40787 trial. P value is from the stratified log-rank test, PATENT Genentech Docket No: P38439-WO adjusted for protocol version (1-4 vs. ^^^^DJH^^^^^^YV. >70 years) and type of occlusion (ICA / M1 vs M2). FIG.14 is a chart showing analyses of prespecified subgroups in the ML40787 trial. NIHSS, National Institutes of Health Stroke Scale; cOR, common odds ratio; ICA, internal carotid artery; MT, mechanical thrombectomy. FIG.15 is a set of stacked bar graphs showing the distribution of modified Rankin Scale (mRS) scores at the 90-day follow-up in patients from the ML40787 trial who had an M1 occlusion and were treated with tenecteplase or a placebo. Upper graph: patients for whom a mechanical thrombectomy was performed. Lower graph: patients for whom a mechanical thrombectomy was not performed. cOR: common odds ratio; CI: confidence interval. cOR was adjusted for protocol version (1-^^YV^^^^^^DJH^^^^^^vs. >70 years) and baseline 1DWLRQDO^,QVWLWXWHV^RI^+HDOWK^6WURNH^6FDOH^^^^^^YV^ >15) for the “mechanical thrombectomy performed” group. cOR was not adjusted for the “mechanical thrombectomy not performed” group. FIG.16 is a stacked bar graph showing the distribution of modified Rankin Scale (mRS) scores at the 90-day follow-up in patients from the ML40787 trial who had an M2 occlusion and were treated with tenecteplase or a placebo. N=171. cOR: common odds ratio; CI: confidence interval. cOR was adjusted for protocol version (1-^^YV^^^^^DQG^DJH^^^^^^YV^^!^^^\HDUV^^^ZLWK^F25^25^!^^ corresponding to values favoring tenecteplase. FIG.17 is a set of stacked bar graphs showing the distribution of modified Rankin Scale (mRS) scores at the 90-day follow-up in patients from the ML40787 trial who had an M2 occlusion and were treated with tenecteplase or a placebo. Upper graph: patients for whom a mechanical thrombectomy was performed. Lower graph: patients for whom a mechanical thrombectomy was not performed. cOR: common odds ratio; CI: confidence interval. cOR was adjusted for protocol version (1-4 vs.5) and DJH^^^^^^YV^^!^^^\HDUV^^IRU^WKH^³PHFKDQLFDO^WKURPEHFWRP\^SHUIRUPHG´^JURXS^^^F25^ was adjusted for protocol version for the “mechanical thrombectomy not performed” group. FIG.18 is a bar graph showing the percentage of patients in the ML40787 trial treated with tenecteplase or a placebo following randomization into the study at a non-endovascular capable center (non-endovascular thrombectomy (non-EVT) center) who had a modified Rankin Scale (mRS) score of between 0 and 2 at the 90-day follow-up. FIG.19 is a bar graph showing the percentage of patients in the ML40787 trial treated with tenecteplase or a placebo no more than 6 minutes before femoral groin puncture for a planned thrombectomy who had a modified Rankin Scale score of between 0 and 2 at the 90-day follow-up. OR: odds ratio; mRS: modified Rankin Scale. OR is adjusted for protocol version (1-4 vs.5) and baseline NIHSS (<15 vs. >15). FIG.20 is a set of stacked bar graphs showing the distribution of modified Rankin Scale (mRS) scores at the 90-day follow-up in patients from the ML40787 trial who had a distal M2 occlusion (occlusion in the second half of an M2 branch) and were treated with tenecteplase or a placebo. Upper graph: patients for whom a mechanical thrombectomy was performed. Lower graph: patients for whom a mechanical thrombectomy was not performed. cOR: common odds ratio; CI: confidence interval. cOR was adjusted for protocol version (1-^^YV^^^^^^DJH^^^^^^YV^^!^^^\HDUV^^DQG^ PATENT Genentech Docket No: P38439-WO baseline 1DWLRQDO^,QVWLWXWHV^RI^+HDOWK^6WURNH^6FDOH^^^15 vs >15) for the “mechanical thrombectomy performed” group. cOR was not adjusted for the “mechanical thrombectomy not performed” group. FIG.21 is a bar graph showing the percentage of patients in the ML40787 trial treated with tenecteplase or a placebo who achieved complete recanalization at 24 hours post-randomization based on occlusion type (M1, proximal M2, or distal M2). FIG.22 is a bar graph showing the percentage of patients in the ML40787 trial treated with tenecteplase or a placebo who had a distal M2 occlusion and achieved complete recanalization at 24 hours post-randomization. EVT: patient received an endovascular therapy; no EVT: patient did not receive an endovascular therapy. Fig.23 is a bar graph showing mean final infarct growth (in mL) at 72-96 hours post- randomization in patients in the ML40787 trial who had an M1 or M2 occlusion and were treated with tenecteplase or a placebo. FIG.24 is a stacked bar graph showing the distribution of modified Rankin Scale (mRS) scores at the 90-day follow-up in patients from the ML40787 trial who had a wake-up stroke and were treated with tenecteplase or a placebo. N=262. cOR: common odds ratio; CI: confidence interval. cOR and the corresponding P value were adjusted for protocol version (1-4 vs.5), DJH^^^^^^YV^^!^^^ years), and type of occlusion (ICA / M1 vs M2), with cOR / OR >1 corresponding to values favoring tenecteplase. Fig.25 is a bar graph showing duration between the last known well time (LKW) and randomization into the ML40787 trial (in hours) in patients who had a symptomatic intracranial hemorrhage (SICH) or parenchymal hematoma type 2 (PH2) or did not have a SICH or PH2. Fig.26 is a bar graph showing the percentage of patients having an internal carotid artery (ICA), M1, or M2 occlusion who had a symptomatic intracranial hemorrhage (SICH) or parenchymal hematoma type 2 (PH2). DETAILED DESCRIPTION Intravenous thrombolysis with alteplase remains the standard of care prior to thrombectomy for eligible patients within 4.5 hours of ischemic stroke onset. However, alteplase succeeds in reperfusing large vessel arterial occlusion prior to thrombectomy in only a minority of patients. Results of previous non-randomized studies have suggested that patients who have a mismatch between the volume of brain tissue that may be salvaged and the volume of infarcted tissue as seen on imaging could benefit from reperfusion of occluded proximal anterior circulation vessels, even when the reperfusion is performed more than 6 hours after the patient was last known to be well. Treatment benefit is strongly dependent on time-to-reperfusion and, as many patients have treatment delays due to inter-hospital transfers (or in some cases difficult vascular access), improved approaches to intravenous thrombolysis that decrease the need for transfer could substantially improve patient outcomes. Thus, there is an unmet need in the field for the development of methods of treating late- window AIS patients. PATENT Genentech Docket No: P38439-WO I. GENERAL TECHNIQUES The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodology by those skilled in the art, such as, for example, the widely utilized methodologies described in Sambrook et al., Molecular Cloning: A Laboratory Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (F.M. Ausubel, et al. eds., (2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual, and Animal Cell Culture (R.I. Freshney, ed. (1987)); Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press; Animal Cell Culture (R.I. Freshney), ed., 1987); Introduction to Cell and Tissue Culture (J.P. Mather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B. Griffiths, and D.G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (D.M. Weir and C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (J.M. Miller and M.P. Calos, eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C.A. Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D. Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of Oncology (V.T. DeVita et al., eds., J.B. Lippincott Company, 1993). II. DEFINITIONS It is to be understood that aspects and embodiments of the disclosure described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments. As used herein, the singular form “a,” “an,” and “the” includes plural references unless indicated otherwise. The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) aspects that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.” As used herein, the term “tenecteplase,” also known as TNK-tPA or brands of tissue-plasminogen activator variants such as TNKASE® and Metalyse®, refers to a tPA variant designatedT103N, N117Q, K296A, H297A, R298A, R299A, available from Genentech, Inc., wherein Thr103 of wild-type tPA is changed to Asn (T103N), Asn117 of wild-type tPA is changed to Gln (N117Q), and Lys-His-Arg-Arg (SEQ ID NO: 1) 296-299 of wild-type tPA is changed to Ala-Ala-Ala-Ala (SEQ ID NO:2) (KHRR296-299AAAA). See the background section of U.S. Patent Application Publication No: US 2010 / 0330083 and U.S. Pat. No.5,612,029, which are incorporated herein by reference in their PATENT Genentech Docket No: P38439-WO entirety. Tenecteplase has the following amino acid sequence: SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQ ALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGNWSTAESGAECTNWQSSALAQKPYSGRR PDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTE SGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSC STCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAAAAASPGERFLCGGILISSCWILSAAHCFQERFPP HHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPP ADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSG GPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP (SEQ ID NO: 3). TNKase is a tissue plasminogen activator, also known as a thrombolytic or clot-dissolving tissue plasminogen activator (tPA) agent, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). Tenecteplase starts a biochemical reaction that can break down fibrin, a component of blood clots. As used herein, a “clinical outcome” is a measure or parameter that describes or reflects how a subject (or population of subjects) feels, functions, or survives, e.g., a measure that describes or reflects a patient’s symptoms, overall mental state, quality of life, or the effects of a disease or condition (e.g., acute ischemic stroke (AIS)) on how the patient functions. For example, in the context of treating AIS, a clinical outcome may be an ordinal modified Rankin scale (mRS) score, a proportion of subjects with functional independence, a National Institutes of Health Stroke Scale (NIHSS) score, a proportion of subjects having a Barthel Index (BI) score of at least 95, a proportion of subjects with good recovery, as identified by a Glasgow Outcome Scale (GOS) score of 5, a proportion of subjects having reperfusion, a proportion of subjects having recanalization of one or more occluded vessels, a median final infarct volume, a median infarct growth, a proportion of subjects for which a planned thrombectomy was obviated, a proportion of subjects for which only one pass with an endovascular therapy device is required to achieve recanalization of one or more occluded vessels, a proportion of subjects having angiographic reperfusion at completion of an angiographic procedure, an overall survival (OS) rate (e.g., assessed 30 or 90 days after the tenecteplase is administered), a proportion of subjects who are re-admitted to a hospital within 30 days of discharge, or a mean Quality of Life in Neurological Disorders (Neuro-QoL) score in a population of subjects having AIS who have been treated with tenecteplase as compared to a reference population of subjects having AIS (e.g., who have been treated with placebo). In another example, in the context of treating AIS, a clinical outcome may be one or more of the following that is measured from a subject: an ordinal modified Rankin scale (mRS) score, functional independence, a National Institutes of Health Stroke Scale (NIHSS) score, a Barthel Index (BI) score, good recovery as identified by a Glasgow Outcome Scale (GOS) score of 5, reperfusion, recanalization of one or more occluded vessels, a median final infarct volume, a median infarct growth, a likelihood of a planned thrombectomy being obviated, a likelihood of only one pass with an endovascular therapy device being required to achieve recanalization of one or more occluded vessels, angiographic reperfusion at completion of an angiographic procedure, an overall survival (OS) rate (e.g., assessed 30 or 90 days after the tenecteplase is administered), PATENT Genentech Docket No: P38439-WO readmission to a hospital within 30 days of discharge, or a mean Quality of Life in Neurological Disorders (Neuro-QoL) score. An “improved” clinical outcome in a subject or population of subjects is a clinical outcome that is more favorable than a clinical outcome in a reference subject or population of subjects (e.g., an untreated subject or population of subjects or a placebo-treated subject or population of subjects) or more favorable than a clinical outcome at baseline. For example, an improved clinical outcome may be an improvement in survival (e.g., duration of survival or survival rate), an improvement in or alleviation of one or more symptoms of disease, an improvement in overall mental state, an improvement in quality of life, an improvement in the subject’s function, or a reduction in one or more effects of a disease or condition relative to a reference subject or population of subjects. In the context of treating AIS, examples of improved clinical outcomes may include, but are not limited to, the improved clinical outcomes described below in Section III(F). As used herein, the terms “salvageable brain tissue” and “salvageable brain pattern” refer to a region of brain tissue in a subject having cerebral ischemia (e.g., a subject who has had a stroke, e.g., an acute ischemic stroke (AIS)) that is ischemic, but could potentially be salvaged by reperfusion. Salvageable brain tissue or a salvageable brain pattern may be identified, for example, by advanced imaging (e.g., imaging comprising use of one or both of a computed tomography perfusion (CTP) scan and a magnetic resonance perfusion (MRP) scan, and / or use of RAPID software (iSchemaView, Inc)), e.g., advanced imaging that identifies the presence of a target mismatch profile, a penumbral pattern, or a penumbral profile. The phrase “significantly different” or “substantially different,” as used herein, denotes a sufficiently high degree of difference between two numeric values (generally one associated with a molecule and the other associated with a reference / comparator molecule, e.g., one associated with tenecteplase and the other associated with a placebo) such that one of skill in the art would consider the difference between the two values to be of statistical significance within the context of the characteristic (e.g., biological characteristic) measured by said values. The difference between said two values may be, for example, greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, or greater than about 50% as a function of the value for the reference / comparator molecule. The term “substantially similar” or “substantially the same,” as used herein, denotes a sufficiently high degree of similarity between two numeric values (for example, one associated with a molecule and the other associated with a reference / comparator molecule, e.g., one associated with tenecteplase and the other associated with a placebo), such that one of skill in the art would consider the difference between the two values to be of little or no biological and / or statistical significance within the context of the characteristic (e.g., biological characteristic) measured by said values. The difference between said two values is, for example, less than about 50%, less than about 40%, less than about 30%, less than about 20%, and / or less than about 10% as a function of the reference / comparator value. As used herein, “administering” is meant providing or giving a dosage of a compound (e.g., tenecteplase) or a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical PATENT Genentech Docket No: P38439-WO composition including tenecteplase) to a subject or population of subjects. The compounds and / or compositions utilized in the methods described herein can be administered, for example, intravenously (e.g., by intravenous infusion, e.g., by a single intravenous bolus injection / infusion). The method of administration can vary depending on various factors (e.g., the compound or composition being administered and the severity of the condition, disease, or disorder being treated). As used herein, the term “treatment” or “treating” refers to clinical intervention designed to alter the natural course of the individual or cell being treated during the course of clinical pathology. Desirable effects of treatment include delaying or decreasing the rate of disease progression, ameliorating or palliating the disease state, and remission or improved prognosis. For example, an individual is successfully “treated” if one or more symptoms associated with the disease (e.g., acute ischemic stroke (AIS)) are mitigated or eliminated, including, but are not limited to, reperfusion of ischemic tissue, recanalization of one or more occluded vessels, decreasing symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, decreasing the need for mechanical intervention (e.g., thrombectomy) required to treat the disease, delaying the progression of the disease, and / or prolonging survival of individuals. For example, treating comprises effective treatment of AIS with an effective amount of a therapeutic agent (e.g., tenecteplase). As used herein, “overall survival” and “OS” refer to the length of time from either the date of diagnosis or the start of treatment for a disease (e.g., AIS) that the patient is still alive. For example, OS may be defined as the time from randomization to death from any cause. As used herein, “overall survival rate” refers to the percentage of subjects in a group who are alive after a particular duration of time, e.g., 30 days, one month, 60 days, two months, 90 days, three months, four months, five months, six months, 1 year, or 5 years from the time of diagnosis or treatment. As used herein, by “subject” or “individual” is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline. In some aspects, the subject is a human. Patients are also subjects herein. The term “patient” refers to a human patient. For example, the patient may be an adult. “Carriers” as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™. PATENT Genentech Docket No: P38439-WO The phrase “pharmaceutically acceptable” indicates that the substance or composition must be compatible chemically and / or toxicologically, with the other ingredients comprising a formulation, and / or the mammal being treated therewith. The term “pharmaceutical formulation” or “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products or medicaments that contain information about the indications, usage, dosage, administration, combination therapy, other medicaments to be combined with the packaged product, and / or contraindications and / or warnings concerning the use of such therapeutic products or medicaments. III. THERAPEUTIC METHODS FOR TREATMENT OF ACUTE ISCHEMIC STROKE In one aspect, the present disclosure provides a method for treating acute ischemic stroke (AIS) in a subject or a population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or each member of the population of subjects, wherein the subject or each member of the population of subjects has salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS). In some embodiments tenecteplase treatment improves clinical outcome in the subject or the population of subjects relative to a placebo-treated reference population of subjects having AIS. In another aspect, the disclosure provides tenecteplase (e.g., TNKASE®) for use in treating acute ischemic stroke (AIS) in a subject or a population of subjects, wherein the subject or each member of the population of subjects has salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is to be administered to the subject or each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS. In some embodiments, tenecteplase treatment improves clinical outcome in the subject or the population of subjects relative to a placebo- treated reference population of subjects having AIS. In another aspect, the disclosure provides use of tenecteplase (e.g., TNKASE®) in the manufacture of a medicament for treating acute ischemic stroke (AIS) in a subject or a population of subjects, wherein the subject or each member of the population of subjects has salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is to be administered to each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS. In some embodiments, tenecteplase treatment improves clinical outcome in the subject or the population of subjects relative to a placebo-treated reference population of subjects having AIS. PATENT Genentech Docket No: P38439-WO A. Population of subjects Vessel occlusions In some aspects, a subject or each member of the population of subjects has a large vessel occlusion (e.g., the AIS is attributable to a large vessel occlusion). In some aspects, a subject or each member of the population of subjects has an internal carotid artery (ICA) occlusion (e.g., a cervical or intracranial ICA occlusion) or a middle cerebral artery (MCA) occlusion. In embodiments, the MCA occlusion involves the sphenoidal or horizontal segment (M1) or the insular segment (M2) (e.g., an MCA M1 occlusion or an MCA M2 occlusion). In some aspects, a subject or each member of the population of subjects has an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion (e.g., the AIS is attributable to an ICA, MCA M1, or MCA M2 occlusion). ICA occlusions may include tandem MCA lesions. Occlusions may be characterized by, e.g., magnetic resonance angiography (MRA) or computed tomography angiography (CTA). In some aspects, a subject or one or more members of the population of subjects has an ICA occlusion or an MCA M1 occlusion. In some aspects, a subject or one or more members of the population of subjects has an MCA M2 occlusion. In some aspects, a subject or one or more members of the population of subjects has a distal M2 occlusion, i.e., has an occlusion in the second half of an M2 branch. In some aspects, intracranial hemorrhage is not present. In some aspects, intracranial hemorrhage is not the primary cause of stroke signs and symptoms prior to initiation of treatment. In some aspects, a subject or each member of the population of subjects does not have acute symptomatic arterial occlusions in more than one vascular territory. In some aspects, a subject or each member of the population of subjects does not have bilateral MCA occlusions or an MCA and a basilar artery occlusion. Subject characteristics In some aspects, a subject or each member of the population of subjects has a National Institutes of Health Stroke Scale (NIHSS) score of at least 5 (Powers et al., Stroke, 49(3): e46-e110, 2018). In some aspects, a subject or one or more members of the population of subjects has a baseline NIHSS score of 15 or less (e.g., a NIHSS score between 5 and 15). In some aspects, a subject or one or more members of the population of subjects has a baseline NIHSS score of at least 15. In some aspects, a subject or one or more members of the population of subjects is more than 70 years old. In some aspects, a subject or one or more members of the population of subjects is 70 years old or younger. In some aspects, a subject or one or more members of the population of subjects has the baseline infarct volume that is less than 20 mL, equal or more than 20 mL but less than 50 mL, or equal or more than 50 mL. In some embodiments, the baseline infarct volume of the subject or one or more members of the subjects in the population is less than 20 mL before tenecteplase or placebo is administered. PATENT Genentech Docket No: P38439-WO In some aspects, a subject, a member of the population of subjects, or each member of the population of subjects had a wake up stroke (e.g., woke up from sleep with a stroke). In other aspects, a subject, a member of the population of subjects, or each member of the population of subjects did not have a wake up stroke. Treatment sites A subject or members of the population of subjects may be identified for treatment at an endovascular capable center (ECC) (e.g., a location capable of performing an endovascular therapy (e.g., thrombectomy, e.g., mechanical thrombectomy) for treatment of AIS) or a non-endovascular capable center (nECC). For example, a subject or members of the population of subjects may be admitted to an ECC, admitted to an nECC, or transferred from an ECC to an nECC. In some aspects, a subject or one or more members of the population of subjects is identified for treatment at an ECC. In some aspects, a subject or each member of the population of subjects is identified for treatment at an ECC. In some aspects, a subject or one or more members of the population of subjects is identified for treatment at an nECC. In some aspects, a subject or each member of the population of subjects is identified for treatment at an nECC. B. Tenecteplase treatment In some aspects of any of the methods provided herein, tenecteplase (e.g., TNKASE®) is administered to a subject or each member of the population of subjects intravenously at a dose of about 0.25 mg / kg (e.g., is administered to a subject or each member of the population of subjects intravenously at a dose of 0.25 mg / kg). In some aspects, tenecteplase is administered to a subject or each member of the population of subjects intravenously at a dose of about 0.25 mg / kg (e.g., a dose of 0.25 mg / kg), not exceeding a maximum dose of 25 mg. In some aspects, the tenecteplase is administered at a single dose (e.g., is administered as a single dose within the late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS)). In some aspects, the tenecteplase is administered as a bolus injection over about 5 seconds (e.g., over 5 seconds). In some aspects, the tenecteplase is administered as an about 5-second, intravenous (IV) bolus injection. In some aspects, the tenecteplase is administered as a 5-second, intravenous (IV) bolus injection. Accordingly, in some aspects, a single dose of tenecteplase is administered to a subject or each member of the population of subjects as a bolus intravenous injection over about 5 seconds at a dose of 0.25 mg / kg, not exceeding a maximum dose of 25 mg. C. Endovascular therapy In some aspects, a subject or one or more members of the population of subjects receives an endovascular therapy subsequent to the administration of tenecteplase (e.g., TNKASE®) (e.g., receives an adjuvant endovascular therapy). The endovascular therapy may be, e.g., a thrombectomy (e.g., a mechanical thrombectomy (MT)). In some aspects, the subject or one or more members of the PATENT Genentech Docket No: P38439-WO population of subjects has an ICA occlusion or an MCA M1 occlusion. In some aspects, the subject or one or more members of the population of subjects has an MCA M2 occlusion. In some aspects, the endovascular therapy is performed or administered immediately after or shortly after the administration of tenecteplase. For example, in some aspects, both the administration of tenecteplase and the endovascular therapy (e.g., thrombectomy) are performed at a time between 4.5 and 24 hours after onset of AIS. In other aspects, the endovascular therapy is performed or administered at a later time point, e.g., is performed more than 24 hours after onset of AIS. In some embodiments, the endovascular therapy (e.g., mechanical thrombectomy) is conducted prior to, concurrently with, or after the administration of tenecteplase. In some embodiments, the endovascular therapy is conducted after the administration of tenecteplase. In some embodiments, the endovascular therapy comprises groin puncture. In some embodiments, the time between the administration of tenecteplase or placebo and the endovascular therapy is six minutes or less, longer than 6 minutes, between 6 minutes and 22 minutes, less than 22 minutes, or longer than 22 minutes. In some embodiments, tenecteplase or placebo is administered in 6 minutes or less before the endovascular therapy is conducted (e.g., endovascular therapy is initiated (e.g., initiated by groin puncture) within 6 minutes of the administration of tenecteplase). In some aspects, an endovascular therapy is planned for a subject or a member of the population of subjects (e.g., is planned based on the AHA / ASA Stroke Early Management Guidelines (2018)), but is not performed. For example, in some aspects, an endovascular therapy is planned based on the subject’s status prior to the administration of tenecteplase, but is not performed (e.g., is made unnecessary) in view of the subject’s response to tenecteplase, e.g., is not performed because partial or complete recanalization of the qualifying vessel occlusion is observed following the administration of tenecteplase. Planning for the endovascular therapy may include, e.g., transferring the subject from an nECC to an ECC. D. Identification of subjects having salvageable brain tissue or a salvageable brain pattern The disclosure is based, at least in part, on the discovery that administration of tenecteplase (e.g., TNKASE®) to AIS patients in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS) improves clinical outcomes in patients having salvageable brain tissue or a salvageable brain pattern (e.g., having brain tissue that is ischemic, but could potentially be salvaged by reperfusion) relative to a placebo. In some aspects, the disclosure provides a method for treating AIS in a subject or population of subjects, the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows salvageable brain tissue or a salvageable brain pattern; and wherein the tenecteplase is administered to the subject or each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS. In some aspects, the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging (e.g., as described below). PATENT Genentech Docket No: P38439-WO In some aspects, the disclosure provides a method for treating AIS in a subject or population of subjects, the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has been determined to have salvageable brain tissue or a salvageable brain pattern. In some aspects, the disclosure provides a method for treating AIS in a subject or population of subjects, the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has been determined to have salvageable brain tissue or a salvageable brain pattern by advanced imaging technology within 24 hours of symptom onset. In some aspects, the disclosure provides a method for treating AIS in a subject or population of subjects, the method comprising determining if the subject or each member of the population of subjects has salvageable brain tissue or a salvageable brain pattern by advanced imaging technology within 24 hours of symptom onset and administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects who has been determined to have salvageable brain tissue or a salvageable brain pattern. In some aspects, the disclosure provides a method for treating AIS in a subject or population of subjects, the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows salvageable brain tissue or a salvageable brain pattern in an ICA or MCA (M1 or M2) by advanced imaging technology; and wherein the tenecteplase is administered to the subject or each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS. In some aspects, the disclosure provides a method for treating AIS in a subject or population of subjects, the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows salvageable brain tissue or a salvageable brain pattern by advanced imaging technology; wherein intracranial hemorrhage is not the primary cause of stroke signs and symptoms prior to initiation of treatment; and wherein the tenecteplase is administered to the subject or each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS symptoms. Methods for identifying salvageable brain tissue or a salvageable brain pattern in AIS patients are known in the art. For example, in some aspects, salvageable brain tissue or a salvageable brain pattern is identified as described in the DEFUSE 3 trial (Albers et al., N Engl J Med, 378: 708-718, 2018, which is incorporated herein by reference in its entirety) or the DAWN trial (Nogueira et al., N Engl J Med, 378: 11-21, 2017, which is incorporated herein by reference in its entirety). In some aspects, the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile, a penumbral pattern, or a penumbral profile. The target mismatch profile, penumbral pattern, or penumbral profile may be defined by one or more of (a) the mismatch ratio; (b) the mismatch volume; and (c) the ischemic core volume (e.g., may be defined by one, two, or all three of the mismatch ratio, the mismatch volume, and the ischemic core volume). In some aspects, each member of the population of subjects has been determined to have a target PATENT Genentech Docket No: P38439-WO mismatch profile based on (a) the mismatch ratio; (b) the mismatch volume; and (c) the ischemic core volume. Mismatch ratio In some aspects, the mismatch ratio is determined by comparing the total ischemic tissue volume (e.g., the volume of brain tissue that is either (a) ischemic, but still viable (ischemic penumbra) or (b) ischemic and irreversibly injured) to the ischemic core volume (e.g., the volume of irreversibly injured ischemic brain tissue), e.g., is determined by dividing the total volume of ischemic tissue by the ischemic core volume. The total volume of ischemic tissue may be defined, e.g., as the volume of tissue in which arrival of an injected tracer agent is delayed by at least 6 seconds. In some aspects, the total volume of ischemic tissue is defined as the time-to-maximum of the residue function (Tmax) of more than 6 seconds (Tmax >6s) lesion volume (Tmax >6s lesion volume). In some aspects, a mismatch ratio that identifies a subject as a candidate for treatment with tenecteplase in the late treatment window (e.g., at a time between 4.5 and 24 hours after onset of AIS) is a mismatch ratio (total ischemic tissue volume to ischemic core volume) of at least 1.8. Accordingly, in some aspects, the target mismatch profile is defined (at least in part) by a mismatch ratio of at least 1.8. In some aspects, one or more members of the population of subjects has a mismatch ratio of 1.8, 1.9, 2.0, 2.1, 2.2., 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2., 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2., 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, or more than 5.0 (e.g., has a mismatch ratio of 1.8-2.0, 2.0-2.5, 2.5-3.0, 3.0-3.5, 3.5-4.0, 4.0-4.5, or 4.5-5.0). Mismatch volume In some aspects, the mismatch volume (also called the ischemic penumbra volume) is determined by subtracting the ischemic core volume from the total volume of ischemic brain tissue. In some aspects, a mismatch volume that identifies a subject as a candidate for treatment with tenecteplase in the late treatment window (e.g., at a time between 4.5 and 24 hours after onset of AIS) is a mismatch volume (ischemic penumbra volume) of at least 15 mL. Accordingly, in some aspects, the target mismatch profile is defined (at least in part) by a mismatch volume of at least 15 mL. In some aspects, one or more members of the population of subjects has a mismatch volume of at least 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, 50 mL, 55 mL, 60 mL, 65 mL, 70 mL, 75 mL, 80 mL, 85 mL, 90 mL, 95 mL, or 100 mL (e.g., has a mismatch volume of 15-20 mL, 20-30 mL, 30-40 mL, 40-50 mL, 50-60 mL, 60-70 mL, 70-75 mL, 75-80 mL, 80-90 mL, or 90-100 mL. In some aspects, one or more members of the population of subjects has a mismatch volume of at least 100 mL. PATENT Genentech Docket No: P38439-WO Ischemic core volume In some aspects, an ischemic core volume that identifies a subject as a candidate for treatment with tenecteplase (e.g., TNKASE®) in the late treatment window (e.g., at a time between 4.5 and 24 hours after onset of AIS) is an ischemic core volume of less than 70 mL. Accordingly, in some aspects, the target mismatch profile is defined (at least in part) by an ischemic core volume of less than 70 mL. Mismatch ratio, mismatch volume, and ischemic core volume In some aspects, the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile, wherein the target mismatch profile is defined by (a) a mismatch ratio of at least 1.8; (b) a mismatch volume of at least 15 mL; and (c) an ischemic core volume of less than 70 mL. Accordingly, in some aspects, a subject or each member of the population of subjects shows or has been determined to have (a) a mismatch ratio of at least 1.8; (b) a mismatch volume of at least 15 mL; and (c) an ischemic core volume of less than 70 mL. In some aspects, a subject or one or more members of the population of subjects has (a) an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion, wherein the occlusion is identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA); and (b) a target mismatch profile defined by (i) a mismatch ratio of at least 1.8; (ii) a mismatch volume of at least 15 mL; and (iii) an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of a CTP scan or a MRP scan. In some aspects, a subject or one or more members of the population of subjects has (a) a Tmax>6s perfusion deficit consistent with an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion; and (b) a target mismatch profile defined by (i) a mismatch ratio of at least 1.8; (ii) a mismatch volume of at least 15 mL; and (iii) an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of RAPID software. Diffusion-weighted imaging (DWI) lesion volume In some aspects, the salvageable brain tissue or salvageable brain pattern is identified by a lesion volume determined by diffusion-weighted imaging (DWI) that is less than a threshold lesion volume. In some aspects, the threshold lesion volume is 25 mL for a subject having an ICA or M1 occlusion. In some aspects, the threshold lesion volume is 15 mL for a subject having an M2 occlusion. Accordingly, in some aspects, a subject or each member of the population of subjects has or has been determined to have (a) an ICA or M1 occlusion and a DWI lesion volume of 25 mL or less; or (b) an M2 occlusion and a DWI lesion volume of 15 mL or less. In some aspects, (a) a subject or one or more members of the population of subjects has an ICA or M1 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume of 25 mL or less; or (b) a subject or one or more members of the population of subjects has an M2 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume of 15 mL or less. PATENT Genentech Docket No: P38439-WO Advanced imaging In some aspects of any of the methods provided herein, the salvageable brain tissue or salvageable brain pattern (e.g., presence of a target mismatch profile, a penumbral pattern, or a penumbral profile) is identified by advanced imaging technology (e.g., advanced imaging technology used within 24 hours of AIS symptom onset). Advanced imaging can estimate the volume of irreversibly injured ischemic brain tissue (known as the ischemic core) and the volume of brain tissue that is ischemic, but still viable (known as the ischemic penumbra). The higher the ratio of total ischemic tissue volume to ischemic core volume (or mismatch ratio) is, the higher potential there is for salvageable (treatable) brain tissue. For example, one or more of the total volume of ischemic brain tissue, the ischemic core volume, the mismatch ratio, and the mismatch volume may be determined using advanced imaging technology. The advanced imaging technology may comprise one or both of a computed tomography perfusion (CTP) scan and a magnetic resonance perfusion (MRP) scan. In some aspects, the advanced imaging comprises use of rapid processing of perfusion and diffusion (RAPID) software (iSchemaView, Inc.). E. Baseline infarct volume In some embodiments, a subject or each member of the subjects in the population has the baseline infarct volume that is less than 20 mL, equal or more than 20 mL but less than 50 mL, or equal or more than 50 mL. In some embodiments, the baseline infarct volume of the subject or each member of the subjects in the population is less than 20 mL before tenecteplase or placebo is administered. F. Placebo-treated reference population In some embodiments, tenecteplase treatment according to certain methods provided herein improves clinical outcome in the population of subjects relative to a placebo-treated reference population of subjects having AIS. The reference population may be composed, e.g., of subjects having comparable demographic and baseline characteristics to the tenecteplase-treated population of subjects, wherein the subjects are treated with a placebo and are not treated with tenecteplase. In some aspects, each member of the placebo-treated reference population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern (e.g., as described in Section III(D), above) and is administered the placebo in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS). In some aspects, each member of the placebo-treated reference population has a vessel occlusion as described in Section III(A), above, e.g., has a large vessel occlusion, e.g., has an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion. In some aspects, one or more members of the placebo-treated reference population has an ICA occlusion or an MCA M1 occlusion. In some aspects, one or more members of the placebo-treated reference population has an MCA M2 occlusion. PATENT Genentech Docket No: P38439-WO In some aspects, each member of the placebo-treated reference population has a NIHSS score of at least 5, e.g., as described in Section III(A), above. In some aspects, one or more members of the placebo-treated reference population has a baseline NIHSS score of 15 or less (e.g., a NIHSS score between 5 and 15). In some aspects, one or more members of the placebo-treated reference population has a baseline NIHSS score of at least 15. In some aspects, one or more members of the placebo-treated reference population is more than 70 years old. In some aspects, one or more members of the placebo-treated reference population is 70 years old or younger. In some aspects, one or more members of the placebo-treated reference population receive an endovascular therapy, e.g., as described in Section III(C), above. In some aspects, the placebo-treated reference population of subjects is a control population. G. Improvement in a subject after tenecteplase treatment In some embodiments, tenecteplase is administered to treat acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern at a time between 4.5 and 24 hours after onset of said AIS, and tenecteplase treatment improves clinical outcome in the subject. H. Clinical outcomes Modified Rankin Scale (mRS) score In some aspects, the clinical outcome is ordinal modified Rankin scale (mRS) score in a subject or population of subjects (e.g., mRS score outcomes are more favorable in the tenecteplase- treated population of subjects than in the placebo-treated reference population). The mRS score may be determined at any time point following administration of tenecteplase to the subject or member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is mRS score at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). In some aspects, the clinical outcome is mRS score at about 30 days after the administration of tenecteplase or placebo (e.g., 30 days ±7 days, e.g., 30 days). mRS score may be determined, e.g., as set forth in Table 1. In some aspects, mRS assesses disability in patients who have suffered a stroke and is measured over time to check for recovery and degree of continued disability. Table 1. Modified Rankin Scale (mRS) PATENT Genentech Docket No: P38439-WO Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or a population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment improves the ordinal modified Rankin scale (mRS) score in the subject or the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., improves the mRS score as determined at about 90 days after the administration of tenecteplase or placebo). In some aspect, the mRS score in the subject is improved (e.g., significantly improved) after the administration of tenecteplase. In some aspects, the distribution of mRS scores in the population of subjects is improved (e.g., significantly improved), after the administration of tenecteplase, relative to the distribution of mRS scores in the placebo-treated reference population. An improvement in the mRS score of the distribution of mRS scores may be, e.g., a shift in the score or distribution of scores toward lower scores, e.g., an average, median, or mode mRS score that is lower in the subject after the administration or population of tenecteplase-administered subjects than in the placebo-treated reference population. In some embodiments, the subject has an MCA M1 occlusion before treatment (e.g., before the administration of tenecteplase, before the administration of tenecteplase and mechanical thrombectomy (MT), before the administration of placebo, or before the administration of placebo and MT); each member of the population of subjects has an MCA M1 occlusion before treatment (e.g., before the administration of tenecteplase and / or before the administration of tenecteplase and MT); and / or each member of the reference population has an MCA M1 occlusion before treatment (e.g., the administration of placebo). In some embodiments, the subject or each member of the population of subjects has an MCA M1 occlusion before treatment (e.g., the administration of tenecteplase), and tenecteplase treatment improves the mRS score in the subject, improves the distribution of mRS scores in the population of subjects, and / or increases the proportion of subjects in the population of subjects having recanalization relative to a placebo-treated reference population of subjects having AIS, wherein each member of the reference population has an MCA M1 occlusion before treatment (e.g., the administration of placebo and / or before the administration of placebo and MT). In some aspects, the distribution of mRS scores in the population of subjects is improved by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the distribution of mRS scores in the reference population, e.g., is improved by about 1-5%, 5-10%, 10- 15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, or 50-55%. In some aspects, the distribution of mRS scores in the population of subjects is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the distribution of mRS scores in the reference population, e.g., is improved by 1-5%, 5-10%, 10-15%, 15-20%, 20- 25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. PATENT Genentech Docket No: P38439-WO In some embodiments, the proportion of subjects having mRS score of 0 in the population after treatment is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to the proportion of subjects having mRS score of 0 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 in the population is improved by about 2% relative to the proportion of subjects having mRS score of 0 in the reference population. In some embodiments, the proportion of subjects having mRS score of 1 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.1%, 3.5%, 4%, 4.5%, or 5% relative to the proportion of subjects having mRS score of 1 in the reference population. In some embodiments, the proportion of subjects having mRS score of 1 in the population is improved by about 3.7% relative to the proportion of subjects having mRS score of 1 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 or 1 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% relative to the proportion of subjects having mRS score of 0 or 1 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 or 1 in the population is improved by about 5.7% relative to the proportion of subjects having mRS score of 0 or 1 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0, 1, or 2 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to the proportion of subjects having mRS score of 0, 1, or 2 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0, 1, or 2 in the population is improved by about 3.7% relative to the proportion of subjects having mRS score of 0, 1, or 2 in the reference population. In some embodiments, each member of the population of subjects has an MCA M1 occlusion. Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or a population of subjects (e.g., a population of human subjects) having an MCA M1 occlusion, the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment improves the ordinal modified Rankin scale (mRS) score in the subject or the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., improves the mRS score as determined at about 90 days after the administration of tenecteplase or placebo). In some embodiments, each member of the population of subjects has an MCA M1 occlusion before the treatment, and the proportion of subjects having mRS score of 0 in the population after the administration of tenecteplase (e.g., at about 90 days after tenecteplase treatment, e.g., at 90 days after tenecteplase treatment) is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to the proportion of subjects having mRS score of 0 in the reference population (e.g., a reference population of subjects having an MCA M1 occlusion before treatment) following placebo treatment (e.g., at about 90 days after placebo treatment, e.g., at 90 days after tenecteplase treatment). In some embodiments, the proportion of subjects having mRS score of 0 in the population PATENT Genentech Docket No: P38439-WO after the administration of tenecteplase is improved by about 2.8% relative to the proportion of subjects having mRS score of 0 in the reference population. In some embodiments, each member of the population of the subject has an MCA M1 occlusion before the treatment and the proportion of subjects having mRS score of 1 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 1 in the reference population. In some embodiments, the proportion of subjects having mRS score of 1 in the population after the administration of tenecteplase is improved by about 11.7% relative to the proportion of subjects having mRS score of 1 in the reference population. In some embodiments, each member of the population of the subject has an MCA M1 occlusion before the treatment and the proportion of subjects having mRS score of 0 or 1 in the population after the administration of tenecteplase is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 0 or 1 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0 or 1 in the population after the administration of tenecteplase is improved by about 14.5% relative to the proportion of subjects having mRS score of 0 or 1 in the reference population. In some embodiments, each member of the population of the subject has an MCA M1 occlusion before the treatment and the proportion of subjects having mRS score of 0, 1, or 2 in the population after the administration of tenecteplase is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 0, 1, or 2 in the reference population. In some embodiments, the proportion of subjects having mRS score of 0, 1, or 2 in the population after the administration of tenecteplase is improved by about 14.5% relative to the proportion of subjects having mRS score of 0, 1, or 2 in the reference population. In some embodiments, the mRS score is measured at Day 90 from or after the treatment of tenecteplase or placebo. In some aspects, the mRS score in the subject is improved by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the administration of tenecteplase, e.g., is improved by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the mRS score in the subject is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is improved by 1- 5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%. In some embodiments, the likelihood of the subject’s mRS score being 0 after the administration of tenecteplase is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5%. In some embodiments, the likelihood of the subject’s mRS score being 0 after the administration of tenecteplase is increased by about 2%. In some embodiments, the likelihood of the subject’s mRS score being 1 after the administration of tenecteplase is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5%. In some embodiments, the likelihood of the subject’s mRS score being 1 after the administration of tenecteplase is increased by about 3.7%. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 after the administration of tenecteplase is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 after the administration of tenecteplase is increased by about 5.7%. In some embodiments, the likelihood PATENT Genentech Docket No: P38439-WO of the subject’s mRS score being 0, 1, or 2 after the administration of tenecteplase is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5%. In some embodiments, the likelihood of the subject’s mRS score being 0, 1, or 2 after the administration of tenecteplase is increased by about 3.7%. In some embodiments, the mRS score of the subject after the treatment of tenecteplase is less than 3. In some embodiments, the subject has an MCA M1 occlusion before the treatment and the likelihood of the subject’s mRS score being 0 after the administration of tenecteplase is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5%. In some embodiments, the likelihood of the subject’s mRS score being 0 after the administration of tenecteplase is increased by about 2.8%. In some embodiments, the subject has an MCA M1 occlusion before the treatment and the likelihood of the subject’s mRS score being 1 after the administration of tenecteplase is increased by at least 1%, 5%, 10%, 15%, or 20%. In some embodiments, the likelihood of the subject’s mRS score being 1 after the administration of tenecteplase is increased by about 11.7% after the administration of tenecteplase. In some embodiments, the subject has an MCA M1 occlusion before the treatment and the likelihood of the subject’s mRS score being 0 or 1 after the administration of tenecteplase is increased by at least 1%, 5%, 10%, 15%, or 20%. In some embodiments, the likelihood of the subject’s mRS score being 0 or 1 after the administration of tenecteplase is increased by about 14.5%. In some embodiments, the subject has an MCA M1 occlusion before the treatment and the likelihood of the subject’s mRS score being 0, 1, or 2 after the administration of tenecteplase is increased by at least 1%, 5%, 10%, 15%, or 20%. In some embodiments, the likelihood of the subject’s mRS score being 0, 1, or 2 after the administration of tenecteplase is increased by about 14.5%. In some embodiments, the mRS score is measured at Day 90 from or after the treatment of tenecteplase. In some aspects, the average mRS score in the population of subjects is lower (e.g., is significantly lower) than the average mRS score in the reference population (e.g., as measured at about 90 days after the tenecteplase or placebo is administered). In some aspects, the average mRS score in the population of subjects is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the average mRS score in the reference population, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the average mRS score in the population of subjects is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the average mRS score in the reference population, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25- 30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the median mRS score in the population of subjects is lower (e.g., is significantly lower) than the median mRS score in the reference population (e.g., as determined at about 90 days after the tenecteplase or placebo is administered). In some aspects, the median mRS score in the population of subjects is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the median mRS PATENT Genentech Docket No: P38439-WO score in the reference population, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20- 25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the median mRS score in the population of subjects is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the median mRS score in the reference population, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30- 35%, 35-40%, 40-45%, or 45-50%. In some aspects, the present disclosure provides a method for treating AIS in a subject (e.g., a human subject) having an MCA M1 occlusion, the method comprising administering tenecteplase to the subject, wherein the subject has or has been determined to have salvageable brain tissue or a salvageable brain pattern, and wherein the tenecteplase is administered to the subject at a time between 4.5 and 24 hours after onset of AIS. In embodiments, the tenecteplase treatment prevents worsening of the ordinal modified Rankin scale (mRS) score in the subject. In embodiments, the tenecteplase treatment improves the ordinal modified Rankin scale (mRS) score in the subject. In embodiments, the tenecteplase treatment prevents worsening or improves the mRS score in the subject within 90 days of treatment. In another aspect, the present disclosure provides a method for treating acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern, the method comprising administering to the subject at a time between 4.5 and 24 hours after onset of said AIS a therapeutically effective amount of tenecteplase, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg, wherein said treatment results in recanalization of one or more occluded vessels in the subject. In some embodiments, the recanalization is complete. In some embodiments, recanalization is detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). In some embodiments, recanalization is assessed 24 hours after the tenecteplase is administered. Functional independence In some aspects, the clinical outcome is functional independence of a subject or the proportion of subjects with functional independence in a population of subjects (e.g., the proportion of subjects with functional independence is greater (e.g., is significantly greater) in the tenecteplase- treated population of subjects than in the placebo-treated reference population). Functional independence may be determined at a time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is functional independence at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). Functional independence may be defined, e.g., as mRS score of 0, 1, or 2 (0-2) (see Table 1). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase PATENT Genentech Docket No: P38439-WO is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases functional independence in the subject or increases the proportion of subjects with functional independence in the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., increases the functional independence in the subject or the proportion of subjects with functional independence at about 90 days after the administration of tenecteplase or placebo). In some aspects, the proportion of subjects with functional independence in the population of subjects is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the proportion of subjects with functional independence in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the proportion of subjects with functional independence in the population of subjects is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the proportion of subjects with functional independence in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45- 50%. In some embodiments, the proportion of subjects with functional independence in the population of subjects is at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% higher than the proportion of subjects with functional independence in the reference population. In some embodiments, the proportion of subjects with functional independence in the population of subjects is about 3.6% higher than the proportion of subjects with functional independence in the reference population. In some aspects, the functional independence in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40- 45%, or 45-50%. In some aspects, the functional independence in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45- 50%. In some embodiments, the functional independence of the subject is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration of tenecteplase. In some embodiments, functional independence of the subject is improved by about 3.6% after the administration. National Institutes of Health Stroke Scale (NIHSS) score In some aspects, the clinical outcome is National Institutes of Health Stroke Scale (NIHSS) score in a subject or population of subjects, e.g., median NIHSS score (e.g., the median score NIHSS score is lower (e.g., is significantly lower) in the tenecteplase-treated population of subjects than in PATENT Genentech Docket No: P38439-WO the placebo-treated reference population). The NIHSS score may be determined at any time point following administration of tenecteplase to the subject or member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is NIHSS score (e.g., median NIHSS score) at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). NIHSS score may be determined, e.g., as set forth in Table 2. Table 2. National Institutes of Health Stroke Scale (NIHSS) PATENT Genentech Docket No: P38439-WO PATENT Genentech Docket No: P38439-WO PATENT Genentech Docket No: P38439-WO Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment improves the NIHSS score (e.g., median NIHSS score) in the subject or population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., improves the NIHSS score (e.g., median NIHSS score) as determined at about 90 days after the administration of tenecteplase or placebo). In some aspects, the median NIHSS score in the population of subjects is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the median NIHSS score in the reference population, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95- 100% (e.g., is decreased by about 20-80%, 30-70%, or 40-60%). In some aspects, the median NIHSS score in the population of subjects is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, PATENT Genentech Docket No: P38439-WO 85%, 90%, 95%, or 100% relative to the median NIHSS score in the reference population, e.g., is 50-55%, In some aspects, the NIHSS score in the subject is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30- 70%, or 40-60%). In some aspects, the NIHSS score in the subject is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25- 30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80- 85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). Barthel Index (BI) score In some aspects, the clinical outcome is a Barthel Index (BI) score in a subject or the proportion of subjects having a Barthel Index (BI) score of at least 95 in a population of subjects (e.g., the proportion of subjects having a BI score of at least 95 is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). The BI score in the subject or the proportion of subjects having a BI score of at least 95 may be determined at any time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is the BI score in the subject or the proportion of subjects having a BI score of at least 95 at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). BI score may be determined, e.g., as described in Mahoney and Barthel, Maryland State Med Journal, 14: 56-61, 1965, which is incorporated herein by reference in its entirety. Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases the BI score in the subject or the proportion of subjects having a BI score of at least 95 in the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., increases the proportion of subjects having a BI score of at least 95 at about 90 days after the administration of tenecteplase or placebo). PATENT Genentech Docket No: P38439-WO In some aspects, the proportion of subjects with a BI score of at least 95 in the population of subjects is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects with a BI score of at least 95 in the reference population, e.g., is increased by about 1-5%, 5-10%, 10- 15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65- 70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the proportion of subjects with a BI score of at least 95 in the population of subjects is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects with a BI score of at least 95 in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the BI score of the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, increased by about 20-80%, 30-70%, or 40- In some aspects, the BI score of the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). Glasgow Outcome Scale (GOS) score In some aspects, the clinical outcome is good recovery as identified by a Glasgow Outcome Scale (GOS) in a subject or the proportion of subjects with good recovery, as identified by a Glasgow Outcome Scale (GOS) score of 5 in a population of subjects (e.g., the proportion of subjects with good recovery, as identified by a GOS score of 5, is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). The GOS score may be determined at any time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome of good recovery, as identified by a GOS score of 5, is measured at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). GOS score may be determined, e.g., as set forth in Table 3 and / or as described in Jennett and Bond, Lancet, Mar.1; 1(7905): 480-484, 1975, which is incorporated herein by reference in its entirety. PATENT Genentech Docket No: P38439-WO Table 3. Glasgow Outcome Scale (GOS) Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases good recovery, as identified by a GOS score of the subject or the proportion of subjects with good recovery, as identified by a GOS score of 5, in the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., increases good recovery, as identified by a GOS score of the subject or the proportion of subjects with good recovery, as identified by a GOS score of 5, at about 90 days after the administration of tenecteplase or placebo). In some aspects, the proportion of subjects with a GOS score of 5 in the population of subjects is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects with a GOS score of 5 in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15- 20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70- 75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the proportion of subjects with a GOS score of 5 in the population of subjects is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects with a GOS score of 5 in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20- 25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75- 80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the a GOS score of the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40- 60%). PATENT Genentech Docket No: P38439-WO In some aspects, the a GOS score of the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25- 30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80- 85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). Reperfusion In some aspects, the clinical outcome is reperfusion in a subject or the proportion of subjects having reperfusion in a population of subjects (e.g., the proportion of subjects having reperfusion is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). Reperfusion may be assessed at any time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is the reperfusion from the subject or the proportion of subjects having reperfusion at about 24 hours after the administration of tenecteplase or placebo (e.g., 24 hours ± 6 hours, e.g., 24 hours). Reperfusion may be, e.g., a greater than 90% reduction in the volume of lesions having a time-to- maximum of the residue function (Tmax) of more than 6 seconds (Tmax >6s) (i.e., a greater than 90% reduction in Tmax >6s lesion volume) (e.g., a reduction relative to a baseline measurement (e.g., a pre-treatment baseline measurement)). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases reperfusion of the subject or the proportion of subjects in the population of subjects having reperfusion relative to a placebo-treated reference population of subjects having AIS (e.g., increases the proportion of subjects having reperfusion at about 24 hours after the administration of tenecteplase or placebo). In some aspects, the proportion of subjects in the population of subjects having reperfusion is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the proportion of subjects having reperfusion in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the proportion of subjects in the population of subjects having reperfusion is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the proportion of subjects having reperfusion in the reference population, e.g., is increased by 1-5%, 5- 10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the reperfusion from the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is PATENT Genentech Docket No: P38439-WO increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the reperfusion from the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is increased by 1- 5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, or 50-55%. In some embodiments, the reperfusion is reperfusion of ischemic tissue. In some embodiments, the reperfusion remains substantially unchanged in the subject of the population treated with tenecteplase relative to the subjects in the reference population. In some embodiments, the reperfusion remains substantially unchanged in the subject after treatment of tenecteplase compared to the reperfusion before the treatment or without the treatment. Recanalization In some aspects, the clinical outcome is recanalization of one or more occluded vessels in a subject or the proportion of subjects having recanalization of one or more occluded vessels in a population of subjects (e.g., the proportion of subjects having recanalization of one or more occluded vessels is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). Recanalization may be assessed at any time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is the recanalization from the subject or the proportion of subjects having recanalization at about 24 hours after the administration of tenecteplase or placebo (e.g., 24 hours ± 6 hours, e.g., 24 hours). Recanalization may be, e.g., complete recanalization of one or more occluded vessels, as detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases recanalization in the subject or the proportion of subjects in the population of subjects having recanalization relative to a placebo-treated reference population of subjects having AIS (e.g., increases the proportion of subjects having recanalization at about 24 hours after the administration of tenecteplase or placebo). In some embodiments, the subject or each member of the population of subjects has an MCA M1 occlusion before the administration of tenecteplase or placebo, and tenecteplase treatment increases recanalization in the subject or increases the proportion of subjects in the population of subjects having recanalization relative to a placebo-treated reference population of subjects having AIS. PATENT Genentech Docket No: P38439-WO In some aspects, the proportion of subjects in the population of subjects having recanalization is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the proportion of subjects having recanalization in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the proportion of subjects in the population of subjects having recanalization is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the proportion of subjects having recanalization in the reference population, e.g., is increased by 1-5%, 5- 10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some embodiments, the proportion of subjects in the population of subjects having recanalization (e.g., complete recanalization) of one or more occluded vessels is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% higher than the proportion of subjects in the reference population having recanalization (e.g., complete recanalization) of one or more occluded vessels. In some embodiments, the proportion of subjects in the population of subjects having recanalization (e.g., complete recanalization) of one or more occluded vessels is about 13% higher than the proportion of subjects in the reference population having recanalization (e.g., complete recanalization) of one or more occluded vessels. In some aspects, the recanalization in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some aspects, the recanalization in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the treatment of tenecteplase, e.g., is increased by 1- 5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, or 45-50%. In some embodiments, recanalization of one or more occluded vessels in the subject is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% after the administration of tenecteplase, wherein the recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). In some embodiments, the recanalization of one or more occluded vessels in the subject is improved by about 13% after the administration of tenecteplase. Final infarct volume and mean or median final infarct volume In some aspects, the clinical outcome is a final infarct volume of a subject or a mean or median final infarct volume of the population of subjects (e.g., the mean or median final infarct volume is lower (e.g., is significantly lower) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). The final infarct volume or the mean or median final infarct volume may be determined at any appropriate time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is final infarct volume or mean or median final infarct volume at a time between 72 hours and 96 hours after the administration PATENT Genentech Docket No: P38439-WO of tenecteplase or placebo. In some aspects, the clinical outcome is final infarct volume or mean or median final infarct volume at discharge. Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment decreases the final infarct volume of the subject or the mean or median final infarct volume in the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., decreases the mean or median final infarct volume as determined at a time between 72 hours and 96 hours after the administration of tenecteplase or placebo or as determined at discharge). In some aspects, the mean or median final infarct volume in the population of subjects is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the mean or median final infarct volume in the reference population, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25- 30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80- 85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30-70%, or 40-60%). In some aspects, the mean or median final infarct volume in the population of subjects is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the mean or median final infarct volume in the reference population, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30- 35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85- 90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). In some aspects, the final infarct volume in the subject is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by about 1-5%, 5-10%, 10- 15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65- 70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30-70%, or 40-60%). In some aspects, the final infarct volume in the subject is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20- 25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75- 80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). In some embodiments, the subject has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the subject is a member of a population of subjects in which each member of the population of subjects has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the method improves final infarct volume in the population of subjects relative to a reference population of PATENT Genentech Docket No: P38439-WO subjects (e.g., placebo-treated subjects), wherein each member of the reference population has an ICA occlusion or an MCA M1 occlusion. Infarct growth and mean or median infarct growth In some aspects, the clinical outcome is infarct growth of a subject or mean or median infarct growth in a population of subjects (e.g., infarct growth relative to a baseline measurement (e.g., a pre- treatment baseline measurement)) (e.g., the mean or median infarct growth is lower (e.g., is significantly lower) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). The mean or median infarct growth may be determined at any appropriate time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is infarct growth or mean or median infarct growth at a time between 72 hours and 96 hours after the administration of tenecteplase or placebo. In some aspects, the clinical outcome is infarct growth or mean or median infarct growth at discharge. Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment decreases the infarct growth in the subject or the mean or median infarct growth in the population of subjects relative to a placebo-treated reference population of subjects having AIS (e.g., decreases the mean or median infarct growth as determined at a time between 72 hours and 96 hours after the administration of tenecteplase or placebo or as determined at discharge). In some aspects, the mean or median infarct growth in the population of subjects is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the mean or median infarct growth in the reference population, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30-70%, or 40-60%). In some aspects, the mean or median infarct growth in the population of subjects is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the mean or median infarct growth in the reference population, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30- 35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85- 90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). In some aspects, the infarct growth in the subject is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by about 1-5%, 5-10%, 10-15%, PATENT Genentech Docket No: P38439-WO 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30- 70%, or 40-60%). In some aspects, the infarct growth in the subject is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20- 25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75- 80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). In some embodiments, the subject has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the subject is a member of a population of subjects in which each member of the population of subjects has an ICA occlusion or an MCA M1 occlusion. In some embodiments, the method improves mean or median infarct growth in the population of subjects relative to a reference population of subjects (e.g., placebo-treated subjects), wherein each member of the reference population has an ICA occlusion or an MCA M1 occlusion. Planned thrombectomy not performed In some instances, treatment with tenecteplase may obviate mechanical thrombectomy. In some aspects, the clinical outcome is a likelihood of obviating a planned thrombectomy in a subject or the proportion of subjects for which a planned thrombectomy was obviated in a population of subjects (e.g., the proportion of subjects for which a planned thrombectomy was obviated is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). For example, in some aspects, a thrombectomy may be planned for a subject based on the subject’s status prior to the administration of tenecteplase or placebo (e.g., at baseline), but may be found to be unnecessary at a time point following the administration of tenecteplase or placebo (e.g., based on a finding of partial or complete recanalization of the qualifying vessel occlusion or another clinical finding that indicates that the thrombectomy is not needed). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases a likelihood of obviating a planned thrombectomy in the subject or the proportion of subjects for which a planned thrombectomy was not performed (e.g., was obviated) in the population of subjects relative to a placebo-treated reference population of subjects having AIS. In some aspects, the proportion of subjects in the population of subjects for which a planned thrombectomy was not performed is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects for which a planned thrombectomy was not performed in the reference PATENT Genentech Docket No: P38439-WO population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35- 40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90- 95%, or 95-100% e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the proportion of subjects in the population of subjects for which a planned thrombectomy was not performed is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects for which a planned thrombectomy was not performed in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of obviating a planned thrombectomy in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45- 50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of obviating a planned thrombectomy in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55- 60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, a subject for which a thrombectomy was planned was transferred from a non-endovascular capable center (nECC) to an endovascular capable center (ECC) for the planned thrombectomy. In some aspects, the clinical outcome is a likelihood of obviating a planned thrombectomy in a subject who was identified for treatment at an nECC and transferred to an ECC for endovascular therapy or the proportion of subjects who were identified for treatment at an nECC and transferred to an ECC for endovascular therapy, but for whom the planned thrombectomy was not performed, (e.g., was obviated) in a population of subjects, (e.g., the proportion of subjects who were identified for treatment at an nECC and transferred to an ECC for a thrombectomy, but for whom the planned thrombectomy was not performed, is higher in the tenecteplase-treated population of subjects than in the placebo-treated reference population). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprisingadministering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population ofsubjects, wherein the subject or each member of the population of subjects has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases a likelihood of obviating a planned thrombectomy in the subject who was PATENT Genentech Docket No: P38439-WO identified for treatment at an nECC and transferred to an ECC for endovascular therapy or the proportion of subjects who were identified for treatment at an nECC and transferred to an ECC for a thrombectomy, but for whom the planned thrombectomy was not performed, in the population of subjects relative to a placebo-treated reference population of subjects having AIS. In some aspects, the proportion of subjects in the population of subjects who were identified for treatment at an nECC and transferred to an ECC for a thrombectomy, but for whom the planned thrombectomy was not performed, is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of such subjects in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20- 80%, 30-70%, or 40-60%). In some aspects, the proportion of subjects in the population of subjects who were identified for treatment at an nECC and transferred to an ECC for a thrombectomy, but for whom the planned thrombectomy was not performed, is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of such subjects in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of obviating a planned thrombectomy in the subject who was identified for treatment at an nECC and transferred to an ECC for endovascular therapy is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55- 60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of obviating a planned thrombectomy in the subject who was identified for treatment at an nECC and transferred to an ECC for endovascular therapy is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5- 10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60- increased PATENT Genentech Docket No: P38439-WO Endovascular therapy In some instances, treatment with tenecteplase reduces the extent to which endovascular therapy is needed in a subject (e.g., reduces the number of passes required with an endovascular therapy device, e.g., reduces the likelihood that the subject will require multiple-pass thrombectomy and / or increases the likelihood that the subject will require only single-pass thrombectomy). In some aspects, the clinical outcome is a likelihood of requiring only one pass with an endovascular therapy device in a subject or the proportion of subjects for which only one pass with an endovascular therapy device is required (e.g., only one pass is required to achieve recanalization (e.g., complete recanalization) of one or more occluded vessels in a population of subjects (e.g., the proportion of subjects for only one pass with an endovascular therapy device is required is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases a likelihood of requiring only one pass with an endovascular therapy device in the subject or the proportion of subjects for which only one pass with an endovascular therapy device is required in the population of subjects relative to a placebo-treated reference population of subjects having AIS. In some aspects, the proportion of subjects in the population of subjects for which only one pass with an endovascular therapy device is required is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects for which only one pass with an endovascular therapy device is required in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15- 20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70- 75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the proportion of subjects in the population of subjects for which only one pass with an endovascular therapy device is required is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects for which only one pass with an endovascular therapy device is required in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of requiring only one pass with an endovascular therapy device in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, PATENT Genentech Docket No: P38439-WO 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of requiring only one pass with an endovascular therapy device in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45- 50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). Overall survival rate In some aspects, the clinical outcome is overall survival (OS) rate (e.g., the OS rate is higher (e.g., is significantly higher) in the tenecteplase-treated subject or the tenecteplase-treated population of subjects than in the placebo-treated reference population). OS rate may be assessed at any time point following administration of tenecteplase to the subject or the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is OS rate at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). In some aspects, the clinical outcome is OS rate at about 30 days after the administration of tenecteplase or placebo (e.g., 30 days ±7 days, e.g., 30 days). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprisingadministering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population ofsubjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases the OS rate in the subject or the population of subjects relative to a placebo- treated reference population of subjects having AIS (e.g., increases the OS rate at 30 days or 90 days after the administration of tenecteplase or placebo). In some aspects, the OS rate in the population of subjects is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 155%, 160%, 165%, 170%, 175%, 180%, 185%, 190%, 195%, or 200% relative to the OS rate in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, 95-100%, 100-105%, 105-110%, 110-115%, 115-120%, 120-125%, 125-130%, 130-135%, 135-140%, 140-145%, 145-150%, 150-155%, 155-160%, 160-165%, 165-170%, 170- 175%, 175-180%, 180-185%, 185-190%, 190-195%, or 195-200% (e.g., is increased by about 20- PATENT Genentech Docket No: P38439-WO 80%, 30-70%, or 40-60%). In some aspects, the OS rate in the population of subjects is increased by more than about 200% relative to the OS rate in the reference population. In some aspects, the OS rate in the population of subjects is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 155%, 160%, 165%, 170%, 175%, 180%, 185%, 190%, 195%, or 200% relative to the OS rate in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, 95-100%, 100-105%, 105-110%, 110-115%, 115-120%, 120-125%, 125-130%, 130-135%, 135- 140%, 140-145%, 145-150%, 150-155%, 155-160%, 160-165%, 165-170%, 170-175%, 175-180%, 180-185%, 185-190%, 190-195%, or 195-200% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the OS rate in the population of subjects is increased by more than 200% relative to the OS rate in the reference population. In some aspects, the OS rate in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 155%, 160%, 165%, 170%, 175%, 180%, 185%, 190%, 195%, or 200% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 195%, or 195-200% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the OS rate in the subject is increased by more than about 200% relative to the OS rate prior to (or without) the treatment. In some aspects, the OS rate in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 155%, 160%, 165%, 170%, 175%, 180%, 185%, 190%, 195%, or 200% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60- 65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, 95-100%, 100-105%, 105-110%, 110- 115%, 115-120%, 120-125%, 125-130%, 130-135%, 135-140%, 140-145%, 145-150%, 150-155%, 155-160%, 160-165%, 165-170%, 170-175%, 175-180%, 180-185%, 185-190%, 190-195%, or 195- 200% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the OS rate in the subject is increased by more than 200% relative to the OS rate prior to (or without) the treatment. PATENT Genentech Docket No: P38439-WO Angiographic reperfusion following angiographic procedure In some aspects, the clinical outcome is angiographic reperfusion after angiographic procedure in a subject or the proportion of subjects having angiographic reperfusion at completion of an angiographic procedure in a population of subjects (e.g., the proportion of subjects having angiographic reperfusion at completion of an angiographic procedure is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). Angiographic reperfusion may be, e.g., a thrombolysis in cerebral infarction (TICI) scale score of 2b or 3 (Table 4). Table 4 presents the Modified Thrombolysis in Cerebral Infarction (TICI) scale as it is currently adopted for emergent large vessel occlusion (ELVO) (Spiotta et al., J Neurointerv Surg., 11(3): 213-214, 2019, which is incorporated herein by reference in its entirety). Table 4. Modified Thrombolysis in Cerebral Infarction (TICI) Scale Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment increases angiographic reperfusion after angiographic procedure in the subject or the proportion of subjects in the population of subjects having angiographic reperfusion at completion of an angiographic procedure relative to a placebo-treated reference population of subjects having AIS. In some aspects, the proportion of subjects in the population of subjects having angiographic reperfusion at completion of an angiographic procedure is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects having angiographic reperfusion at completion of an angiographic procedure in the reference population, e.g., is increased by about 1-5%, 5-10%, 10- 15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65- 70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). PATENT Genentech Docket No: P38439-WO In some aspects, the proportion of subjects in the population of subjects having angiographic reperfusion at completion of an angiographic procedure is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects having angiographic reperfusion at completion of an angiographic procedure in the reference population, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). In some aspects, the angiographic reperfusion after angiographic procedure in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45- 50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the angiographic reperfusion after angiographic procedure in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55- 60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). Readmission In some aspects, the clinical outcome is a likelihood of being re-admitted to a hospital within 30 days of discharge in a subject or the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in a population of subjects (e.g., the proportion of subjects who are re-admitted to a hospital within 30 days of discharge is lower (e.g., is significantly lower) in the tenecteplase- treated population of subjects than in the placebo-treated reference population). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or to each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase treatment decreases a likelihood of being re-admitted to a hospital within 30 days of discharge in the subject or the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in the population of subjects relative to a placebo-treated reference population of subjects having AIS. In some aspects, the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in the population of subjects is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in PATENT Genentech Docket No: P38439-WO the reference population, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25- 30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80- 85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30-70%, or 40-60%). In some aspects, the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in the population of subjects is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in the reference population, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30- 35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85- 90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of being re-admitted to a hospital within 30 days of discharge in the subject is decreased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40- 45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by about 20-80%, 30-70%, or 40-60%). In some aspects, the likelihood of being re-admitted to a hospital within 30 days of discharge in the subject is decreased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is decreased by 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45- 50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is decreased by 20-80%, 30-70%, or 40-60%). Neuro-QoL score In some aspects, the clinical outcome is Quality of Life in Neurological Disorders (Neuro-QoL) score in a subject or mean Quality of Life in Neurological Disorders (Neuro-QoL) score in a population of subjects (e.g., the mean Neuro-QoL score is higher (e.g., is significantly higher) in the tenecteplase-treated population of subjects than in the placebo-treated reference population). The Neuro-QoL score may be determined at any time point following administration of tenecteplase to the subject or to the member of the population of subjects or administration of the placebo to a member of the reference population. In some aspects, the clinical outcome is the mean Neuro-QoL score at about 90 days after the administration of tenecteplase or placebo (e.g., 90 days ±14 days, e.g., 90 days). Accordingly, in some aspects, the present disclosure provides a method for treating AIS in a subject or population of subjects (e.g., a population of human subjects), the method comprising administering tenecteplase (e.g., TNKASE®) to the subject or each member of the population of subjects, wherein the subject or each member of the population of subjects shows or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject or to each member of the population of subjects in a late window for treatment (e.g., at a time between 4.5 and 24 hours after onset of AIS); and wherein tenecteplase PATENT Genentech Docket No: P38439-WO treatment increases the Neuro-QoL score in the subject or the mean Neuro-QoL score in the population of subjects relative to a placebo-treated reference population of subjects having AIS. In some aspects, the mean Neuro-QoL score in the population of subjects is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the mean Neuro-QoL score in the reference population, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40- 45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30-70%, or 40-60%). In some aspects, the mean Neuro-QoL score in the population of subjects is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the mean Neuro-QoL score in the reference population, e.g., is increased 50-55%, increased In some aspects, the Neuro-QoL score in the subject is increased by at least about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by about 1-5%, 5-10%, 10-15%, 15-20%, 20-25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75-80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by about 20-80%, 30- 70%, or 40-60%). In some aspects, the Neuro-QoL score in the subject is increased by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% after the treatment of tenecteplase, e.g., is increased by 1-5%, 5-10%, 10-15%, 15-20%, 20- 25%, 25-30%, 30-35%, 35-40%, 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75%, 75- 80%, 80-85%, 85-90%, 90-95%, or 95-100% (e.g., is increased by 20-80%, 30-70%, or 40-60%). I. Safety outcomes In some aspects, the incidence of symptomatic intracranial hemorrhage (sICH) (e.g., the incidence of sICH within 36 hours of administration of tenecteplase (e.g., TNKASE®) or placebo) is not increased in the subject or the population of subjects relative to the placebo-treated reference population (e.g., the incidence of sICH is substantially the same in the population of subjects and the placebo-treated reference population). In some aspects, the incidence or severity of adverse events (e.g., adverse events as defined by the International Council on Harmonisation guideline for Good Clinical Practice) is not increased in subject or in the population of subjects relative to the placebo-treated reference population (e.g., the incidence or severity of adverse events is substantially the same in the population of subjects and the placebo-treated reference population). In some aspects, the mortality rate (e.g., the mortality rate in the 30 days following the administration of tenecteplase or placebo or the mortality rate in the 90 days following the administration of tenecteplase or placebo) is not increased in the subject or in the population of PATENT Genentech Docket No: P38439-WO subjects relative to the placebo-treated reference population (e.g., the mortality rate is substantially the same in the population of subjects and the placebo-treated reference population). In some aspects, the proportion of subjects with parenchymal hematoma type 2 (PH2) is not increased in the subject or in the population of subjects relative to the placebo-treated reference population (e.g., the proportion of subjects with PH2 is substantially the same in the population of subjects and the placebo-treated reference population). In some aspects, TNKase treatment may not be used in the following conditions due to an increased risk of bleeding: active internal bleeding, history of stroke, brain or spinal surgery or a serious head injury within 2 months, brain tumor, an abnormal connection between veins and arteries in the brain or spinal cord, or abnormal bulge in the wall of an artery, problems with blood clotting, and severe uncontrolled high blood pressure. V. PHARMACEUTICAL COMPOSITIONS, FORMULATIONS, AND KITS Tenecteplase (e.g., TNKASE®) may be used in a pharmaceutical composition or formulation. Pharmaceutical compositions and formulations of tenecteplase can be prepared by mixing tenecteplase having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington’s Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), e.g., in the form of lyophilized formulations or aqueous solutions. An exemplary tenecteplase formulation is provided in the TNKASE® (tenecteplase) United States Package Insert. Tenecteplase may be formulated as a sterile, lyophilized powder in a 50-mg vial under partial vacuum, to be reconstituted in 10 mL sterile water for injection. In some aspects, a vial of tenecteplase nominally contains 52.5 mg tenecteplase, 0.55 g L-Arginine, 0.17 g phosphoric acid, and 4.3 mg polysorbate 20, which includes a 5% overfill. A tenecteplase formulation may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide an additional therapeutic agent. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended. The disclosure provides articles of manufacture and kits that include tenecteplase for treating an acute ischemic stroke (AIS) in a subject in need thereof according to any of the methods described herein. In some instances, the article of manufacture or kit further comprises package insert comprising instructions for using the tenecteplase to treat AIS in a subject in need thereof. In one aspect, a kit is provided comprising tenecteplase for treating a subject having an AIS according to any of the methods described herein. In some instances, the kit further comprises a package insert comprising instructions for using tenecteplase to treat AIS in a subject in need thereof (e.g., wherein the package insert comprises instructions for using tenecteplase to treat a subject having an AIS, wherein the subject has been determined to have salvageable brain tissue or a salvageable brain pattern, and wherein the administration of tenecteplase is to occur between 4.5 and 24 hours after AIS symptom onset). For example, in one aspect, provided herein is a kit comprising tenecteplase for treating a subject having an AIS, wherein the subject has been determined to have PATENT Genentech Docket No: P38439-WO salvageable brain tissue or a salvageable brain pattern, and wherein the administration of tenecteplase is to occur between 4.5 and 24 hours after AIS symptom onset. In some aspects, the tenecteplase is formulated for intravenous administration, e.g., at a dose of 0.25 mg / kg. Suitable containers for tenecteplase include, for example, bottles, vials, bags and syringes. The container may be formed from a variety of materials such as glass, plastic (such as polyvinyl chloride or polyolefin), or metal alloy (such as stainless steel or hastelloy). In some instances, the container holds the formulation and the label on, or associated with, the container may indicate directions for use. The article of manufacture or kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. In some instances, the article of manufacture further includes one or more of another agent. Suitable containers for the one or more agents include, for example, bottles, vials, bags and syringes. Any of the articles of manufacture or kits may include instructions to administer tenecteplase to a subject in accordance with any of the methods described herein. VI. EXAMPLES The following are examples of the methods of the disclosure. It is understood that various other embodiments may be practiced, given the general description provided above. Example 1. A Phase III, Prospective, Double-Blind, Randomized, Placebo Controlled Trial of Thrombolysis in Imaging-Eligible, Late-Window Patients to Assess the Efficacy and Safety of Tenecteplase (Timeless) ML40787 is a Phase III, prospective, double-blind, randomized, placebo-controlled clinical trial that evaluates the efficacy and safety of tenecteplase compared with placebo in patients with acute ischemic stroke (AIS) who meet predefined imaging criteria, i.e., have evidence of salvageable tissue on their baseline computed tomography perfusion (CTP) scan or magnetic resonance imaging (MRI) who present in the 4.5- to 24-hour time window with an internal carotid artery (ICA) or middle cerebral artery (MCA; M1 or M2) occlusion. Specific objectives and corresponding endpoints for the study are outlined in Table 5, below. The study design is shown in Fig.1. Table 5. Objectives and Endpoints of ML40787 Study PATENT Genentech Docket No: P38439-WO PATENT Genentech Docket No: P38439-WO A. Study design Patients who meet the inclusion criteria (see Example 2) are randomized to receive tenecteplase (0.25 mg / kg, maximum 25 mg) or placebo, both administered as a single bolus injection over 5 seconds. All patients receive standard-of-care therapy according to American Heart Association / American Stroke Association (AHA / ASA) Stroke Early Management Guidelines (2018). For patients with internal carotid artery (ICA) / M1 occlusions, this includes adjuvant endovascular therapy following administration of the study drug (tenecteplase or placebo) if criteria, as stipulated in the AHA / ASA guidelines, are met. Per guideline recommendations, patients with M2 occlusions generally do not undergo endovascular therapy following treatment with the study drug (tenecteplase or placebo). Study drug administration is recommended to occur before the start of endovascular therapy (defined as groin puncture). If it appears that it will be challenging to administer study drug prior to the femoral groin puncture for a planned thrombectomy, it is recommended that the patient not be randomized. However, if the patient has already been randomized, and due to unforeseen circumstances the drug cannot be administered prior to groin puncture for the planned thrombectomy, the drug must be administered as soon as possible and prior to manipulation of the clot. To determine eligibility for randomization, all patients will undergo multimodal CT or MRI at baseline. Only patients with a vessel occlusion (ICA or MCA) and penumbral tissue are randomized. 5DQGRPL]DWLRQ^LV^VWUDWLILHG^E\^DJH^^^^^^YV^^!^^^\HDUV^^^W\SH^RI^RFFOXVLRQ^^,&$^0^^YV^^0^^^ baseline National Institutes of HealtK^6WURNH^6FDOH^^1,+66^^VFRUH^^^^^^YV^^!^^^^^DQG^UDQGRPL]DWLRQ^ site (endovascular capable center (ECC) vs. non-endovascular capable center (nECC)). The primary goal of the trial is to compare the effect of treatment with tenecteplase vs. placebo and standard-of- care on 90-day functional outcomes (i.e., ordinal modified Rankin scale (mRS) scores) in patients who present in the 4.5- to 24-hour time window with an ICA or MCA (M1, M2) occlusion and evidence of target mismatch on multimodal CT or MRI of the brain. U.S. Food and Drug Administration (FDA)- approved and validated perfusion imaging software for determination of core volumes is used. Both patients transferred from an nECC as well as patients admitted directly to an ECC are eligible for the study. PATENT Genentech Docket No: P38439-WO Patients undergo two follow-up MRI scans. Patients who cannot undergo an MRI undergo a multimodal CT at the first follow-up and a non-contrast CT at the second follow-up. The first follow-up scan is obtained at approximately 24 hours (±6 hours) after randomization and includes an assessment of recanalization and reperfusion, per standard-of-care. The second MRI is obtained between 72 to 96 hours after randomization for assessment of final infarct volumes. All patients are evaluated using mRS at discharge or Day 5 (whichever occurs earlier), Day 30 (±7 days), and Day 90 (±7 days) after randomization for clinical outcome evaluation. The primary analysis is to compare the efficacy of tenecteplase versus placebo in all patients at Day 90, as assessed by the mRS score with an ordinal analysis. As a key prespecified subgroup analysis, the trial also assesses the effect of tenecteplase separately in patients with ICA / M1 and in patients with M2 occlusions. Number of Patients Approximately 456 patients with AIS are enrolled in this study at approximately 90 sites (consisting of both ECCs and nECCs) primarily in the U.S. and Canada. End of Study and Length of Study The end of this study is defined as the date when the last patient, last visit (LPLV) occurs or the date at which the last data point required for safety follow-up is received from the last patient, whichever occurs later. The end of the study is expected to occur 90 days (±14 days) after randomization of the last patient in (LPI) the study. The total length of the study, from screening of the first patient to LPLV, is expected to be approximately 3 years. B. Rationale for study design The ML40787 study assesses whether treatment with tenecteplase 0.25 mg / kg (maximum dose of 25 mg) and standard-of-care results in improved clinical outcomes (as assessed by mRS) when compared with standard-of-care alone.
[0002] PATENT Genentech Docket No: P38439-WO Study rationale Recent endovascular stroke trials have demonstrated benefit from endovascular therapy in patients with middle cerebral artery (MCA) or internal carotid artery (ICA) occlusions treated within 6 hours of symptom onset (SWIFT PRIME (Saver et al., Int J Stroke, 10(3): 439-448, 2015), MR CLEAN (Berkhemer et al., N Engl J Med, 372: 1009-1018, 2015), EXTEND-IA-TNK (Sacks et al., Int J Stroke, 13(6): 612-632, 2018), REVASCAT (Jovin et al., N Engl J Med, 372: 2296-2307, 2015), and ESCAPE (Goyal et al., N Engl J Med, 372: 1019-1030, 2015)). Two subsequent trials-- DEFUSE 3 (Albers et al., N Engl J Med, 378: 708-718, 2018) and DAWN (Nogueira et al., N Engl J Med, 378: 11-21, 2017) -- have shown benefit on computed tomography (CT) or MRI perfusion imaging in patients who were treated up to 24 hours after stroke with endovascular therapy and who had evidence of a clinical / ischemic core mismatch (i.e., mismatch between the severity of the clinical deficit and the infarct volume, as defined by Nogueira et al., N Engl J Med, 378: 11-21, 2017) or a perfusion / core mismatch (i.e., initial infarct volume (ischemic core) of less than 70 mL, a ratio of volume of ischemic tissue to initial infarct volume of 1.8 or more, and an absolute volume of potentially reversible ischemia (penumbra) of 15 mL or more (Albers et al., N Engl J Med, 378: 708-718, 2018)). American Heart Association / American Stroke Association (AHA / ASA) 2018 clinical guidelines recommend that patients who present to the hospital in the early time window (within 4.5 hours) and meet criteria for intravenous (IV) alteplase are treated with alteplase prior to endovascular therapy. The advantage of alteplase-induced recanalization is that it can often be achieved more quickly than endovascular recanalization and can be initiated in any emergency room, whereas endovascular therapy often requires transfer to a hospital with neuro-endovascular capability. According to the AHA / ASA clinical guidelines (2018), in selected acute stroke patients within 6-16 hours of last-known well time who have a large vessel occlusion in the anterior circulation and meet other DEFUSE 3 or DAWN (Albers et al., N Engl J Med, 378: 708-718, 2018; Nogueira et al., N Engl J Med, 378: 11-21, 2017) eligibility criteria, mechanical thrombectomy is recommended; in selected acute stroke patients within 6-24 hours of last-known well time who have large vessel occlusion in the anterior circulation and meet other DAWN eligibility criteria, mechanical thrombectomy with a stent retriever is reasonable. While treatment with thrombolytics is standard-of-care for patients arriving within 0 to 4.5 hours, thrombolytics have not been shown to benefit patients who present beyond this time window (Emberson et al., The Lancet, 384(9958): 1929-1935, 2014). Consequently, only a few patients in the recently completed late-window endovascular trials (DEFUSE 3 and DAWN) received IV thrombolytics. Whether a ‘‘bridging’’ thrombolysis approach comprising treatment with a thrombolytic agent outside of established treatment windows is beneficial compared with thrombectomy alone, when neurointervention is immediately available, has been questioned and is now the subject of randomized trials. However, for many institutions, thrombectomy involves transfer to an external hospital. There are also situations in which a planned thrombectomy is delayed or the neuro- interventionist is either unable to gain access to the cerebral circulation or unable to completely remove the thrombus. Improved IV thrombolysis options may increase the proportion of patients with PATENT Genentech Docket No: P38439-WO early reperfusion prior to thrombectomy. This would have substantial clinical benefits and likely improve patient outcomes, and may reduce costs given the strong relationship between time to reperfusion and disability as well as potential reductions in the requirement for resource-intensive thrombectomy. Tenecteplase is a three-point-mutated variant of alteplase, bioengineered to achieve longer half-life, higher fibrin specificity, and increased resistance toward plasminogen activator inhibitor-1 (Logallo et al., CNS Drugs, 29: 811-818, 2015). In animal and in vitro models, tenecteplase has shown a better thrombolytic profile and potency compared with alteplase (Benedict et al., Circulation, 92: 3032-3040, 1995). Due to the biochemical changes, tenecteplase can be administered as a 5- second bolus as opposed to alteplase, which is administered as a 1-hour infusion. The ease of administration of tenecteplase is of particular importance for patients who may need to be transported to another hospital for endovascular treatment. A meta-analysis has suggested a lower rate of sICH with 0.25 mg / kg tenecteplase compared with alteplase (Bivard et al., Circulation, 135(5), 440-448, 2017). In a study by Sacks et al. (Int J Stroke, 13(6): 612-632, 2018), 0.25 mg / kg tenecteplase was associated with higher recanalization rates than alteplase. Consequently, favorable functional outcomes have been reported among AIS patients treated with tenecteplase compared with those who were treated with alteplase. In the present trial, the goal is to determine if pre-treatment with an IV thrombolytic (tenecteplase) increases the proportion of recanalization and results in good clinical outcomes. The trial evaluates whether treatment with IV tenecteplase, administered between 4.5 and 24 hours of a patient’s last-known well time (DEFUSE 3 and DAWN (Albers et al., N Engl J Med, 378: 708-718, 2018; Nogueira et al., N Engl J Med, 378: 11-21, 2017)) is superior to placebo in patients who have a vessel occlusion and evidence of salvageable tissue on their baseline CTP or MRI. Placebo is being used as the comparator because a thrombolytic is only U.S. Food and Drug Administration (FDA)-approved in the United States for use out to 3 hours, and the standard-of-care guidelines support use only out to 4.5 hours. Rationale for control group All patients are randomized first to receive tenecteplase 0.25 mg / kg (maximum of 25 mg) versus placebo, and then endovascular eligible patients receive mechanical thrombectomy. According to the guidelines, other than endovascular therapy, which has its limitations (i.e., it cannot always be guaranteed that a patient in the 4.5- to 24-hour time window with a mismatch will be eligible for such treatment, that access can be obtained, or that the procedure will be a success), there are no treatment options for this patient population. C. Background Tenecteplase Tenecteplase (e.g., TNKASE®) is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin. In vitro studies demonstrated that in the presence of fibrin, tenecteplase conversion of plasminogen to plasmin is increased relative to its PATENT Genentech Docket No: P38439-WO conversion in the absence of fibrin. This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen compared with a molecule lacking this property, which could potentially decrease the incidence of bleeding. Acute myocardial infarction Following administration of 30, 40, or 50 mg of tenecteplase for use in mortality reduction associated with acute myocardial infarction (AMI), decreases in circulating fibrinogen (4%-15%) and plasminogen (11%-24%) were observed (Tenecteplase U.S. Package Insert (USPI)). The clinical significance of fibrin specificity on safety (e.g., bleeding) or efficacy has not been established. Biological potency is determined by an in vitro clot lysis assay and is expressed in tenecteplase- specific units. The specific activity of tenecteplase has been defined as 200 units / mg. In patients with AMI, tenecteplase administered as a single bolus exhibits a biphasic disposition from the plasma. Tenecteplase was cleared from the plasma with an initial half-life of 20 to 24 minutes. The terminal phase half-life of tenecteplase was 90 to 130 minutes. In 99 of 104 patients treated with tenecteplase, mean plasma clearance ranged from 99 to 119 mL / min (Tenecteplase USPI). Example 2. Materials and Methods A. Patients Approximately 456 patients with AIS are enrolled in the ML40787 study at approximately 90 sites (consisting of both endovascular capable centers (ECCs) and non-endovascular capable centers (nECCs)) primarily in the U.S. and Canada. Inclusion and exclusion criteria for the study are provided below. B. Inclusion criteria ^^^$JH^^^^^^\HDUV^ 2. Acute ischemic stroke (AIS) symptom onset within 4.5 to 24 hours. Stroke onset is defined as the time the patient was last known to be at their neurologic baseline. (Wake-up strokes are eligible if they present within the 4.5- to 24-hour time limits of last known well.) All study-related treatment needs to be initiated within 24 hours. 4. Signs and symptoms consistent with the diagnosis of an acute anterior circulation ischemic stroke involving occlusion of the internal carotid artery (ICA), M1, or M2 vessels. 5. Functionally independent (modified Rankin scale (mRS) score 0-2) prior to stroke onset. 6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ^^^^DQG^WKDW^UHPDLQV^^^^^ immediately prior to randomization. 7. Neuroimaging: ICA or M1, M2 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions) by magnetic resonance angiography (MRA) or computed tomography angiography (CTA) AND target mismatch profile on computed tomography perfusion (CTP) or magnetic resonance (MR) perfusion (MRP) (ischemic core volume <70 mL, mismatch ratio is ^^^^^^DQG^PLVPDWFK^YROXPH^LV^^^^^^P / ^^ PATENT Genentech Docket No: P38439-WO – The mismatch volume is determined by FDA-approved imaging software in real time based on the difference between the ischemic core lesion volume and the time to maximum of the residue function (Tmax) >6s lesion volume. If both a CTP and a multimodal MRI scan are performed prior to enrollment, the later of the 2 scans is assessed to determine eligibility. For patients screened with MRA, only an intracranial MRA is required (cervical MRA is not required). Cervical and intracranial CTA are typically obtained simultaneously in patients screened with CTA, but only the intracranial CTA is required for enrollment. – Enrollment of patients with an ICA (including proximal and tandem ICA occlusions) is capped at no more than 15% of the target study population. Alternative neuroimaging: – If CTA (or MRA) is technically inadequate: Tmax >6s perfusion deficit consistent with an ICA or 0^^^0^^RFFOXVLRQ^$1'^WDUJHW^PLVPDWFK^SURILOH^^LVFKHPLF^FRUH^YROXPH^^^^^P / ^^PLVPDWFK^UDWLR^^^^^^^ DQG^PLVPDWFK^YROXPH^^^^^^P / ^DV^GHWHUPLQHG^E\^5$3,'^VRIWZDUH^^ – If MRP is technically inadequate: ICA or M1, M2 occlusion by MRA AND diffusion-weighted LPDJLQJ^^':,^^OHVLRQ^YROXPH^^^^^^P / ^IRU^DQ^0^^RU^,&$ RFFOXVLRQ^DQG^^^^^^P / ^IRU^DQ^0^^RFFOXVLRQ^^^,I^ MRA is technically inadequate, a CTA can be used if performed within 60 minutes prior to the MRI. Carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions. – If CTP is technically inadequate: Patient can be screened with MRI and randomized if neuroimaging criteria are met. 8. Ability to comply with the study protocol, in the investigator’s judgment C. Exclusion criteria Patients who meet any of the following criteria are excluded from study entry: General exclusion criteria 1. Current participation in another investigational drug or device study. 2. Known hypersensitivity or allergy to any ingredients of tenecteplase. 3. Active internal bleeding. 4. Known bleeding diathesis. 5. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with international normalised ratio (INR) > 1.7. 6. Use of one of the following new oral anticoagulants within the last 48 hours: dabigatran, rivaroxaban, apixaban, and edoxaban. 7. Treatment with a thrombolytic within the last 3 months prior to randomization. 8. Intracranial neoplasm (except small meningioma), arteriovenous malformation, or aneurysm. Any patient with an aneurysm located anywhere where a catheter or wire may be used in the thrombectomy procedure should be excluded. Additionally, patients with proximally thrombosed aneurysms suspected to be the mechanism of thromboembolism of the affected vascular territory should not be considered for enrollment due to the need for additional surgical or endovascular treatment that may require additional antithrombotic therapy. PATENT Genentech Docket No: P38439-WO Aneurysms located elsewhere in the intracranial vasculature do not constitute an exclusion criterion per se, subject to the standards of care and the discretion of the treating physician. Additionally, previously treated intracranial aneurysms are not a criterion for exclusion, although, patients who underwent intracranial surgery within 2 months of screening are excluded. 9. Seizures at stroke onset if it precludes obtaining an accurate baseline NIHSS score. 10. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluation. COVID-19 positive and / or suspected (i.e., symptomatic) patients are not eligible unless previously tested positive for COVID-19 AND have been asymptomatic at a minimum 10 days from time of screening. 11. Severe, uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure > 110 mmHg). 12. For patients with suspected coagulopathy, platelet count must be checked prior to randomization and patient is excluded if baseline platelet count <100,000 / µL. 13. Baseline blood glucose >400 mg / dL (22.20 mmol / L). 14. Baseline blood glucose <50 mg / dL (2.78 mmol / L) needs to be normalized prior to randomization. 15. Clot retrieval attempted using a neurothrombectomy device prior to randomization. 16. Intracranial or intraspinal surgery or trauma within 2 months. 17. Other serious, advanced, or terminal illness with life expectancy less than 6 months (investigator judgment). 18. History of acute ischemic stroke in the last 90 days. 19. History of hemorrhagic stroke. 20. Presumed septic embolus; suspicion of bacterial endocarditis. 21. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed. 22. Pregnant. Imaging exclusion criteria 23. Unable to undergo a contrast brain perfusion scan with either MRI or CT. 24. Extensive early ischemic change (hypodensity) on non-contrast CT estimated to be >1 / 3 MCA territory, or significant hypodensity outside the Tmax >6s perfusion lesion that invalidates mismatch criteria (if patient is enrolled based on CT perfusion criteria). 25. Significant mass effect. 26. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA / MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion). 27. Evidence of intracranial tumor (except small meningioma) acute intracranial hemorrhage, neoplasm, or arteriovenous malformation. PATENT Genentech Docket No: P38439-WO D. Method of treatment assignment and blinding Treatment assignment Patients meeting all eligibility criteria are randomized 1:1 to receive a single bolus injection of tenecteplase or placebo over 5 seconds. Patients should be treated as soon as possible after randomization. Patients are considered enrolled in the study once they have been randomized. 5DQGRPL]DWLRQ^LV^VWUDWLILHG^E\^DJH^^^^^^YV^^!^^^\HDUV^RI^DJH^^^W\SH^RI^RFFOXVLRQ^^,&$^0^^YV^^ M2), baseline NIHSS scorH^^^^^^YV^^!^^^^^DQG^UDQGRPL]DWLRQ^VLWH^^(&&^YV^^Q(&&^^^^3HUPXWHG^EORFN^ randomization is used to achieve the balance of treatment arm assignments within each randomization stratum. Treatment blinding and unblinding Study site personnel and patients are blinded to treatment assignment during the study. E. Study treatment and other treatments relevant to the study design The investigational medicinal product (IMP) for the ML40787 study is tenecteplase. Tenecteplase and placebo are supplied as a sterile, lyophilized powder in a 50-mg vial under partial vacuum. Sites provide the diluent, 10 mL sterile water for injection. Tenecteplase is for IV administration only. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose is administered over 5 seconds based on patient weight. Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard-of-care guidelines support use out to 4.5 hours. F. Concomitant therapy Concomitant therapy consists of any medication (e.g., prescription drugs, over-the-counter drugs, vaccines (including COVID-19 vaccines), herbal or homeopathic remedies, nutritional supplements) used by a patient in addition to protocol-mandated treatment from 7 days prior to initiation of study drug to the study completion / discontinuation visit. All such medications should be reported to the investigator. Patients enrolled in the trial cannot receive intra-arterial thrombolytic agents or intracranial stenting. Devices used during endovascular procedures should be used according to the product instructions for use. Cautionary therapy Formal interaction studies of tenecteplase with other drugs have not been performed. Patients studied in clinical trials of tenecteplase were routinely treated with heparin and aspirin. Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and glycoprotein (GP) IIb / IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after tenecteplase therapy. The investigator should PATENT Genentech Docket No: P38439-WO consult the prescribing information when determining whether a concomitant medication can be safely administered with study treatment. Prohibited therapy Use of the following concomitant therapies is prohibited as described below: Ɣ Investigational therapy (other than protocol-mandated study treatment) is prohibited within 30 days prior to initiation of study treatment, during study treatment, and until the patient’s last study assessment. Ɣ Oral or parenteral anticoagulants are prohibited for the first 24 hours after treatment with study drug, excluding (1) prophylactic doses, if administered per institutional practice and (2) low doses of IV heparin during the thrombectomy procedure, if this practice is considered standard-of- care for patients who have recently received an intravenous thrombolytic at the treating institution. Ɣ Any additional thrombolytic is prohibited for the first 90 days after treatment with study drug with the exception of CATHFLO® ACTIVASE®, if needed for central venous catheter occlusion management. Ɣ Anti-platelet agents are prohibited for 24 hours after the study drug administration. o If the patient has a cervical ICA occlusion, they may require a cervical angioplasty. Stenting the patient is strongly discouraged because of the need for dual anti-platelet therapy. However, if the vessel collapses after the angioplasty, then there is no choice but to stent, which would require dual anti-platelet therapy. o According to the American Heart Association (AHA) Guidelines, the recommendation for use of aspirin (for non-tissue plasminogen activator (tPA) patients) is to administer within 24-48 hours: this is compatible with waiting for 24 hours, even in participants receiving placebo. G. Study assessments Study assessments are described below. All activities must be performed and documented for each patient. Patients are monitored for safety and tolerability throughout the study. Medical history, concomitant medication, and demographic data Medical history, including clinically significant diseases, surgeries, cancer history (including prior cancer therapies and procedures), reproductive status, smoking history, and use of alcohol and drugs of abuse, is recorded at baseline. In addition, all medications (e.g., prescription drugs, over- the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by the patient within 7 days prior to initiation of study treatment are recorded. Demographic data include age, sex, self-reported race / ethnicity, and veteran status. Vital signs Vital signs include measurements of respiratory rate, pulse rate, and systolic and diastolic blood pressure, and temperature. Temperature is required prior to randomization and will be performed with subsequent frequency per standard-of-care (SOC). The frequency of respiratory rate, PATENT Genentech Docket No: P38439-WO pulse rate, and systolic and diastolic blood pressure measurements should reflect post-IV thrombolytic monitoring in AIS per SOC. Modified Rankin Scale A pre-stroke modified Rankin scale (mRS) score (Table 1) is estimated at baseline. At discharge or day 5 after examination (whichever occurs earlier), at 30 days (±7 days) after randomization, and at 90 days (±7 days) after randomization, patients are evaluated using mRS, preferably in the clinic. If an in-person visit is not feasible, the patient can be evaluated by telephone. National Institutes of Health Stroke Scale Formal stroke scores or scales, such as the NIHSS (Table 2), may be performed rapidly, have demonstrated utility, and may be administered by a broad spectrum of healthcare providers with accuracy and reliability. Use of a standardized scale quantifies the degree of neurological deficit, facilitates communication, helps identify patients for thrombolytic or mechanical intervention, allows objective measurement of changing clinical status, and identifies those at higher risk for complications such as ICH (Powers et al., Stroke, 49(3): e46-e110, 2018). A baseline NIHSS is used to determine stroke severity and study eligibility. The NIHSS assessment is then performed at specific intervals (at 24 (±6) hours after randomization, at 72-96 hours after randomization, at discharge or day 5 after examination (whichever occurs earlier), at 30 days (±7 days) after randomization, and at 90 days (±7 days) after randomization). Barthel Index The Barthel index (BI) (Mahoney and Barthel, Maryland State Med Journal, 14: 56-61, 1965) is an ordinal scale used to measure performance in activities of daily living (ADL). A 10-item scale describing ADL and mobility (e.g., feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation, and stair climbing) is used. Each performance item is rated on this scale with a given number of points assigned to each level or ranking. BI scoring ranges from 0 to 100, and lower scores represent greater dependency. Patients are assessed using the BI to measure their ability to perform activities of daily living at specific intervals (at discharge or day 5 after examination (whichever occurs earlier), at 30 days (±7 days) after randomization, and at 90 days (±7 days) after randomization). Glasgow Outcome Scale The Glasgow Outcome Scale (GOS) (Table 3) is a scale used to assess recovery of patients with brain damage. The scale has 5 categories, with scale ranging from low disability to death (Appendix 5). Patients are assessed using the GOS at specific intervals (at discharge or day 5 after examination (whichever occurs earlier), at 30 days (±7 days) after randomization, and at 90 days (±7 days) after randomization). The scale presented in Table 3 is based on Jennett and Bond, Lancet, Mar.1; 1(7905): 480- 484, 1975; however, it has become common in clinical practice to use a modified version that places the scores in reverse order (i.e., “good recovery” = 1, “moderate disability’ = 2, etc.). PATENT Genentech Docket No: P38439-WO Quality of Life in Neurological Disorders (Neuro-QoL) Quality of Life in Neurological Disorders (Neuro-QoL) is a set of self-reported measures that assesses the physical, mental, and social effects experienced by adults living with neurological conditions. Patients are assessed using the Neuro-QoL at 90 days (±7 days) after randomization). Brain imaging Brain imaging requirements for the study are provided below. Study drug administration must occur within 90 minutes of qualifying RAPID brain imaging. If 90 minutes is exceeded, computed tomography perfusion (CTP) / magnetic resonance perfusion (MRP) imaging must be repeated to validate that the patient is still eligible for the study. Patients undergo two follow-up MRI scans. Patients who cannot undergo an MRI undergo a multimodal computed tomography (CT) / computed tomography angiography (CTA) / computed tomography perfusion (CTP) at the first follow-up and a non-contrast CT at the second follow-up. The first follow-up scan is obtained at approximately 24 hours (±6 hours) after study drug administration and includes a magnetic resonance angiography (MRA) of the Circle of Willis to assess for recanalization and an MRP study to assess for reperfusion in addition to standard fluid-attenuated inversion recovery (FLAIR), gradient recalled echo (GRE), and diffusion-weighted imaging (DWI) sequences, per standard-of-care. The second follow-up scan is obtained at the 72-96 hour visit after study drug administration and includes only FLAIR, GRE, and DWI for assessment of final infarct volumes. Brain imaging requirements Images are sent to a central reader in order to provide more uniform reading and interpretation of results for this multi-center study, leading to a more precise estimate of treatment effect. Imaging readers are blinded to a patient’s treatment assignment to eliminate bias. All sites are required to use RAPID software to provide brain imaging assessments. There will be no software variations, allowing for calibration standards across sites in order to ensure imaging consistency and quality control. Imaging required at baseline: Ɣ Alberta stroke programme early CT score (ASPECTS) scores documented, if applicable. Ɣ If screened by CT: Computed tomography (CT) to rule out hemorrhage. Ɣ Neuroimaging: internal carotid artery (ICA) or M1, M2 occlusion by magnetic resonance angiography (MRA) or CT angiography (CTA) AND target mismatch profile on CT perfusion (CTP) or MR perfusion (MRP) imaging (MRI) (ischemic core volume ^^^^^P / ^^PLVPDWFK^UDWLR^LV^^^^^^^DQG^ PLVPDWFK^YROXPH^LV^^^^^^P / ^^^^&DURWLG^RFFOXVLRQV^FDQ^EH^FHUYLFDO^RU^LQWUDFUDQLDO^ZLWK^RU^ZLWKRXW^ tandem middle cerebral artery (MCA) lesions. The mismatch volume is determined by the software in real time based on the difference between the ischemic core lesion volume and the Tmax >6s lesion volume. If both a CTP and a PATENT Genentech Docket No: P38439-WO multimodal MRI scan are performed prior to enrollment, the later of the 2 scans is assessed to determine eligibility. Only an intracranial MRA is required for patients screened with MRA; cervical MRA is not required. Cervical and intracranial CTA are typically obtained simultaneously in patients screened with CTA, but only the intracranial CTA is required for enrollment. Anatomic Definitions for M1 and M2: ƒ M1: Horizontal segment of the proximal MCA from the bifurcation of the ICA (into the anterior and middle cerebral arteries) to the genu of the MCA branch or branches at the entrance to the insula. ƒ M2: Vertical MCA branches in the Sylvian fissure originating at the genu and extending to the next genu at the level of the operculum. Ɣ Alternative neuroimaging: – If CTA (or MRA) is technically inadequate: Tmax >6s perfusion deficit consistent with an ICA RU^0^^^0^^RFFOXVLRQ^$1'^WDUJHW^PLVPDWFK^SURILOH^^LVFKHPLF^FRUH^YROXPH^^^^^^P / ^^PLVPDWFK^UDWLR^^^ ^^^^DQG^PLVPDWFK^YROXPH^^^^^^P / ^DV^GHWHUPLQHG^E\^5$3,'^VRIWZDUH^^ – If MR perfusion (MRP) is technically inadequate: ICA or M1, M2 occlusion by MRA AND diffusion-ZHLJKWHG^LPDJLQJ^^':,^^OHVLRQ^YROXPH^^^^^^P / ^IRU^DQ^0^^RU^,&$^RFFOXVLRQ^DQG^^^^^^P / ^IRU^ an M2 occlusion. If MRA is technically inadequate, a CTA can be used if performed within 60 minutes prior to the MRI. Carotid occlusions can be cervical or intracranial; with or without tandem MCA lesions. – If CTP is technically inadequate: patient can be screened with MRI and randomized if neuroimaging criteria are met. Ɣ Digital subtraction angiography (DSA) images: baseline, mechanical thrombectomy, and post- thrombectomy images obtained during angiogram to determine the required thrombolysis in cerebral infarction (TICI) scores. 24-hour imaging: Ɣ An MRI is performed 18-30 hours (approximately 24 hours (±6 hours)) post-randomization to assess reperfusion, recanalization, and ischemic core growth. This includes an MRA of the Circle of Willis to assess for recanalization and an MRP study to assess for reperfusion in addition to standard fluid-attenuated inversion recovery (FLAIR), gradient recalled echo (GRE), and DWI sequences per standard-of-care. At the investigator’s discretion, a repeat CTP may be performed at 18-30 hours if MRI is not possible (e.g., due to unstable medical condition). Patients who cannot undergo an MRI / MRA / MRP will undergo a multimodal CT / CTA / CTP instead. Ɣ Occurrence of an ICH event within 36 hours: In the event of an intracranial hemorrhage (ICH) event that occurs within 36 hours of drug administration, a NIHSS assessment is to be completed (see Table 2). PATENT Genentech Docket No: P38439-WO 72-96-hour imaging: Ɣ The second MRI is obtained at 72-96 hours after randomization and only includes FLAIR, GRE, and DWI for assessment of final infarct volumes. Patients who cannot undergo an MRI undergo a non-contrast CT. Example 3. Assessment of Safety A. Safety plan Tenecteplase is not approved for AIS, and clinical development is ongoing. The safety plan for patients in the ML40787 study is based on clinical experience with tenecteplase in completed and ongoing studies. The anticipated important safety risks for tenecteplase are outlined below. Several measures are taken to ensure the safety of patients participating in the study. Eligibility criteria have been designed to exclude patients at higher risk for toxicities. Patients undergo safety monitoring during the study, including assessment of the nature, frequency, and severity of adverse events. In addition, guidelines for managing adverse events are provided below. B. Risks associated with tenecteplase Standard management of stroke is implemented concomitantly with tenecteplase treatment. Arterial and venous punctures are minimized. Non-compressible arterial puncture must be avoided, and internal jugular and subclavian venous punctures should be avoided to minimize bleeding from the non-compressible sites. In the event of serious bleeding, heparin and antiplatelet agents should be discontinued immediately and treated appropriately. Heparin effects can be reversed by protamine. Bleeding The most common complication encountered during tenecteplase therapy is bleeding. This may be either superficial from punctures or damaged blood vessels or internal bleeding at any site or body cavity. Bleeding may result in life-threatening situations, permanent disability, or death. The incidence of intracranial hemorrhage (ICH), especially symptomatic intracranial hemorrhage (sICH), in patients with AIS is higher in alteplase-treated patients than placebo-treated patients in published studies. The type of bleeding associated with thrombolytic therapy can be divided into two broad categories: Ɣ Internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts. Ɣ Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or sites of recent surgical intervention. Management of Bleeding Patients are excluded for the presence of conditions related to risks of bleeding (as outlined in Example 2(C)). PATENT Genentech Docket No: P38439-WO Fibrin, which is part of the hemostatic plug formed at needle puncture sites, may be lysed during tenecteplase therapy. In the event of serious bleeding (not controlled by local pressure) in a critical location (intracranial, gastrointestinal, retroperitoneal, or pericardial), study drug should be discontinued immediately, and any concomitant heparin or antiplatelet agents should be discontinued immediately and appropriate treatment initiated. Arrhythmias Coronary thrombolysis may result in arrhythmias associated with reperfusion. These arrhythmias (such as sinus bradycardia, accelerated idioventricular rhythm, ventricular premature depolarizations, ventricular tachycardia) are not different from those often seen in the ordinary course of acute myocardial infarction and may be managed with standard anti-arrhythmic measures. It is recommended that anti-arrhythmic therapy for bradycardia and / or ventricular irritability be available when tenecteplase is administered. Use with percutaneous coronary intervention In patients with large ST segment elevation myocardial infarction, physicians should choose either thrombolysis or percutaneous coronary intervention (PCI) as the primary treatment strategy for reperfusion. Rescue PCI or subsequent elective PCI may be performed after administration of thrombolytic therapies if medically appropriate; however, the optimal use of adjunctive antithrombotic and antiplatelet therapies in this setting is unknown. C. Safety parameters and definitions Safety assessments consist of monitoring and recording adverse events, including serious adverse events and adverse events of special interest, performing protocol-specified safety laboratory assessments, measuring protocol-specified vital signs, and conducting other protocol-specified tests that are deemed critical to the safety evaluation of the study. Adverse events According to the International Council on Harmonisation guideline for Good Clinical Practice, an adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. An adverse event can therefore be any of the following: Ɣ Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Ɣ Any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition). Ɣ Recurrence of an intermittent medical condition (e.g., headache) not present at baseline. Ɣ Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug. PATENT Genentech Docket No: P38439-WO Ɣ Adverse events that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment (e.g., screening invasive procedures such as biopsies or venipuncture). Ɣ Any bleeding that does not qualify as an adverse event of special interest, including hemorrhagic infarction 1 and 2 (HI1 and HI2), subarachnoid hemorrhage (SAH), and intraventricular hemorrhage (IVH). Serious adverse events A serious adverse event (SAE) is any adverse event that meets any of the following criteria: Ɣ Is fatal (i.e., the adverse event actually causes or leads to death). Ɣ Is life threatening (i.e., the adverse event, in the view of the investigator, places the patient at immediate risk of death). This does not include any adverse event that, had it occurred in a more severe form or was allowed to continue, might have caused death. Ɣ Requires or prolongs inpatient hospitalization. Ɣ Results in persistent or significant disability / incapacity (i.e., the adverse event results in substantial disruption of the patient’s ability to conduct normal life functions). Ɣ Is a congenital anomaly / birth defect in a neonate / infant born to a mother exposed to study drug. Ɣ Is a significant medical event in the investigator's judgment (e.g., may jeopardize the patient or may require medical / surgical intervention to prevent one of the outcomes listed above). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an adverse event (e.g., rated as mild, moderate, or severe, or according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0; the event itself may be of relatively minor medical significance (such as severe headache without any further findings). Adverse events of special interest Non-serious adverse events of special interest (AESIs) for this study are as follows: Ɣ $Q\^V\PSWRPDWLF^LQWUDFUDQLDO^KHPRUUKDJH^^V,&+^^^GHILQHG^DV^^^^SRLQWV^RI^FOLQLFDO^ZRUVHQLQJ^ on the NIHSS compared with the most proximal NIHSS reported, attributed to a bleed on CT scan (preferred) or MRI performed within 36 hours after study drug administration) if not already reported as an SAE. (All other hemorrhages, including HI1, HI2, SAH, and IVH should be reported as an AE.) Ɣ The non-drug specific AESIs: Ɣ Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law. Ɣ Suspected transmission of an infectious agent by the study drug. Example 4. Statistical considerations and analysis plan The primary efficacy analysis in the ML40787 study is based on the intent-to-treat (ITT) population, defined as all randomized patients who provided informed consent, and analyzed according to the randomized treatment assignment. Safety analyses are based on the safety PATENT Genentech Docket No: P38439-WO population, defined as all randomized patients who received any amount of study drug, and analyzed according to the actual treatment received. The final study analysis is performed when all patients have completed or discontinued from the study, all data from the study are in the database, and the database is locked. A. Determination of sample size The purpose of the study is to demonstrate superiority of tenecteplase over placebo, when administered between 4.5 to 24 hours of last-known well time, in patients who have a vessel occlusion and evidence of salvageable tissue on their baseline CTP or MRI. The primary efficacy endpoint is the modified Rankin scale (mRS) score at Day 90. The distribution of the ordinal mRS scores is compared between the two treatment groups. Approximately 456 patients are to be enrolled in the study. Assuming the distribution of mRS scores at Day 90 in the two treatment arms as shown in Table 6 and a 5% dropout rate in the study, approximately 228 patients in each treatment group will provide at least 90% power to detect the specified difference in the distribution of the mRS scores at the 2-sided 0.049 significance level (after adjustment for one interim efficacy analysis, as described below). This calculation is based on the EAST® 6.4.1 software. This corresponds to being able to detect a common odds ratio of at least 1.76 (tenecteplase vs. placebo), with a total sample size of approximately 432 evaluable patients, assuming a 5% dropout rate. Table 6. Assumed distribution of 90-day mRS in sample size determination The sample size estimation is highly dependent on the distribution assumption of 90-day ordinal mRS score for both treatment arms; thus, additional power calculation is provided with 456 total patients for different distribution scenarios on the mRS at Day 90. As shown in Table 7, compared with the assumption used in current sample size calculation (Table 6), Scenario 1 (from the DEFUSE 3 trial) assumes a more optimistic outcome in the tenecteplase treatment arm than the placebo arm, while Scenario 2 (from the EXTEND-IA-TNK trial) assumes less treatment difference between the two treatment arms. The resulting power for both scenarios are shown in Table 8. Table 7. Distribution of 90-Day mRS from Different Scenarios PATENT Genentech Docket No: P38439-WO Table 8. Power Consideration by 90-Day mRS Distribution Scenarios B. Summaries of conduct of study Patient disposition (number of patients randomized, treated, and completed study) and reasons for premature study discontinuation are summarized by treatment group. C. Summaries of demographic and baseline characteristics Demographic and baseline characteristics, such as age, sex, race, randomization site, and baseline stroke characteristics (such as baseline NIHSS score, type of occlusion), are summarized for all randomized patients who provided informed consent using descriptive statistics. Summaries will be presented overall and by treatment group. D. Efficacy analyses The analysis population for the efficacy analyses consists of all randomized patients who provided informed consent (i.e., ITT population), with patients grouped according to their assigned treatment. Efficacy analyses are stratified by the randomization strata and adjusted for mechanical thrombectomy planned status at baseline (Yes vs. No), unless otherwise noted. For the purpose of the primary efficacy analysis, patients with missing mRS scores at Day 90 are imputed. Robustness of the primary analysis results is explored by the tipping point approach, where departures from the missing at random (MAR) assumption are assessed. Primary efficacy endpoint The primary endpoint is the ordinal mRS score at Day 90. The distribution of the mRS scores is compared between the treatment groups by a proportional odds model controlling for the randomization strata and baseline mechanical thrombectomy planned status. If the proportional-odds assumptions are not met, alternative assumption-free ordinal analysis on the mRS score is used (Agresti, Biometrics, 36: 59-67, 1980; Howard et al., Stroke, 43: 664-669, 2012; Churilov et al., Int J Stroke, 9(8): 999-1005, 2014). Superiority of tenecteplase over placebo is declared if the p-value of WKH^HVWLPDWHG^WUHDWPHQW^HIIHFW^IURP^WKH^SURSRUWLRQDO^RGGV^PRGHO^LV^^^^^^^^^WZR-sided). An unadjusted analysis is also performed using the Wilcoxon-Mann-Whitney test. PATENT Genentech Docket No: P38439-WO Secondary efficacy endpoints For the following binary secondary efficacy endpoints, treatment groups are compared using logistic regression models adjusted by the randomization strata and baseline mechanical thrombectomy planned status, as appropriate: Ɣ Proportion of patients with functional independence, defined as an mRS of 0-2 at Day 90 from randomization. Ɣ Proportion of patients with angiographic reperfusion (thrombolysis in cerebral infarction (TICI) 2b / 3 or TICI 3) at completion of angiographic procedure (endovascular patients only). Ɣ Proportion of patients with recanalization at 24 hours post-treatment, defined as complete recanalization on CTA / MRA. Ɣ Proportion of patients with reperfusion at 24 hours post-treatment, defined as > 90% reduction in Tmax > 6s lesion volume. Ɣ 3URSRUWLRQ^RI^SDWLHQWV^ZLWK^D^%DUWKHO^LQGH[^^%,^^VFRUH^^^^^DW^'D\^^^^IURP^UDQGRPL]DWLRQ^ Ɣ Proportion of patients with good recovery based on the Glasgow Outcome Scale (GOS) at Day 90 from randomization. For the following continuous secondary endpoint, treatment groups are compared using the van Elteren’s test, adjusting for the randomization stratification factors: Ɣ Median NIHSS score at 24 hours, 72-96 hours, 30 days, and 90 days. Key secondary endpoints are compared between the two treatment groups, gated on the success of the primary efficacy comparison (2-sided p-YDOXH^^^^^^^^^^^^+\SRWKHVLV^WHVWLQJ^RI^WKH^NH\^ secondary endpoints is performed in a sequential manner at the 2-sided significance level of 0.049. Exploratory analyses The mRS score at Day 90 is analyzed in the following subgroups: Ɣ Occlusion type (ICA / M1 or M2 occlusions). Ɣ Randomization site (endovascular capable center (ECC) or non-endovascular capable center (nECC)). Ɣ Proportion of patients where planned thrombectomy was not performed (including patients with partial or complete recanalization of the qualifying vessel occlusion, which includes patients who did not go to angiography suite because non-invasive imaging demonstrated recanalization, or patients who have undergone catheter angiography and are found to no longer to have an occlusion of the qualifying vessel). Ɣ Overall survival at Day 90. For each of the above-mentioned subgroups, the distribution of the mRS scores is compared between the treatment groups by a proportional odds model controlling for the randomization strata and baseline mechanical thrombectomy planned status, as appropriate. For patients who are randomized at an nECC and transferred to an ECC for endovascular therapy (EVT), the proportion of patients where planned thrombectomy was not performed is compared between treatment groups using a logistic regression model adjusted by baseline age group and baseline NIHSS score. PATENT Genentech Docket No: P38439-WO For the following continuous exploratory endpoints, treatment groups are compared using the van Elteren’s test, adjusting for the randomization stratification factors and baseline mechanical thrombectomy planned: Ɣ Median final infarct volumes at the 72-96 hour visit or discharge (if patient is being discharged prior to the 72-96 hour visit); and Ɣ Median infarct growth at the 72-96 hour visit or discharge (if patient is being discharged prior to the 72-96 hour visit). The appropriate scoring algorithm is employed to score the Neuro-QoL responses and scores are compared between the treatment groups. E. Safety analyses Safety analyses are performed for all randomized patients who receive tenecteplase or placebo, with patients grouped according to the treatment actually received. All verbatim adverse event terms are mapped to Medical Dictionary for Regulatory Activities (MedDRA) thesaurus terms, and adverse event severity is graded according to NCI CTCAE, v5. Preferred terms (PTs) for intracranial hemorrhage (ICH) are based on the latest version of the MedDRA Standardized Medical Query (SMQ) “haemorrhagic central nervous system vascular conditions.” Incidence and severity of treatment-emergent adverse events, including incidence of hemorrhage, and other adverse events of special interest are summarized by treatment group. A treatment-emergent adverse event is defined as any new adverse event reported or any worsening of an existing condition on or after study drug administration. Deaths and primary cause of death are summarized. Example 5. Results of ML40787 study A. Study Design The design of study ML40787 is presented in Fig.2. The study is designed to test the efficacy and safety of tenecteplase compared with placebo in patients with AIS and evidence of salvageable tissue on their baseline CTP or MRI who present in the 4.5- to 24-hour time window with an ICA or MCA (M1 or M2) occlusion. Fig.3 shows the disposition of patients in the study according to the design. Table 9 shows major deviations from the protocol. There are generally well-balanced across the treatment arms and the impact from COVID-19 on the major protocol deviations is determined minimal. Table 9. Major Protocol Deviations PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous. IMP = Investigational medicinal product. CTP = Computed tomography perfusion. MRP = Magnetic resonance perfusion, NIHSS = National Institutes of Health Stroke Scale, mRS = modified Rankin Scale. Percentages are based on N. Percentage of “Relationship to COVID-19” based on total number of major protocol deviations. B. Baseline Characteristics Various characteristics representing the baseline of the patients participating the study are presented in Tables 10-14. Table 10 shows characteristics representing demographic profiles of the patients. Tables 11-13 show baseline characteristics relating to hospital admissions and stroke background. Table 14 presents various imaging based baseline characteristics. In general, there are well balanced baselines across treatment arms. Table 10. Baseline Characteristics – Demographics PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, SD = standard deviation, Min = minimum, max = maximum. n = number of patients with a non-missing value. Percentages are based on n. Table 11. Baseline Characteristics – Hospital Admission and Stroke Characteristics PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, SD = standard deviation, Min = minimum, max = maximum, mRS = modified Rankin scale, NIHSS = National Institutes of Health Stroke Scale, ICA = internal carotid artery, MCA – M1, MCA – M2 = middle cerebral artery, ECC = endovascular capable center, nECC = not endovascular capable center. n = number of patients with a non-missing value. Percentages are based on n, except for subcategories where percentages are based on the category total. Table 12. Baseline Characteristics – Hospital Admission and Stroke Characteristics Abbreviations: IV = intravenous, SD = standard deviation, Min = minimum, max = maximum, mRS = modified Rankin scale, NIHSS = National Institutes of Health Stroke Scale, ICA = internal carotid artery, MCA – M1, MCA – M2 = middle cerebral artery, ECC = endovascular capable center, nECC = not endovascular capable center. n = number of patients with a non-missing value. Percentages are based on n, except for subcategories where percentages are based on the category total. Table 13. Baseline Characteristics – Hospital Admission and Stroke Characteristics PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, SD = standard deviation, Min = minimum, max = maximum, mRS = modified Rankin scale, NIHSS = National Institutes of Health Stroke Scale, ICA = internal carotid artery, MCA – M1, MCA – M2 = middle cerebral artery, ECC = endovascular capable center, nECC = not endovascular capable center. n = number of patients with a non-missing value. Percentages are based on n, except for subcategories where percentages are based on the category total. Table 14. Baseline Imaging-Based Characteristics PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, CT = computerized tomography, MRI = magnetic resonance imaging, ASPECTS = Alberta stroke program early CT score, SD = standard deviation, Min = minimum, max = maximum. n = number of patients with a non-missing value. Percentages are based on n. Percentage for Mismatch ratio=100 is based on N. Mismatch ratio = 100 when Infarct Volume = 0. * Variable collected on Case Report Form. Remaining parameters are provided by the central reader. C. Efficacy Ɣ Primary Efficacy Endpoint – Ordinal modified Rankin scale score at Day 90 The efficacy of tenecteplase on the treatment of AIS patients is observed by measuring ordinal modified Rankin scale score at Day 90. The common OR (odds ratio) is based on proportional odds model (p-value=0.435 for the test of proportional odds assumption) adjusted for protocol version (1-4 vs.5), age (<=70 vs. >70 years), type of occlusion (ICA / M1 vs. M2), with OR > 1 corresponding to values favoring tenecteplase. P-value is based on the Wald test of the null hypothesis of OR=1. Death prior to Day 90 is included as mRS=6. Missing mRS responses at Day 90 other than death is imputed using LOCF. Treatment policy strategy is applied to non-COVID-19 and COVID-19 related intercurrent events. “n” in each arm means a number of patients with mRS values at Day 90 (observed + imputed). Percentages are based on n. Three patients did not have a post-baseline mRS and were excluded from the analysis. Based on the common OR value being higher than 1, the tenecteplase-treated arm shows a positive (or favorable) trend toward effectiveness of the treatment although the odds of having a lower mRS at Day 90 in the tenecteplase arm compared with the placebo was found not statistically significant. See Fig.4. In particular, there is an increase of the portion of the patients showing mRS score of 0 or 1 (no symptoms or no significant disability) in the tenecteplase-treated arm relative to the placebo arm by about 2.0% for mRS=0 or about 3.7% for mRS=1. As for the patient subgroup showing mRS score of 0 or 1, there is about 5.7% increase observed in the tenecteplase treatment arm relative to the placebo arm. Also, as for the patient group showing mRS score of 0-2, there is about 3.7% increase in the tenecteplase treatment arm when compared to the placebo arm. Figs.5 and 6 show the primary endpoint data for various subgroups. Common ORs are based on proportional odds model and covariate adjustment varies based on the actual sample size in each subgroup (refer to source table outputs for details), with OR > 1 corresponding to values favoring tenecteplase. P-value is based on the Wald test of the null hypothesis of OR=1. Death prior to Day 90 is included as mRS=6. Missing mRS responses at Day 90 other than death is imputed using LOCF. Treatment policy strategy is applied to non-COVID-19 and COVID-19 related intercurrent events. “n” is a number of patients included in analysis. Percentages are based on n. Three patients did not have a post-baseline mRS and were excluded from the analysis. The tenecteplase treatment arm shows positive or favorable trend in multiple subgroups. For example, in Fig.5, the subgroup of patients PATENT Genentech Docket No: P38439-WO having a baseline infarct volume less than 20 mL who were treated with tenecteplase renders a positive readout supporting the effectiveness of the treatment relative to the placebo treated subgroup. Also, the subgroup having M1 occlusion shows a positive readout supporting the effectiveness of tenecteplase when compared to the corresponding M1 occlusion placebo subgroup. Similarly many subgroups presented in Fig.6 render values favoring tenecteplase treatment. For example, there are three subgroups that are divided by the time between the study drug administration and groin puncture (see the boxed area from the figure). Among these three subgroups, tenecteplase administered in 6 minutes or less from groin puncture (i.e., groin puncture occurs no more than six minutes after tenecteplase administration) shows the most favorable readout supporting the effectiveness of tenecteplase over the placebo. As is shown in Fig.19, 41.0% of patients who received tenecteplase 6 minutes or less before femoral puncture achieved functional independence (a modified Rankin Scale score (mRS) between 0 and 2) at Day 90, as compared to only 33.9% of placebo-treated patients. Odds ratio (OR) 1.41, 95% confidence interval (CI) 0.65-3.10. It is hypothesized that residual perfusion lesions associated with endovascular therapy (EVT) (e.g., mechanical thrombectomy) may respond to intra-procedure or post-procedure thrombolytics. Ɣ Secondary Efficacy Endpoint – Functional independence (mRS 0-2) at Day 90 Fig.7 shows the data from one secondary efficacy endpoint that is functional independence (mRS 0-2) at Day 90. OR is based on logistic regression model adjusted for protocol version (1-4 vs. 5), age (<=70 vs. >70 years), type of occlusion (ICA / M1 vs. M2), with OR > 1 corresponding to values favoring tenecteplase. P-value is based on the Wald test of the null hypothesis of OR=1. Death prior to Day 90 is included as mRS=6. Missing mRS responses at Day 90 other than death is imputed using LOCF. Treatment policy strategy is applied to non-COVID-19 and COVID-19 related intercurrent events. “n” is a number of patients with mRS values at Day 90 (observed + imputed). Percentages are based on n. Three patients did not have a post-baseline mRS and were excluded from the analysis. While the OR of functional independence is not found statistically significant, numerically higher proportion of patients treated with tenecteplase achieves functional independence at Day 90 vs. the placebo patients: 0.460 vs.0.424, which is about 3.6% increase in the tenecteplase treatment arm relative to the placebo arm. Fig.8 shows the data from another secondary efficacy endpoint that is complete recanalization at 24 hours post-randomization. Recanalization is defined as the restoration of blood flow through a previously blocked blood vessel in the brain. OR is based on logistic regression model adjusted for protocol version (1-4 vs.5), age (<=70 vs. >70 years), type of occlusion (ICA / M1 vs. M2), with OR > 1 corresponding to values favoring tenecteplase. P-value is based on the Wald test of the null hypothesis of OR=1. P-value is nominal and not adjusted for multiple hypothesis testing, no formal conclusion of treatment effect should be made based on the p-value. Treatment policy strategy is applied to non-COVID-19 and COVID-19 related intercurrent events. “n” is a number of patients with an evaluable degree of recanalization from MRI or CT at 24 hours post-randomization. Percentages are based on n. There is a higher proportion of patients treated with tenecteplase achieved complete recanalization at 24 hours post-randomization vs. the placebo patients: 0.767 vs.0.639, which is PATENT Genentech Docket No: P38439-WO about 13% (or 12.8%) increase in the tenecteplase treatment arm relative to the placebo arm. The OR of complete recanalization at 24 hours was significant at the nominal significance level of 0.049, favoring tenecteplase. Further, Fig.21 shows the proportion of patients who achieved complete recanalization at 24 hours post-randomization in the M1, proximal M2, and distal M2 subgroups. The percentage of tenecteplase-treated patients who achieved complete recanalization was numerically greater than placebo in each of the M1, proximal M2, and distal M2 subgroups. Fig.9 shows the data from still another secondary efficacy endpoint that is reperfusion at 24 hours post-randomization. Reperfusion at 24 hours post-randomization is defined as >90% reduction in Tmax>6s lesion volume, compared with the baseline value. OR is based on logistic regression model adjusted for protocol version (1-4 vs.5), age (<=70 vs. >70 years), type of occlusion (ICA / M1 vs. M2), with OR > 1 corresponding to values favoring tenecteplase. P-value is based on the Wald test of the null hypothesis of OR=1. Treatment policy strategy is applied to non-COVID-19 and COVID-19 related intercurrent events. “n” is a number of patients with MRI or CT at 24 hours post- randomization. Percentages are based on n. There is a similar proportion of patients achieved reperfusion at 24 hours post-randomization in the tenecteplase arm vs. the placebo arm: 0.569 vs. 0.577 while the OR of reperfusion at 24 hours was not statistically significant. Fig.10 shows the distribution of mRS scores for the subgroup having M1 occlusion, i.e., patients who have an occlusion in M1 before treatment with tenecteplase or placebo. Based on the common OR value being higher than 1, the tenecteplase-treated arm shows a positive (or favorable) trend toward effectiveness of the treatment. P values provided are nominal and not controlled for multiplicity. An mRS shift in favor of tenecteplase was observed throughout the full distribution. There is an increase of the portion of the patients showing mRS score of 0 or 1 (no symptoms or no significant disability) in the tenecteplase-treated arm relative to the placebo arm by about 2.8% for mRS=0 or about 11.7% for mRS=1. As for the patient subgroup showing mRS score of 0 or 1, there is about a 14.5% increase observed in the tenecteplase treatment arm relative to the placebo arm. Also, as for the patient group showing mRS score of 0-2, there is about 14.5% increase in the tenecteplase treatment arm when compared to the placebo arm (45.9% with tenecteplase vs.31.4% with placebo; OR (95% CI), 2.03 (1.14-3.66), adjusted nominal P=0.017). This result shows a trend in improved treatment response with patients having M1 occlusion as compared to patients having ICA or M2 occlusion. Subgroup analyses are generally consistent with the primary efficacy result. There is no evidence that mechanical thrombectomy (MT) or dwell time would have significantly impacted the study result. D. Safety Table 15 shows overall safety summary. ICH are identified by neuroimaging and are recorded as AEs using preferred terms from “haemorrhagic central nervous system vascular conditions” (narrow) SMQ. Investigator text for AEs encoded using MedDRA version 25.1 is used. Percentages are based on N in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for “Total number of AEs” row in which multiple occurrence of the same AE PATENT Genentech Docket No: P38439-WO are counted separately. The result includes treatment-emergent AEs, defined as any new AE reported or any worsening of an existing condition on or after study drug administration. The result includes deaths from first dose of study drug to 120 days and deaths suspected to be caused by study drug. Overall, SAEs, fatal AEs, sICH, and AESI were balanced across treatment arms. Table 15. Overall Safety Summary – Safety Population Abbreviations: IV = intravenous, AE = adverse event, ICH = intracranial hemorrhage, sICH = symptomatic ICH, ALT = alanine transaminase, AST = aspartate aminotransferase, PH-2 = parenchymal hematoma type 2. Table 16 shows symptomatic intracranial hemorrhage within 36 hours in the treatment arms. sICH is defined as >=4 points of clinical worsening on the NIHSS compared with the most proximal NIHSS reported, attributed to a bleeding on CT scan (preferred) or MRI performed within 36 hours after study drug administration. Bleeding subtype data is from central reader. Percentages are based on N in the column headings. There are comparable incidence rates of sICH events across the treatment arms, providing no safety concerns or issues in the tenecteplase treatment relative to the placebo treatment. Table 16. Symptomatic Intracranial Hemorrhage within 36 Hours – Safety Population PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, sICH = symptomatic intracranial hemorrhage, NIHSS = National Institutes of Health Stroke Scale, HI-1 = hemorrhagic infarction type 1, HI-2 = hemorrhagic infarction type 2, PH-1 = parenchymatous hematoma type 1, PH-2 = parenchymatous hematoma type 2, IVH = intraventricular hemorrhage, SAH = subarachnoid hemorrhage, CT = computed tomography, MRI = magnetic resonance imaging. Example 6. Further results of ML40787 study: tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection A. Background Intravenous thrombolytic therapy with alteplase is the standard of care for eligible patients within 4.5 hours of ischemic stroke onset (Powers et al., Stroke, 50: e344-418, 2019). Although previous thrombolytic studies indicated that treatment benefit is strongly dependent on time to reperfusion (Emberson et al., The Lancet, 384(9958): 1929-1935, 2014), a meta-analysis detected a benefit of alteplase administered during the 4.5- to 9-hour time window after stroke onset in selected patients with evidence of potential viable tissue by computed tomography (CT) perfusion or perfusion- diffusion magnetic resonance imaging (MRI) (Campbell et al., Lancet, 394: 139-147, 2019). Tenecteplase is a modified form of human tissue plasminogen activator that was approved in 2000 to reduce mortality in acute myocardial infarction (Tanswell et al., Clin Pharmacokinet, 41: 1229-1245, 2002). Several studies have demonstrated non-inferiority of tenecteplase vs. alteplase within 4.5 hours of stroke onset (Wang et al., Lancet, 401(10377): 645-654, 2023; Menon et al., Lancet, 400: 161-169, 2022; Campbell et al., N Engl J Med, 378: 1573-1582, 2018; Alamowitch et al., Eur Stroke J, 8: 8-54, 2023), and the most recent American Heart Association / American Stroke Association (AHA / ASA) acute ischemic stroke (AIS) guidelines recognized tenecteplase as a reasonable alternative to alteplase in restricted patient populations (Powers et al., Stroke, 50: e344-418, 2019). There are limited data, however, on using tenecteplase beyond 4.5 hours of symptom onset. A study of tenecteplase in patients with stroke symptoms upon waking and without selection by CT perfusion or perfusion-diffusion MRI showed neutral results but demonstrated safety comparable to that of thrombolytic therapy given at 0 to 4.5 hours (Roaldsen et al., Lancet Neurol, 22: 117-126, 2023). A proof-of-concept study demonstrated feasibility of treatment with tenecteplase up to 24 hours after onset in patients with evidence of an ischemic penumbra demonstrated with blood-flow imaging (Kate et al., J Stroke, 20: 122-130, 2018). The Thrombolysis in Imaging Eligible, Late Window Patients to Assess the Efficacy and Safety of Tenecteplase (TIMELESS) trial, described in Examples 1-4, was designed to test the hypothesis that intravenous tenecteplase, initiated 4.5 to 24 hours after stroke onset, would provide a benefit in patients with a large-vessel occlusion who had evidence of salvageable ischemic brain PATENT Genentech Docket No: P38439-WO tissue, as identified by CT perfusion or perfusion-diffusion MRI. B. Methods Trial design As described in Examples 1-4, a multicenter, randomized, double-blind, placebo-controlled trial was conducted involving patients in an extended time window, 4.5 to 24 hours after they were last known to be well, who had evidence of a middle cerebral artery or internal carotid artery (ICA) occlusion and salvageable tissue on CT perfusion or MRI perfusion-diffusion brain imaging. Patients (OLJLEOH^SDWLHQWV^ZHUH^^^^^\HDUV^RI^DJH^ZLWK^LQGHSHQGHQW^SUH-morbid function and had ischemic stroke 4.5 to 24 hours after the time they were last known to be well, with National Institutes RI^+HDOWK^6WURNH^6FDOH^^1,+66^^^^^GXH^WR^RFFOXVLRQ^RI^WKH^internal carotid artery (ICA; either cervical or intracranial) or the middle cerebral artery M1 or M2 segment, or both, on CT angiography or MRI angiography. Study drug administration was required within 90 minutes of qualifying brain imaging; if the 90 minutes was exceeded, a repeat CT / MRI was done to validate that the patient remained eligible. Patients were required to have evidence of salvageable brain tissue with an initial ischemic FRUH^YROXPH^RI^^^^^P / ^^D^UDWLR^RI^YROXPH^RI^LVFKHPLF^WLVVXH^WR^LQLWLDO^LQIDUFW^YROXPH^RI^^^^^^^DQG^DQ^ DEVROXWH^YROXPH^RI^SRWHQWLDOO\^UHYHUVLEOH^LVFKHPLD^^SHQXPEUD^^RI^^^^^P / ^^^(VWLPDWHs of the volume of the ischemic core and penumbral regions from CT perfusion or MRI diffusion and perfusion scans were calculated at each site with the use of RAPID software (RapidAI, San Mateo, CA), an image post-processing system. The size of the penumbra was estimated from the volume of tissue for which there was delayed arrival of an injected tracer agent (time to maximum of the residue function (Tmax))exceeding six seconds (Straka et al., J Magn Reson Imaging, 32: 1024-1037, 2010). Patients were randomized if they met both clinical and imaging eligibility requirements and could undergo administration of tenecteplase or placebo between 4.5 and 24 hours after the time that they were last known to be well. The medication was given as soon as possible, ideally prior to arterial puncture for a planned thrombectomy. Detailed study inclusion and exclusion criteria are provided in Example 2 and in Albers et al., Int J Stroke, 18: 237-241, 2023. Trial interventions As described in Examples 1-4, patients who met all eligibility criteria were randomly assigned in a 1:1 ratio to tenecteplase (at a dose of 0.25 mg per kilogram; maximum dose, 25 mg) vs. placebo, administered as an intravenous bolus over 5 seconds. Randomization used permuted blocks stratified by DJH^^^^^^YV. >70 years), occlusion site (ICA / M1 vs.0^^^^EDVHOLQH^1,+66^VFRUH^^^^^^YV. >15), and randomization site (endovascular capable center (ECC) vs. non-ECC. All patients received medical care according to institutional protocols in accordance with the guidelines of the American Heart Association / American Stroke Association (AHA / ASA). Endovascular thrombectomy was performed based on each site’s standard of care, with the use of any US Food and Drug PATENT Genentech Docket No: P38439-WO Administration–cleared thrombectomy device(s) selected at the discretion of the individual neuro- interventionalist. Outcomes The primary outcome was the ordinal score on the modified Rankin Scale (Table 1) at day 90. The modified Rankin Scale is a measure of disability with scores ranging from 0 (no symptoms) to 6 (death). The first secondary outcome was functional independence at day 90, defined as a modified Rankin Scale score of 0 to 2. Additional secondary outcomes were reperfusion and recanalization at 24 hours post-randomization; angiographic reperfusion at completion of thrombectomy in those who received endovascular therapy (EVT), defined as grade 2b to 3 on the modified Treatment in Cerebral Ischemia Scale (range, 0 to 3, with higher grades indicating increased reperfusion; grade 2b indicates UHSHUIXVLRQ^RI^^^^^^RI^WKH^DIIHFWHG^YDVFXODU^WHUULWRU\^^^PHGLDQ^1,+66^VFRUH^DW^GD\^^^^^%DUWKHO^,QGH[^ score ^^^^DW^GD\^^^^^DQG^JRRG^UHFRYHU\^RQ^WKH^*ODVJRZ^2XWFRPH^6FDOH^DW^GD\^^^^^GHILQHG^DV^ resumption of normal life with minor neurological and psychological deficits. Baseline and follow-up MRI and CT images were assessed independent of each other and blinded to treatment allocation at the core imaging laboratory. Angiographic studies from the endovascular procedure were assessed at the core laboratory. The primary safety endpoints were death up to day 30 and at 90 days and the occurrence of symptomatic intracranial hemorrhage (sICH) within 36 hours of study drug administration. sICH was GHILQHG^DV^D^^^-point worsening of the NIHSS within 36 hours of study drug administration attributed to any intracranial bleeding (Mayza et al., Stroke, 43: 1524-1531, 2012). Trial conduct Five clinical assessments were performed between baseline and 90 days after randomization. Trained, certified assessors blinded to trial-group assignments collected 30-day and 90-day outcomes. The score on the modified Rankin Scale was assessed at in-person visits or by telephone interviews (Janssen et al., Cerebrovasc Dis, 29: 137-139, 2010) with the patient or a surrogate. Statistical analysis The sample size calculation assumed the full distributions of the modified Rankin Scale scores at day 90 in both treatment arms that correspond to a common odds ratio (cOR) of around 1.76. This assumption was developed based on the results from the DEFUSE 3 and EXTEND-IA TNK trials. With this assumption, it was estimated that 456 patients, after accounting for a 5% dropout rate, would provide at least 90% power to detect the difference of a shift towards improvement (i.e., a lower score) in the 90-day modified Rankin Scale between the two treatment arms. Two safety-only interim analyses were planned and conducted when the first 25 and 50 patients had completed the 72-to-96-hours visit assessment post-randomization. Additionally, two safety data reviews were later added to occur when the first 100 and 200 patients had completed the 72-to-96-hours visit assessment post-randomization. PATENT Genentech Docket No: P38439-WO All efficacy outcomes were analyzed according to the intention-to-treat principle, and treatment policy strategy was employed to handle all pre-specified intercurrent events. Moreover, efficacy analyses were adjusted for baseline factors, which included the randomization stratification factors (i.e., baseline age group, occlusion location, baseline NIHSS, and the endovascular capability of the enrolling site), protocol version (version 1-4 vs.5), and the intention to perform mechanical thrombectomy at the time of randomization. The final set of adjustment variables varied by the endpoint being analyzed and was determined by a pre-specified algorithm that ensured a minimum sample size was met in all cells formed by the combination of the adjustments. The primary efficacy outcome was analyzed using the proportional odds model. An adjusted common odds ratio (cOR) and the corresponding 95% confidence interval were calculated, and the P value of the treatment effect was reported. To maintain an overall two-sided type I error rate at 0.05 level, the final analysis was performed at the two-sided significance level of 0.049, after accounting for an alpha of 0.003 spent at one interim efficacy analysis performed at approximately 50% enrollment (n=233). These type I error levels were determined according to the Lan-DeMets theory for alpha-spending function that approximates the O’Brien-Fleming boundary. Missing data in the primary outcome were imputed from the last observation post study baseline. Several sensitivity analyses of the primary outcome were conducted to assess the robustness of the primary analysis result. The primary outcome was also analyzed in several pre-specified subgroups. Secondary efficacy endpoints were compared between the two treatment groups, gated on the success of the primary efficacy comparison. Any subsequent analyses following a negative test, indicated by a P-value >0.049, of the secondary outcomes should not be used for hypothesis testing to account for multiplicity. Safety analyses were performed in the safety population, defined as all randomized patients who provided informed consent and received any amount of the study treatment, and patients were grouped according to the treatment actually received. Descriptive summaries were produced for safety analyses without formal statistical comparison being performed. C. Results Patient characteristics From March 2019 through December 2023, 458 patients were randomized at 108 centers in the US and four in Canada. A total of 228 patients were randomized to tenecteplase and 230 to placebo (Fig.11); six patients (1.3%) were lost to follow-up before study completion, 400 patients (87.3%) had an endovascular procedure planned, and 354 patients (77.3%) had the procedure initiated. The baseline demographic and clinical characteristics of the two treatment groups at baseline were well balanced (Table 15). Table 15. Baseline Demographics and Clinical Characteristics PATENT Genentech Docket No: P38439-WO Unless otherwise noted, the number of evaluable patients for each measure was the same as the total number of patients in each group. * Scores on the NIHSS, a standardized neurologic examination, range from 0 (normal) to 42 (death), with lower scores indicating less-severe stroke. ** Values for the ischemic core volume (CT perfusion relative cerebral blood flow<30% of normal brain tissue or MRI diffusion imaging apparent diffusion coefficient <620×10í6mm2per second) and the critically hypoperfused perfusion lesion (time to maximum, > 6 seconds) were calculated by RAPID software. *** The Alberta stroke program early computed tomography (CT) score (ASPECTS) is a 10-point quantitative topographic CT scan score used for patients with MCA stroke. PATENT Genentech Docket No: P38439-WO Primary and secondary clinical outcomes Treatment with tenecteplase did not affect the distribution of disability scores on the modified Rankin Scale at 90 days (adjusted cOR, 1.13; 95 %CI, 0.81-1.56; P=0.48; Fig.4, Fig.12, and Table 16^^^^7KH^SURSRUWLRQ^RI^SDWLHQWV^ZKR^ZHUH^IXQFWLRQDOO\^LQGHSHQGHQW^^PRGLILHG^5DQNLQ^6FDOH^VFRUH^^^^^ at 90 days was numerically higher in the tenecteplase group (n=104 (46.0%)) than in the control group (n=97 (42.4%)); absolute difference of ±3.6%, with an OR of 1.18). Study medication was administered at a median time of 16 minutes prior to arterial puncture. Of patients intended to receive endovascular therapy (EVT), 10 patients (4.9%) treated with tenecteplase did not require thrombectomy due to partial or complete recanalization vs. two patients (1.0%) receiving placebo (OR, 4.84; 95% CI, 1.03-22.65). Table 16. Clinical, Safety, and Imaging Outcomes PATENT Genentech Docket No: P38439-WO Analyses were adjusted for protocol version (1-^^YV^^^^DQG^DJH^^^^^^YV^!^^^\HDUV^^IRU^DOO^HQGSRLQWV^^^ In addition, modified Rankin Scale score at Day 90, functional independence at Day 90, recanalization at 24 hours, reperfusion at 24 hours, and good recovery in Glasgow Outcome Score at Day 90 were adjusted for type of occlusion (ICA / M1 vs M2), and reperfusion at the conclusion of endovascular WKHUDS\^ZDV^DGMXVWHG^IRU^EDVHOLQH^1,+66^VFRUH^^^^^^YV^!^^^^^3^YDOXH^LV^IRU^WKH^:DOG^WHVW^RI the null hypothesis of common OR=1. * Scores on the modified Rankin Scale range from 0 to 6, with higher scores indicating greater disability. The secondary outcomes were tested sequentially to control type II error. Because the primary functional independence outcome was not statistically significant, the subsequent confidence intervals for secondary outcomes should not be used for hypothesis testing. Functional independence was defined as a score on the modified Rankin Scale of 0 to 2. Recanalization at 24 hours is defined as complete recanalization, arterial occlusive lesion score=3. Reperfusion at 24 hour is defined as >90% reduction in Tmax>6 second lesion volume between baseline and 24-hour perfusion imaging. Reperfusion at the conclusion of endovascular therapy (in those treated) was defined as grade 2b to 3 on the modified Thrombectomy in the Cerebral Ischemia System; range, 0 to 3, with higher grades LQGLFDWLQJ^LQFUHDVHG^UHSHUIXVLRQ^^JUDGH^^E^LQGLFDWHV^UHSHUIXVLRQ^RI^^^^^^RI^WKH^RFFOXGHG^PLGGOH cerebral artery territory at the end of the thrombectomy procedure^^^F^LQGLFDWHV^UHSHUIXVLRQ^RI^^^^^^ and grade 3 indicates reperfusion of 100%). Glasgow Outcome Scale was rescaled from observed data so that 1=good recovery and 5=death. Good recovery score =1 on rescaled data. ^^^6\PSWRPDWLF^LQWUDFUDQLDO^KHPRUUKDJH^LV^GHILQHG^DV^^^^^SRLQWV^RI^FOLQLFDO^ZRUVHQLQJ^RQ^WKH^1,+66^ compared with the most proximal NIHSS reported and attributed to a bleed on CT scan (preferred) or MRI performed within 36 hours after study drug administration. The safety population included 218 patients who received tenecteplase and 214 who received placebo. Safety Mortality rates at 90 days did not differ between the two groups (tenecteplase, 43 patients (9.7%); placebo, 42 patients (19.6%); Table 16 and Fig.13). The rates of sICH was similar between the groups (tenecteplase, 7 patients (3.2%); placebo, 5 patients (2.3%), as were the rates of parenchymal hematoma type 2 or any ICH). The incidence of adverse events, serious adverse events, and patients withdrawn from the study due to adverse events did not differ between groups (Table 17). Table 17. Safety Summary AE, adverse event; SAE, serious adverse event. PATENT Genentech Docket No: P38439-WO Imaging outcomes Complete recanalization on 24-hour angiography by MRI or CT angiography was improved in the tenecteplase group (77%) compared with 64% in placebo (odds ratio (OR),1.89; 95% CI, 1.20- 2.96). Angiographic reperfusion (Thrombolysis in Cerebral Infarction scale (TICI) 2b / 3) with tenecteplase was 89.1% vs. placebo at 85.4%. Final infarct volume was numerically lower in the tenecteplase group at a mean of 47.9 mL (standard deviation (SD) 71.1 mL) compared with the placebo group at a mean of 56.5 mL (SD, 81.5 mL). Subgroup analyses Fig.14 shows the subgroup analysis of the adjusted common odds ratio, indicating the odds that the trial patients assigned to receive tenecteplase would have better functional recovery at 90 days (as reflected by a shift in the distribution of scores on the modified Rankin Scale toward more favorable outcomes) than patients assigned to receive placebo. The widths of the confidence intervals were not adjusted for multiple comparisons, and the reported confidence intervals should not be used for hypothesis testing. Scores on the NIHSS range from 0 to 42, with higher scores indicating worse neurologic deficits. Alberta Stroke Program Early Computed Tomography Scores (ASPECTS) range from 0 to 10, with lower values indicating larger infarction. The mismatch ratio is the ratio of critically hypoperfused tissue to the ischemic-core estimate, and the mismatch volume is the volumetric difference between critically hypoperfused tissue and the ischemic-core estimate. The sizes of the boxes in the plot correspond to the number of patients in each subgroup. The arrow indicates that the 95% confidence interval was beyond the scale. In Fig.14, both age subgroups were adjusted for protocol version (1-4 vs 5) and baseline 1,+66^^^^^^YV^!^^^^^WKH^VXEJURXS^ZLWK^DJH^^^^^\HDUV^ZDV^DGGLWLRQDOO\^DGMXVWHG^IRU^W\SH^RI^RFFOXVLRQ (ICA / M1 vs M2). Both NIHSS subgroups were adjusted for protocol version (1-^^YV^^^^DQG^DJH^^^^^^YV^!^^^ \HDUV^^^WKH^1,+66^^^^^VXEJURXS^ZDV^DGGLWLRQDOO\^DGMXVWHG^IRU^W\SH^RI^RFFOXVLRQ^^,&$^0^^YV^0^^^ Both subgroups for time between stroke onset to randomization were adjusted for protocol version (1-4 vs 5) and type of occlusion (ICA / M1 vs M2); additionally, the subgroup that had <16 KRXUV^EHWZHHQ^VWURNH^RQVHW^WR^UDQGRPL]DWLRQ^ZDV^DGMXVWHG^IRU^DJH^^^^^^YV^!^^^\HDUV^^ Both subgroups for planned mechanical thrombectomy (planned or not planned) were adjusted for protocol version (1-4 vs 5); additionally, the subgroup with planned mechanical WKURPEHFWRP\^ZDV^DOVR^DGMXVWHG^IRU^W\SH^RI^RFFOXVLRQ^^,&$^0^^YV^0^^^DQG^DJH^^^^^^YV^!^^^\HDUV^^ Both subgroups for performed mechanical thrombectomy (performed or not performed) were adjusted for protocol version (1-4 vs 5); additionally, the subgroup that underwent mechanical WKURPEHFWRP\^ZDV^DOVR^DGMXVWHG^IRU^DJH^^^^^^YV^!^^^\HDUV^^DQG^EDVHOLQH^1,+66^^^^^^YV^!^^^^^)RU^ the subgroup that did not undergo mechanical thrombectomy, the model was also adjusted for mechanical thrombectomy planned (yes vs no). All three subgroups for elapsed time between study drug administration and groin puncture were adjusted for protocol version (1-^^YV^^^^^DGGLWLRQDOO\^^WKH^^^^PLQXWHV^VXEJURXS^ZDV^DOVR^DGMXVWHG^ PATENT Genentech Docket No: P38439-WO IRU^EDVHOLQH^1,+66^^^^^^YV^!^^^^^DQG^WKH^!^^WR^^^^^PLQXWHV^DQG^>22 minutes subgroups were also DGMXVWHG^IRU^DJH^^^^^^YV^!^^^\HDUV^^ $OO^WKUHH^VXEJURXSV^IRU^EDVHOLQH^LQIDUFW^YROXPH^ZHUH^DGMXVWHG^IRU^DJH^^^^^^YV^!^^^\HDUV^^^ additionally, the subgroups with baseline infarct volume <20 mL and ^20 mL to <50 mL were also adjusted for protocol version (1-4 vs 5). The subgroup with baseline infarct volume <20 mL was also adjusted for type of occlusion (ICA / M1 vs M2). (DFK^RFFOXVLRQ^VXEJURXS^ZDV^DGMXVWHG^IRU^DJH^^^^^^YV^!^^^\HDUV^^^DGGLWLRQDOO\^^WKH^0^^DQG^ M2 subgroups were also adjusted for protocol version (1-4 vs 5), and the M1 subgroup was also DGMXVWHG^IRU^EDVHOLQH^1,+66^^^^^^YV^!^^^^ There was a trend toward better outcomes in tenecteplase patients with an M1 segment occlusion of the middle cerebral artery (OR 1.59, 95% CI 1.00-2.52). For these patients, functional independence (modified Rankin Scale (mRS) 0-2 at 90 days) was achieved in 45.9% with tenecteplase vs.31.4% with placebo (adjusted odds ratio (aOR) 2.03; 95% CI, 1.14-3.66). Patients with M2 segment occlusions of the middle cerebral artery, and those in whom thrombectomy was not planned, trended toward less favorable outcomes in the tenecteplase group. The effect of tenecteplase did not differ in patients with known onset vs. unknown onset times or in earlier- vs. later- treated patients. However, as further illustrated below in Example 7, tenecteplase treatment resulted in a favorable outcome in improving complete recanalization in patients with M2 segment occlusions as compared to placebo treatment of the same group. Therefore, tenecteplase can be particularly effective in treating patients having M1 and / or M2 occlusions and improving one or more symptoms associated with stroke. D. Discussion TIMELESS is the first study to demonstrate that an intravenous thrombolytic can be given safely up to 24 hours after last known well time. In a pooled analysis of 6756 patients in nine randomized trials comparing alteplase with placebo or open control with treatment up to 6 hours after stroke onset, alteplase significantly increased the odds of sICH (defined as type 2 parenchymal hemorrhage within 7 days; 6.8% vs.1.3%; OR, 5.55; 95% CI, 4.01–7.70; P<0.001) (Emberson et al., The Lancet, 384(9958): 1929-1935, 2014). In TIMELESS, despite treatment up to 24 hours after last known well time, no increase in rate of brain hemorrhage was observed in patients who were selected based on a favorable perfusion imaging profile. Most patients in TIMELESS were also treated with thrombectomy, and reperfusion at conclusion of EVT was 89.1% in the tenecteplase arm vs.85.4% in the placebo group (OR, 1.41 (0.75-2.66)). Subgroup analysis suggested a favorable treatment response in the M1 subgroup. Recent studies have suggested that substantial recanalization occurs during transport in patients who are treated with thrombolysis prior to their transfer to an EVT (ECC) center. More than 95% of the patients were recruited at ECCs. Improvements in hospital workflow to reduce door to arterial puncture and the small number of patients who underwent interhospital transfer after tenecteplase and before planned thrombectomy limited the time for the full opportunity for lytic activity to achieve recanalization prior to EVT. Sixteen patients were recruited at non-ECCs. As shown in PATENT Genentech Docket No: P38439-WO Fig.18, 57.1% of tenecteplase-treated patients and 33.3% of placebo-treated patients who were randomized at a non-ECC (non-EVT center) had a modified Rankin Scale score of between 0 and 2 at the 90-day follow-up. In conclusion, despite treatment with tenecteplase up to 24 hours after patients were last known well, no increase was observed in the rate of brain hemorrhage or other safety events. Example 7. Analysis of patients having middle cerebral artery (MCA) M2 occlusions Table 18 shows demographics, and baseline characteristics, hospital admission and stroke characteristics, and baseline imaging results in patients having M2 occlusions who were treated with tenecteplase or placebo as described in Examples 1-4. Table 18. Demographics and Baseline Characteristics, Hospital Admission and Stroke Characteristics, And Baseline Imaging Results: Intent-to-Treat Population, Baseline Occlusion Type = M2 PATENT Genentech Docket No: P38439-WO PATENT Genentech Docket No: P38439-WO n = number of patients with a non-missing value. Percentages are based on n. Table 19 VKRZV^WKH^OLNHOLKRRG^RI^IXQFWLRQDO^LQGHSHQGHQFH^^PRGLILHG^5DQNLQ^6FRUH^^P56^^^^^^LQ^ patients having M2 occlusions who were treated with tenecteplase or placebo as described in Examples 1-4. Fig.16 shows the distribution of mRS scores for the subgroup having an M2 occlusion (i.e., patients who had an occlusion in M2 before treatment with tenecteplase or placebo) at the 90-day follow-up. 50% of patients treated with tenecteplase and 57.8% of patients treated with the placebo had an mRS of between 0 and 2 at 90 days (odds ratio (OR) (95% confidence interval (CI)), 0.72 (0.39-1.33); nominal P=0.30). PATENT Genentech Docket No: P38439-WO Table 19. Summary of Logistic Regression Analysis for Functional Independence at Day 90: Intent-to-Treat Population, Baseline Occlusion Type = M2 Missing mRS response at Day 90 is imputed using LOCF. Death prior to Day 90 is included as mRS=6. n = number of patients with mRS values (observed + imputed). Percentages are based on n. Odds ratio (OR) for functional independence is adjusted for protocol version (1-^^YV^^^^^DQG^DJH^^^^^^ vs. > 70 years of age), with OR > 1 corresponding to values favoring tenecteplase. P-value is for the Wald test of the null hypothesis OR = 1. Table 20 shows the likelihood of recanalization at 24 hours post-randomization in patients having M2 occlusions who were treated with tenecteplase or placebo as described in Examples 1-4. It is notable that the M2 patients treated with IV tenecteplase shows a significant improvement in complete recanalization as compared to the M2 patients with placebo treatment, e.g., about 21% increase (from 55.1% from the placebo arm to 76.6% from the tenecteplase arm) in the number of patients showing complete recanalization after the treatment. This shows a favorable outcome in treating ischemic stroke patients, especially those had M2 occlusions, using tenecteplase. Table 20. Summary Of Logistic Regression Analysis For Recanalization At 24 Hours Post- Randomization: Intent-To-Treat Population, Baseline Occlusion Type = M2 n = number of patients with an evaluable degree of recanalization from MRI or CT at 24 hours post- randomization. Percentages are based on n. Missing mRS response at Day 90 is imputed using LOCF. Death prior to Day 90 is included as mRS=6. Odds ratio (OR) for functional independence is adjusted for protocol version (1-^^YV^^^^^DQG^DJH^^^^^^ vs. > 70 years of age), with OR > 1 corresponding to values favoring tenecteplase. P-value is for the Wald test of the null hypothesis OR = 1. Table 21 shows the likelihood of reperfusion at 24 hours post-randomization in patients having M2 occlusions who were treated with tenecteplase or placebo as described in Examples 1-4. PATENT Genentech Docket No: P38439-WO Table 21. Summary Of Logistic Regression Analysis For Reperfusion At 24 Hours Post- Randomization: Intent-To-Treat Population, Baseline Occlusion Type = M2 n = number of patients with MRI or CT at 24 hours post-randomization. Percentages are based on n. Missing mRS response at Day 90 is imputed using LOCF. Death prior to Day 90 is included as mRS=6. Odds ratio (OR) for functional independence is adjusted for protocol version (1-^^YV^^^^^DQG^DJH^^^^^^ vs. > 70 years of age), with OR > 1 corresponding to values favoring tenecteplase. P-value is for the Wald test of the null hypothesis OR = 1. Example 8. Analysis of modified Rankin Scale (mRS) scores stratified by mechanical thrombectomy Fig.15 shows modified Rankin Scale scores at the 90-day follow-up in patients from the ML40787 trial who had an M1 occlusion, were treated with tenecteplase or a placebo, and (i) had mechanical thrombectomy (upper panel) or (ii) did not have a mechanical thrombectomy (lower panel). The common odds ratio (cOR) and 95% confidence interval (CI) for patients for whom a mechanical thrombectomy was performed were 1.48 and 0.91-2.43, respectively, with a cOR of >1 corresponding to values favoring tenecteplase. The cOR and 95% CI for patients for whom a mechanical thrombectomy was not performed were 2.00 and 0.51-8.09, respectively, with a cOR of >1 corresponding to values favoring tenecteplase. 44.2% of tenecteplase-treated patients who had a mechanical thrombectomy achieved a modified Rankin Scale score of between 0 and 2, as compared to 33.3% of placebo-treated patients who had a mechanical thrombectomy. 53.3% of tenecteplase- treated patients who did not have a mechanical thrombectomy achieved a modified Rankin Scale score of between 0 and 2, as compared to 23.1% of placebo-treated patients who did not have a mechanical thrombectomy. Fig.17 shows modified Rankin Scale scores at the 90-day follow-up in patients from the ML40787 trial who had an M2 occlusion, were treated with tenecteplase or a placebo, and (i) had mechanical thrombectomy (upper panel) or (ii) did not have a mechanical thrombectomy (lower panel). The common odds ratio (cOR) and 95% confidence interval (CI) for patients for whom a mechanical thrombectomy was performed were 0.76 and 0.39-1.50, respectively. The cOR and 95% CI for patients for whom a mechanical thrombectomy was not performed were 0.78 and 0.32-1.92, respectively. Fig.20 shows modified Rankin Scale scores at the 90-day follow-up in patients from the ML40787 trial who had a distal M2 occlusion, were treated with tenecteplase or a placebo, and (i) had mechanical thrombectomy (upper panel) or (ii) did not have a mechanical thrombectomy (lower panel). The common odds ratio (cOR) and 95% confidence interval (CI) for patients for whom a PATENT Genentech Docket No: P38439-WO mechanical thrombectomy was performed were 0.58 and 0.17-1.92, respectively. The cOR and 95% CI for patients for whom a mechanical thrombectomy was not performed were 0.89 and 0.26-3.08, respectively. 36% of tenecteplase-treated patients and 25% of placebo-treated patients who had a distal M2 occlusion and did not have mechanical thrombectomy achieved an mRS of 0-1 at the 90- day follow-up. 45% of tenecteplase-treated patients and 50% of placebo-treated patients who had a distal M2 occlusion and had mechanical thrombectomy achieved an mRS of 0-1 at the 90-day follow- up. 50% of patients with distal M2 occlusions had EVT (mechanical thrombectomy) performed. As shown in Fig.22, the percentage of patients who achieved complete recanalization at 24 hours after randomization was numerically higher in the group of all patients having distal M2 occlusions, and in the group of patients having distal M2 occlusions who did not have EVT. Example 9. Analysis of patients having wake up vs. non-wake up strokes Stroke onset is defined as the time the patient was last known to be at their neurologic baseline. Wake-up strokes (when a patient wakes up from sleep with a stroke) were eligible for inclusion in the ML40787 study if they presented (e.g., to the ER) within the 4.5-24 hour time limits of last known well (see Example 2B), i.e., had been seen to be normal within the last 24 hours. Table 22 presents infarct volume and infarct growth data for patients having wake up strokes as compared to non-wake up strokes. In patients having wake up strokes, the mean baseline infarct volume was larger (14.2 mL) in the tenecteplase treatment group than in the placebo group (12.6 mL); however, the tenecteplase treatment group had a mean final infarct volume smaller than that of the placebo group at 39.8 mL (compared to placebo 50.7 mL) and demonstrated a mean final infarct growth of only 25.8 mL (n = 130) (approximately 12mL less than the mean final infarct growth in the placebo group (37.7 mL; n = 121), with a p-value of 0.052. Table 22. Summary of final infarct volumes and infarct growth at 72-96 hours post-baseline: wake up vs. non-wake up stroke patients: intent-to-treat population PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, CI = confidence interval, SD = standard deviation, ICA = internal carotid artery. n = number of patients with a measured infarct growth / volume obtained 72-96 hours post baseline or imaging scan obtained at discharge if patient discharged prior to 72 hours. If no imaging is available within the 72-96 hours window, and the subject was identified as an early discharge, the latest post-baseline imaging is used for the final infarct growth / volume. Confidence interval for the median difference is computed using the Hodges-Lehmann method. P-value is for the van Elteren’s test adjusting for protocol version (1-4 vs.5), age (<=70 vs. > 70 years of age), and type of occlusion (ICA / M1 vs. M2). Table 23 and Fig.24 present modified Rankin Scale (mRS) scores in patients having wake up strokes as compared to non-wake up strokes. An absolute difference of 7.4% in the proportion of patients having mRS 0-1 was observed in the tenecteplase-treated population as compared to the placebo-treated population in the wake up stroke population (i.e., the likelihood of achieving a mRS of 0-1 was observed to be higher in the tenecteplase-treated population). Table 23. Summary of proportional odds analysis for ordinal modified Rankin Scale at Day 90: wake up vs. non-wake up stroke patients: intent-to-treat population PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, CI = confidence interval, mRS = modified Rankin Scale, LOCF = last observation carried forward, OR = odds ratio, ICA = internal carotid artery, NIHSS = National Institutes of Health Stroke Scale. Death prior to Day 90 is included as mRS=6. Missing mRS response at Day 90 other than death is imputed using LOCF. n = number of patients with mRS values at Day 90 (observed + imputed). Percentages are based on n. 3 patients did not have a post-baseline mRS. Common Odds ratio is adjusted for protocol version (1-4 vs.5), age (<=70 vs. > 70 years of age), and type of occlusion (ICA / M1 vs. M2), with OR > 1 corresponding to values favoring tenecteplase. P- value is for the Wald test of the null hypothesis OR = 1. Example 10. Analysis of final infarct growth and volume by occlusion type Table 24 presents occlusion segregation data for the intent-to-treat (ITT) (all patients) population of the ML40787 study. Fig.23 shows mean final infarct growth in patients having ICA / M1 vs. M2 occlusions. In the ICA / M1 group, tenecteplase-treated patients had a smaller mean and median final infarct volume than placebo-treated patients (even though the baseline infarct volume was slightly larger in the tenecteplase-treated group) (p=0.0611), and the mean final infarct growth at 72-96 hours post-baseline was significantly smaller in tenecteplase-treated patients than in placebo-treated patients (p=0.0116). Table 24. Summary of final infarct volumes and infarct growth at 72-96 hours post-baseline by occlusion type PATENT Genentech Docket No: P38439-WO Abbreviations: IV = intravenous, CI = confidence interval, SD = standard deviation, ICA = internal carotid artery. n = number of patients with a measured infarct growth / volume obtained 72-96 hours post baseline or imaging scan obtained at discharge if patient discharged prior to 72 hours. If no imaging is available within the 72-96 hours window, and the subject was identified as an early discharge, the latest post- baseline imaging is used for the final infarct growth / volume. Confidence interval for the median difference is computed using the Hodges-Lehmann method. P-value is for the van Elteren’s test adjusted for age (<=70 vs. > 70 years of age) for each occlusion subgroup. Additionally, the M1 and M2 subgroups are also adjusted for protocol version (1-4 vs.5). Further the M1 subgroup is also adjusted for baseline NIHSS (<=15 vs. >15). PATENT Genentech Docket No: P38439-WO Example 11. Predictors of symptomatic intracranial hemorrhage or parenchymal hematoma type 2 As is shown in Fig.25, patients who had a longer duration between the last known well time (LKW) and randomization into the study had a higher incidence of symptomatic intracranial hemorrhages (SICH) or parenchymal hematoma type 2 (PH2) (serious bleeds). As is shown in Fig.26, patients having an ICA (internal carotid artery) occlusion had the highest incidence of both SICH and PH2 bleeds, followed by patients having M1 and M2 occlusions. Risk of SICH / PH2 thus correlated with vessel size: as vessels got smaller, the risk of these major hemorrhages decreased. VII. OTHER EMBODIMENTS Some embodiments of the technology described herein can be defined according to any of the following numbered embodiments: 1. Tenecteplase for use in treating acute ischemic stroke (AIS) in a population of subjects, wherein each member of the population of subjects has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is to be administered to each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS; and wherein tenecteplase treatment improves clinical outcome in the population of subjects relative to a placebo-treated reference population of subjects having AIS. 2. The tenecteplase for use of embodiment 1, wherein the placebo is to be administered to each member of the reference population of subjects at a time between 4.5 and 24 hours after onset of AIS. 3. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is ordinal modified Rankin scale (mRS) score. 4. The tenecteplase for use of embodiment 3, wherein the distribution of mRS scores in the population of subjects is improved relative to the distribution of mRS scores in the reference population. 5. The tenecteplase for use of embodiment 4, wherein the distribution of mRS scores in the population of subjects is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% relative to the distribution of mRS scores in the reference population. 6. The tenecteplase for use of any one of embodiments 3-5, wherein the mRS score is assessed 90 days after the tenecteplase is to be administered. 7. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects with functional independence. 8. The tenecteplase for use of embodiment 7, wherein functional independence is an mRS score of 0-2. PATENT Genentech Docket No: P38439-WO 9. The tenecteplase for use of embodiment 7 or 8, wherein the proportion of subjects with functional independence in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects with functional independence in the reference population. 10. The tenecteplase for use of any one of embodiments 7-9, wherein functional independence is assessed 90 days after the tenecteplase is to be administered. 11. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is National Institutes of Health Stroke Scale (NIHSS) score. 12. The tenecteplase for use of embodiment 11, wherein the median NIHSS score in the population of subjects is lower than the median NIHSS score in the reference population. 13. The tenecteplase for use of embodiment 11 or 12, wherein the median NIHSS score in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the median NIHSS score in the reference population. 14. The tenecteplase for use of any one of embodiments 11-13, wherein the NIHSS score is assessed 90 days after the tenecteplase is to be administered. 15. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects having a Barthel Index (BI) score of at least 95. 16. The tenecteplase for use of embodiment 15, wherein the proportion of subjects in the population of subjects having a BI score of at least 95 is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects in the reference population having a BI score of at least 95. 17. The tenecteplase for use of embodiment 15 or 16, wherein the BI score is assessed 90 days after the tenecteplase is to be administered. 18. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects with good recovery, as identified by a Glasgow Outcome Scale (GOS) score of 5. 19. The tenecteplase for use of embodiment 18, wherein the proportion of subjects in the population of subjects having a GOS score of 5 is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects in the reference population having a GOS score of 5. 20. The tenecteplase for use of embodiment 18 or 19, wherein the GOS score is assessed 90 days after the tenecteplase is to be administered. 21. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects having reperfusion. 22. The tenecteplase for use of embodiment 21, wherein reperfusion is a greater than 90% reduction in the volume of lesions having a time-to-maximum of the residue function (Tmax) of more than 6 seconds (Tmax >6s). 23. The tenecteplase for use of embodiment 21 or 22, wherein the proportion of subjects in the population of subjects having reperfusion of ischemic tissue is at least 1%, 5%, 10%, 15%, 20%, 25%, PATENT Genentech Docket No: P38439-WO 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects in the reference population having reperfusion of ischemic tissue. 24. The tenecteplase for use of any one of embodiments 21-23, wherein reperfusion is assessed 24 hours after the tenecteplase is to be administered. 25. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects having recanalization of one or more occluded vessels. 26. The tenecteplase for use of embodiment 25, wherein recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA). 27. The tenecteplase for use of embodiment 25 or 26, wherein the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels. 28. The tenecteplase for use of any one of embodiments 25-27, wherein recanalization is assessed 24 hours after the tenecteplase is to be administered. 29. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the median final infarct volume. 30. The tenecteplase for use of embodiment 29, wherein the median final infarct volume in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the median final infarct volume in the reference population. 31. The tenecteplase for use of embodiment 29 or 30, wherein the median final infarct volume is assessed at discharge. 32. The tenecteplase for use of embodiment 29 or 30, wherein the median final infarct volume is assessed between 72 hours and 96 hours after the tenecteplase is to be administered. 33. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the median infarct growth. 34. The tenecteplase for use of embodiment 33, wherein the median infarct growth in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the median infarct growth in the reference population. 35. The tenecteplase for use of embodiment 33 or 34, wherein the infarct growth is assessed at discharge. 36. The tenecteplase for use of embodiment 33 or 34, wherein the median infarct growth is assessed between 72 hours and 96 hours after the tenecteplase is to be administered. 37. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects for which a planned thrombectomy was obviated. 38. The tenecteplase for use of embodiment 37, wherein the proportion of subjects in the population of subjects for which a planned thrombectomy is not performed is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or PATENT Genentech Docket No: P38439-WO 100% higher than the proportion of subjects for which a planned thrombectomy is not performed in the reference population. 39. The tenecteplase for use of embodiment 37 or 38, wherein the planned thrombectomy is not performed based on a finding of partial or complete recanalization of the qualifying vessel occlusion. 40. The tenecteplase for use of any one of embodiments 37-39, wherein the subject for which a thrombectomy was planned was transferred from a non-endovascular capable center (nECC) to an endovascular capable center (ECC) for the planned thrombectomy. 41. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects for which only one pass with an endovascular therapy device is required to achieve recanalization of one or more occluded vessels. 42. The tenecteplase for use of embodiment 41, wherein the proportion of subjects in the population of subjects for which only one pass with an endovascular therapy device is required is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects for which only one pass with an endovascular therapy device is required in the reference population. 43. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects having angiographic reperfusion at completion of an angiographic procedure. 44. The tenecteplase for use of embodiment 43, wherein angiographic reperfusion is a thrombolysis in cerebral infarction (TICI) scale score of 2b or 3. 45. The tenecteplase for use of embodiment 43 or 44, wherein the proportion of subjects in the population of subjects having angiographic reperfusion at completion of an angiographic procedure is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the proportion of subjects having angiographic reperfusion at completion of an angiographic procedure in the reference population. 46. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is overall survival (OS) rate. 47. The tenecteplase for use of embodiment 46, wherein the OS rate in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the OS rate in the reference population. 48. The tenecteplase for use of embodiment 46 or 47, wherein OS is assessed 30 days after the tenecteplase is to be administered. 49. The tenecteplase for use of embodiment 46 or 47, wherein OS is assessed 90 days after the tenecteplase is to be administered. 50. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is the proportion of subjects who are re-admitted to a hospital within 30 days of discharge. 51. The tenecteplase for use of embodiment 50, wherein the proportion of subjects in the population of subjects who are re-admitted to a hospital within 30 days of discharge is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% lower than the proportion of subjects who are re-admitted to a hospital within 30 days of discharge in the reference population. PATENT Genentech Docket No: P38439-WO 52. The tenecteplase for use of embodiment 1 or 2, wherein the clinical outcome is mean Quality of Life in Neurological Disorders (Neuro-QoL) score. 53. The tenecteplase for use of embodiment 52, wherein the mean Neuro-QoL score in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% higher than the mean Neuro-QoL score in the reference population. 54. The tenecteplase for use of any one of embodiments 1-53, wherein the incidence of symptomatic intracranial hemorrhage (sICH) is not increased in the population of subjects relative to the reference population. 55. The tenecteplase for use of embodiment 54, wherein the incidence of sICH is an incidence within 36 hours of administration of tenecteplase. 56. The tenecteplase for use of any one of embodiments 1-55, wherein the incidence or severity of adverse events is not increased in the population of subjects relative to the reference population. 57. The tenecteplase for use of any one of embodiments 1-56, wherein the mortality rate is not increased in the population of subjects relative to the reference population. 58. The tenecteplase for use of embodiment 57, wherein the mortality rate is a mortality rate up to 30 days after the tenecteplase is to be administered or a mortality rate up to 90 days after the tenecteplase is to be administered. 59. The tenecteplase for use of any one of embodiments 1-58, wherein the proportion of subjects with parenchymal hematoma type 2 (PH2) is not increased in the population of subjects relative to the reference population. 60. The tenecteplase for use of any one of embodiments 1-59, wherein the tenecteplase is to be administered intravenously at a dose of 0.25 mg / kg. 61. The tenecteplase for use of embodiment 60, wherein the tenecteplase is to be administered at a maximum dose of 25 mg. 62. The tenecteplase for use of any one of embodiments 1-61, wherein the tenecteplase is to be administered as a single dose. 63. The tenecteplase for use of any one of embodiments 60-62, wherein the tenecteplase is to be administered as a bolus injection over 5 seconds. 64. The tenecteplase for use of any one of embodiments 1-63, wherein each member of the population of subjects has a large vessel occlusion. 65. The tenecteplase for use of any one of embodiments 1-64, wherein each member of the population of subjects has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA) M1 occlusion, or an MCA M2 occlusion. 66. The tenecteplase for use of any one of embodiments 1-65, wherein one or more members of the population of subjects has an ICA occlusion or an MCA M1 occlusion. 67. The tenecteplase for use of any one of embodiments 1-65, wherein one or more members of the population of subjects has an MCA M2 occlusion. 68. The tenecteplase for use of any one of embodiments 1-67, wherein each member of the reference population has an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion. PATENT Genentech Docket No: P38439-WO 69. The tenecteplase for use of any one of embodiments 1-68, wherein no member of the population of subjects has acute symptomatic arterial occlusions in more than one vascular territory. 70. The tenecteplase for use of embodiment 69, wherein no member of the population of subjects has bilateral MCA occlusions or an MCA and a basilar artery occlusion. 71. The tenecteplase for use of any one of embodiments 1-70, wherein each member of the population of subjects has a NIHSS score of at least 5. 72. The tenecteplase for use of any one of embodiments 1-71, wherein one or more members of the population of subjects is identified for treatment at an ECC. 73. The tenecteplase for use of embodiment 72, wherein each member of the population of subjects is identified for treatment at an ECC. 74. The tenecteplase for use of any one of embodiments 1-72, wherein one or more members of the population of subjects is identified for treatment at a nECC. 75. The tenecteplase for use of embodiment 74, wherein each member of the population of subjects is identified for treatment at an nECC. 76. The tenecteplase for use of any one of embodiments 1-75, wherein one or more members of the population of subjects is to receive an endovascular therapy subsequent to the administration of tenecteplase. 77. The tenecteplase for use of embodiment 76, wherein the endovascular therapy is a thrombectomy. 78. The tenecteplase for use of any one of embodiments 1-77, wherein the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile. 79. The tenecteplase for use of embodiment 78, wherein the target mismatch profile is defined by one or more of: (a) the mismatch ratio; (b) the mismatch volume; and (c) the ischemic core volume. 80. The tenecteplase for use of embodiment 79, wherein the mismatch ratio is determined by comparing the total volume of ischemic tissue to the ischemic core volume. 81. The tenecteplase for use of embodiment 79 or 80, wherein the target mismatch profile is defined by a mismatch ratio of at least 1.8. 82. The tenecteplase for use of any one of embodiments 79-81, wherein the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue. 83. The tenecteplase for use of any one of embodiments 79-82, wherein the target mismatch profile is defined by a mismatch volume of at least 15 mL. 84. The tenecteplase for use of any one of embodiments 79-83, wherein the target mismatch profile is defined by an ischemic core volume of less than 70 mL. 85. The tenecteplase for use of any one of embodiments 80-84, wherein the total volume of ischemic tissue is the Tmax >6s lesion volume. 86. The tenecteplase for use of any one of embodiments 1-85, wherein the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging technology. PATENT Genentech Docket No: P38439-WO 87. The tenecteplase for use of embodiment 86, wherein the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan. 88. The tenecteplase for use of embodiment 86 or 87, wherein the advanced imaging comprises use of RAPID software. 89. The tenecteplase for use of any one of embodiments 78-88, wherein the target mismatch profile is defined by: (a) a mismatch ratio of at least 1.8; (b) a mismatch volume of at least 15 mL; and (c) an ischemic core volume of less than 70 mL. 90. The tenecteplase for use of any one of embodiments 1-89, wherein one or more members of the population of subjects has: (a) an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion, wherein the occlusion is identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA); and (b) a target mismatch profile defined by: (i) a mismatch ratio of at least 1.8; (ii) a mismatch volume of at least 15 mL; and (iii) an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of a CTP scan or a MRP scan. 91. The tenecteplase for use of any one of embodiments 1-89, wherein one or more members of the population of subjects has: (a) a Tmax>6s perfusion deficit consistent with an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion; and (b) a target mismatch profile defined by: (i) a mismatch ratio of at least 1.8; (ii) a mismatch volume of at least 15 mL; and (iii) an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of RAPID software. 92. The tenecteplase for use of any one of embodiments 1-77, wherein: (a) one or more members of the population of subjects has an ICA or M1 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a diffusion-weighted imaging (DWI) lesion volume of 25 mL or less; or (b) one or more members of the population of subjects has an M2 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume of 15 mL or less. 93. The tenecteplase for use of any one of embodiments 1-92, wherein the population of subjects is a population of human subjects. 94. Use of tenecteplase in the manufacture of a medicament for treating acute ischemic stroke (AIS) in a population of subjects, PATENT Genentech Docket No: P38439-WO wherein each member of the population of subjects has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is to be administered to each member of the population of subjects at a time between 4.5 and 24 hours after onset of AIS; and wherein tenecteplase treatment improves clinical outcome in the population of subjects relative to a placebo-...
Claims
PATENT Genentech Docket No: P38439-WO WHAT IS CLAIMED IS:
1. A method for treating acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern, the method comprising administering to the subject at a time between 4.5 and 24 hours after onset of said AIS a therapeutically effective amount of tenecteplase, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg, and wherein the subject has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA) M1 occlusion, and / or an MCA M2 occlusion.
2. The method of claim 1, wherein the subject has an MCA M1 occlusion.
3. The method of claim 1, wherein the subject has an MCA M2 occlusion.
4. The method of any one of claims 1-3, wherein the subject is a member of a population of subjects, wherein each member of the population: (i) has AIS and salvageable brain tissue or a salvageable brain pattern, (ii) has an ICA occlusion, an MCA M1 occlusion, and / or an MCA M2 occlusion; and (iii) is administered a therapeutically effective amount of tenecteplase at a time between 4.5 and 24 hours after onset of the AIS, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg; and wherein the method improves clinical outcome in the population of subjects relative to a reference population of subjects, wherein each member of the reference population: (iv) has AIS and salvageable brain tissue or a salvageable brain pattern, (v) has an ICA occlusion, an MCA M1 occlusion, and / or an MCA M2 occlusion; and (vi) is administered placebo at a time between 4.5 and 24 hours after onset of AIS.
5. The method of claim 4, wherein the clinical outcome is ordinal modified Rankin scale (mRS) score, and wherein the distribution of mRS scores in the population of subjects is improved relative to the distribution of mRS scores in the reference population.
6. The method of claim 4, wherein the clinical outcome is the proportion of subjects with functional independence, wherein functional independence is an mRS score of 0-2.
7. The method of any one of claims 4-6, wherein the clinical outcome is assessed 90 days after the tenecteplase is administered.
8. The method of claim 4, wherein the clinical outcome is the proportion of subjects having recanalization of one or more occluded vessels.PATENT Genentech Docket No: P38439-WO 9. The method of claim 8, wherein recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA), and / or wherein recanalization is assessed 24 hours after the tenecteplase is administered.
10. The method of any one of claims 4-9, wherein the subject has an ICA occlusion or an MCA M1 occlusion.
11. The method of claim 10, wherein the subject is a member of a population of subjects in which each member of the population of subjects has an ICA occlusion or an MCA M1 occlusion.
12. The method of claim 11, wherein the method improves clinical outcome in the population of subjects relative to the reference population of subjects, wherein each member of the reference population has an ICA occlusion or an MCA M1 occlusion.
13. The method of any one of claims 10-12, wherein the clinical outcome is final infarct volume.
14. The method of any one of claims 10-12, wherein the clinical outcome is infarct growth.
15. The method of claim 13 or 14, wherein the clinical outcome is assessed between 72 hours and 96 hours after a baseline measurement of infarct volume.
16. The method of any one of claims 1-15, further comprising conducting a mechanical thrombectomy to the subject, wherein the mechanical thrombectomy is conducted prior to, concurrently with, or after the administration of tenecteplase or placebo.
17. The method of claim 16, wherein the mechanical thrombectomy is conducted after the administration of tenecteplase or placebo.
18. The method of claim 16 or 17, wherein the time between the administration of tenecteplase or placebo and the mechanical thrombectomy is six minutes or less.
19. The method of any one of claims 1-18, wherein the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile, wherein the target mismatch profile is defined by one or more of: a. a mismatch ratio; b. a mismatch volume; and c. an ischemic core volume.
20. The method of claim 19, wherein: a. the mismatch ratio is determined by comparing the total volume of ischemic tissue to the ischemic core volume, and the target mismatch profile is defined by a mismatch ratio of at least 1.8;PATENT Genentech Docket No: P38439-WO b. the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue, and the target mismatch profile is defined by a mismatch volume of at least 15 mL; and / or c. the target mismatch profile is defined by an ischemic core volume of less than 70 mL.
21. The method of any one of claims 1-20, wherein the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging technology, and wherein: a. the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan; and / or b. the advanced imaging comprises use of RAPID software.
22. A method for treating acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern, the method comprising administering to the subject at a time between 4.5 and 24 hours after onset of said AIS a therapeutically effective amount of tenecteplase, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg.
23. The method of claim 22, wherein the therapeutically effective amount of tenecteplase is administered intravenously.
24. The method of claim 22 or claim 23, wherein the tenecteplase is administered as a single bolus injection over 5 seconds.
25. The method of any one of claims 22-24, wherein the subject is a member of a population of subjects, wherein each member of the population (i) has AIS and salvageable brain tissue or a salvageable brain pattern, and (ii) is administered a therapeutically effective amount of tenecteplase at a time between 4.5 and 24 hours after onset of the AIS, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg; and wherein the method improves clinical outcome in the population of subjects relative to a reference population of subjects, wherein each member of the reference population (iii) has AIS and salvageable brain tissue or a salvageable brain pattern, and (iv) is administered placebo at a time between 4.5 and 24 hours after onset of AIS.
26. The method of claim 25, wherein the clinical outcome is ordinal modified Rankin scale (mRS) score.
27. The method of claim 26, wherein the distribution of mRS scores in the population of subjects is improved relative to the distribution of mRS scores in the reference population.PATENT Genentech Docket No: P38439-WO 28. The method of claim 27, wherein the distribution of mRS scores in the population of subjects is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the distribution of mRS scores in the reference population.
29. The method of claim 27, wherein a proportion of subjects having mRS score of 0 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to a proportion of subjects having mRS score of 0 in the reference population.
30. The method of claim 29, wherein the proportion of subjects having mRS score of 0 in the population is improved by about 2% relative to a proportion of subjects having mRS score of 0 in the reference population.
31. The method of claim 27, wherein a proportion of subjects having mRS score of 1 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.1%, 3.5%, 4%, 4.5%, or 5% relative to a proportion of subjects having mRS score of 1 in the reference population.
32. The method of claim 31, wherein the proportion of subjects having mRS score of 1 in the population is improved by about 3.7% relative to a proportion of subjects having mRS score of 1 in the reference population.
33. The method of claim 27, wherein a proportion of subjects having mRS score of 0 or 1 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% relative to a proportion of subjects having mRS score of 0 or 1 in the reference population.
34. The method of claim 33, wherein the proportion of subjects having mRS score of 0 or 1 in the population is improved by about 5.7% relative to a proportion of subjects having mRS score of 0 or 1 in the reference population.
35. The method of claim 27, wherein a proportion of subjects having mRS score of 0, 1, or 2 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to a proportion of subjects having mRS score of 0, 1, or 2 in the reference population.
36. The method of claim 35, wherein the proportion of subjects having mRS score of 0, 1, or 2 in the population is improved by about 3.7% relative to a proportion of subjects having mRS score of 0, 1, or 2 in the reference population.
37. The method of any one of claims 26-36, wherein the mRS score is assessed 90 days after the tenecteplase is administered.PATENT Genentech Docket No: P38439-WO 38. The method of claim 25, wherein the clinical outcome is the proportion of subjects with functional independence.
39. The method of claim 38, wherein functional independence is an mRS score of 0-2.
40. The method of claim 38 or 39, wherein the proportion of subjects with functional independence in the population of subjects is at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% higher than the proportion of subjects with functional independence in the reference population.
41. The method of any one of claims 38-40, wherein the proportion of subjects with functional independence in the population of subjects is about 3.6% higher than the proportion of subjects with functional independence in the reference population.
42. The method of any one of claims 38-41, wherein functional independence is assessed 90 days after the tenecteplase is administered.
43. The method of claim 25, wherein the clinical outcome is the proportion of subjects having recanalization of one or more occluded vessels.
44. The method of claim 43, wherein recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA).
45. The method of claim 43 or 44, wherein the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels.
46. The method of any one of claims 43-45, wherein the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is about 13% higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels.
47. The method of any one of claims 43-46, wherein recanalization is assessed 24 hours after the tenecteplase is administered.
48. The method of any one of claims 25-47, wherein the subject has an internal carotid artery (ICA) occlusion or a middle cerebral artery (MCA) M1 occlusion.
49. The method of claim 48, wherein the subject is a member of a population of subjects in which each member of the population of subjects has an ICA occlusion or an MCA M1 occlusion.PATENT Genentech Docket No: P38439-WO 50. The method of claim 49, wherein the method improves clinical outcome in the population of subjects relative to the reference population of subjects, wherein each member of the reference population has an ICA occlusion or an MCA M1 occlusion.
51. The method of any one of claims 48-50, wherein the clinical outcome is final infarct volume.
52. The method of claim 51, wherein the mean final infarct volume in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% lower than the mean final infarct volume of subjects in the reference population.
53. The method of claim 51 or 52, wherein final infarct volume is assessed between 72 hours and 96 hours after a baseline measurement of infarct volume.
54. The method of any one of claims 48-53, wherein the clinical outcome is infarct growth.
55. The method of claim 54, wherein the mean infarct growth in the population of subjects is at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% lower than the mean infarct growth of subjects in the reference population.
56. The method of claim 54 or 55, wherein infarct growth is assessed between 72 hours and 96 hours after a baseline measurement of infarct volume.
57. The method of any one of claims 22-56, further comprising conducting a mechanical thrombectomy to the subject.
58. The method of claim 57, wherein the mechanical thrombectomy is conducted prior to, concurrently with, or after the administration of tenecteplase or placebo.
59. The method of claim 57 or claim 58, wherein the mechanical thrombectomy is conducted after the administration of tenecteplase or placebo.
60. The method of any one of claims 57-59, wherein the mechanical thrombectomy comprises groin puncture.
61. The method of any one of claims 57-60, wherein the time between the administration of tenecteplase or placebo and the mechanical thrombectomy is six minutes or less.
62. The method of any one of claims 57-61, wherein tenecteplase or placebo is administered 6 minutes or less before the mechanical thrombectomy is conducted.PATENT Genentech Docket No: P38439-WO 63. The method of any one of claims 25-62, wherein the incidence of symptomatic intracranial hemorrhage (sICH) is not increased in the population of subjects relative to the reference population.
64. The method of claim 63, wherein the incidence of sICH is an incidence within 36 hours of administration of tenecteplase.
65. The method of any one of claims 25-64, wherein the incidence or severity of adverse events is not increased in the population of subjects relative to the reference population.
66. The method of any one of claims 25-65, wherein the mortality rate is not increased in the population of subjects relative to the reference population.
67. The method of claim 66, wherein the mortality rate is a mortality rate up to 30 days after the tenecteplase is administered or a mortality rate up to 90 days after the tenecteplase is administered.
68. The method of any one of claims 25-67, wherein the proportion of subjects with parenchymal hematoma type 2 (PH2) is not increased in the population of subjects relative to the reference population.
69. The method of any one of claims 25-68, wherein each member of the population of subjects has a baseline infarct volume that is less than 20 mL prior to the administration.
70. The method of any one of claims 25-69, wherein each member of the population of subjects has a large vessel occlusion.
71. The method of any one of claims 25-70, wherein each member of the population of subjects has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA) M1 occlusion, and / or an MCA M2 occlusion.
72. The method of any one of claims 25-71, wherein one or more members of the population of subjects has an ICA occlusion or an MCA M1 occlusion.
73. The method of any one of claims 25-72, wherein one or more members of the population of subjects has an MCA M1 occlusion.
74. The method of any one of claims 25-73, wherein one or more members of the population of subjects has an MCA M2 occlusion.PATENT Genentech Docket No: P38439-WO 75. The method of any one of claims 25-74, wherein each member of the reference population has an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion.
76. The method of any one of claims 25-75, wherein no member of the population of subjects has active internal bleeding or hemorrhagic stroke.
77. The method of any one of claims 25-76, wherein no member of the reference population has active internal bleeding or hemorrhagic stroke.
78. The method of any one of claims 25-77, wherein no member of the population of subjects has acute symptomatic arterial occlusions in more than one vascular territory.
79. The method of claim 78, wherein no member of the population of subjects has bilateral MCA occlusions or an MCA and a basilar artery occlusion.
80. The method of any one of claims 25-79, wherein each member of the population of subjects has a NIHSS score of at least 5 before the administration.
81. The method of any one of claims 25-80, wherein one or more members of the population of subjects is identified for treatment at an ECC.
82. The method of claim 81, wherein each member of the population of subjects is identified for treatment at an ECC.
83. The method of any one of claims 25-82, wherein one or more members of the population of subjects is identified for treatment at a nECC.
84. The method of claim 83, wherein each member of the population of subjects is identified for treatment at an nECC.
85. The method of any one of claims 25-84, wherein one or more members of the population of subjects receives an endovascular therapy subsequent to the administration of tenecteplase.
86. The method of claim 85, wherein the endovascular therapy is a thrombectomy.
87. The method of any one of claims 22-86, wherein the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile.
88. The method of claim 87, wherein the target mismatch profile is defined by one or more of: a. a mismatch ratio;PATENT Genentech Docket No: P38439-WO b. a mismatch volume; and c. an ischemic core volume.
89. The method of claim 88, wherein the mismatch ratio is determined by comparing the total volume of ischemic tissue to the ischemic core volume.
90. The method of claim 88 or 89, wherein the target mismatch profile is defined by a mismatch ratio of at least 1.
8.
91. The method of any one of claims 88-90, wherein the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue.
92. The method of any one of claims 88-91, wherein the target mismatch profile is defined by a mismatch volume of at least 15 mL.
93. The method of any one of claims 88-92, wherein the target mismatch profile is defined by an ischemic core volume of less than 70 mL.
94. The method of any one of claims 88-93, wherein the total volume of ischemic tissue is the Tmax >6s lesion volume.
95. The method of any one of claims 22-94, wherein the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging technology.
96. The method of claim 95, wherein the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan.
97. The method of claim 95 or 96, wherein the advanced imaging comprises use of RAPID software.
98. The method of any one of claims 87-97, wherein the target mismatch profile is defined by: a. a mismatch ratio of at least 1.8; b. a mismatch volume of at least 15 mL; and c. an ischemic core volume of less than 70 mL.
99. The method of any one of claims 25-98, wherein one or more members of the population of subjects has: (a) an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion, wherein the occlusion is identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA); andPATENT Genentech Docket No: P38439-WO (b) a target mismatch profile defined by: i. a mismatch ratio of at least 1.8; ii. a mismatch volume of at least 15 mL; and iii. an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of a CTP scan or a MRP scan.
100. The method of any one of claims 25-99, wherein one or more members of the population of subjects has: (a) a T >6s perfusion deficit consistent with an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion; and (b) a target mismatch profile defined by: i.a mismatch ratio of at least 1.8; ii. a mismatch volume of at least 15 mL; and iii. an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of RAPID software.
101. The method of any one of claims 25-100, wherein: a. one or more members of the population of subjects has an ICA or M1 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a diffusion-weighted imaging (DWI) lesion volume 25 mL or less; or b. one or more members of the population of subjects has an M2 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume 15 mL or less.
102. The method of any one of claims 25-101, wherein the population of subjects is a population of human subjects.
103. The method of any one of claims 22-24, wherein mRS score of the subject is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the administration.
104. The method of any one of claims 22-24, wherein the likelihood of the subject’s mRS score being 0 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration.
105. The method of claim 104, wherein the likelihood of the subject’s mRS score being 0 is increased by about 2% after the administration.
106. The method of any one of claims 22-24, wherein the likelihood of the subject’s mRS score being 1 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration.PATENT Genentech Docket No: P38439-WO 107. The method of claim 106, wherein the likelihood of the subject’s mRS score being 1 is increased by about 3.7% after the administration.
108. The method of any one of claims 22-24, wherein the likelihood of the subject’s mRS score being 0 or 1 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% after the administration.
109. The method of clam 108, wherein the likelihood of the subject’s mRS score being 0 or 1 is increased by about 5.7% after the administration.
110. The method of any one of claims 22-24, wherein the likelihood of the subject’s mRS score being 0, 1, or 2 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration.
111. The method of claim 110, wherein the likelihood of the subject’s mRS score being 0, 1, or 2 is increased by about 3.7% after the administration.
112. The method of any one of claims 103-111, wherein mRS score of the subject is less than 3 after the administration.
113. The method of any one of claims 103-112, wherein the mRS score is assessed 90 days after the tenecteplase is administered.
114. The method of any one of claims 22-24, wherein functional independence of the subject is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration.
115. The method of claim 114, wherein functional independence of the subject is improved by about 3.6% after the administration.
116. The method of claim 114 or 115, wherein the functional independence is an mRS score of 0- 2.
117. The method of any one of claims 114-116, wherein functional independence is assessed 90 days after the tenecteplase is administered.
118. The method of any one of claims 22-24, wherein recanalization of one or more occluded vessels of the subject is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, or 30% after the administration, wherein the recanalization is complete recanalization detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA).PATENT Genentech Docket No: P38439-WO 119. The method of claim 118, wherein the recanalization of one or more occluded vessels of the subject is improved by about 13% after the administration.
120. The method of claim 118 or 119, wherein the recanalization is assessed 24 hours after the tenecteplase is administered.
121. The method of any one of claims 22-24, further comprising conducting a mechanical thrombectomy to the subject.
122. The method of claim 121, wherein the mechanical thrombectomy is conducted prior to, concurrently with, or after the administration of tenecteplase.
123. The method of claim 121 or 122, wherein the mechanical thrombectomy is conducted after the administration of tenecteplase.
124. The method of any one of claims 121-123, wherein the mechanical thrombectomy comprises groin puncture.
125. The method of any one of claims 121-124, wherein a time between the administration of tenecteplase and the mechanical thrombectomy is six minutes or less.
126. The method of any one of claims 121-125, wherein tenecteplase is administered 6 minutes or less before the mechanical thrombectomy is conducted.
127. The method of any one of claims 22-24 and 103-126, wherein the incidence of symptomatic intracranial hemorrhage (sICH) is not increased in the subject after the administration.
128. The method of claim 127, wherein the incidence of sICH is an incidence within 36 hours of administration of tenecteplase.
129. The method of any one of claims 22-24 and 103-128, wherein the incidence or severity of adverse events is not increased in the subject after the administration.
130. The method of any one of claims 22-24 and 103-129, wherein the mortality rate is not increased in the subject after the administration.
131. The method of claim 130, wherein the mortality rate is a mortality rate up to 30 days after the tenecteplase is administered or a mortality rate up to 90 days after the tenecteplase is administered.
132. The method of any one of claims 22-24 and 103-131, wherein if the subject has parenchymal hematoma type 2 (PH2), the pH2 is not increased after the administration.PATENT Genentech Docket No: P38439-WO 133. The method of any one of claims 22-24 and 103-132, wherein the subject has a baseline infarct volume that is less than 20 mL prior to the administration.
134. The method of any one of claims 22-24 and 103-133, wherein the subject has a large vessel occlusion.
135. The method of any one of claims 22-24 and 103-134, wherein the subject has an internal carotid artery (ICA) occlusion, a middle cerebral artery (MCA) M1 occlusion, and / or an MCA M2 occlusion.
136. The method of any one of claims 22-24 and 103-135, wherein the subject has an ICA occlusion or an MCA M1 occlusion.
137. The method of any one of claims 22-24 and 103-136, wherein the subject has an MCA M1 occlusion.
138. The method of any one of claims 22-24 and 103-137, wherein the subject does not have active internal bleeding or hemorrhagic stroke.
139. The method of any one of claims 22-24 and 103-138, wherein the subject does not have acute symptomatic arterial occlusions in more than one vascular territory.
140. The method of claim 139, wherein the subject does not have bilateral MCA occlusions or an MCA and a basilar artery occlusion.
141. The method of any one of claims 22-24 and 103-140, wherein the subject has a NIHSS score of at least 5 before the administration.
142. The method of any one of claims 22-24 and 103-141, wherein the subject is identified for treatment at an ECC.
143. The method of claim 142, wherein the subject is identified for treatment at an ECC.
144. The method of any one of claims 22-24 and 103-143, wherein the subject is identified for treatment at a nECC.
145. The method of claim 144, wherein the subject is identified for treatment at an nECC.
146. The method of any one of claims 22-24 and 103-145, wherein the subject receives an endovascular therapy subsequent to the administration of tenecteplase.PATENT Genentech Docket No: P38439-WO 147. The method of claim 146, wherein the endovascular therapy is a thrombectomy.
148. The method of any one of claims 22-24 and 103-147, wherein the salvageable brain tissue or salvageable brain pattern is identified by the presence of a target mismatch profile.
149. The method of claim 148, wherein the target mismatch profile is defined by one or more of: a. a mismatch ratio; b. a mismatch volume; and c. an ischemic core volume.
150. The method of claim 149, wherein the mismatch ratio is determined by comparing the total volume of ischemic tissue to the ischemic core volume.
151. The method of claim 149 or 150, wherein the target mismatch profile is defined by a mismatch ratio of at least 1.
8.
152. The method of any one of claims 149-151, wherein the mismatch volume is determined by subtracting the ischemic core volume from the total volume of ischemic tissue.
153. The method of any one of claims 149-152, wherein the target mismatch profile is defined by a mismatch volume of at least 15 mL.
154. The method of any one of claims 149-153, wherein the target mismatch profile is defined by an ischemic core volume of less than 70 mL.
155. The method of any one of claims 152-154, wherein the total volume of ischemic tissue is the Tmax >6s lesion volume.
156. The method of any one of claims 22-24 and 103-155, wherein the salvageable brain tissue or salvageable brain pattern is identified by advanced imaging technology.
157. The method of claim 156, wherein the advanced imaging technology comprises a computed tomography perfusion (CTP) scan or a magnetic resonance perfusion (MRP) scan.
158. The method of claim 156 or 157, wherein the advanced imaging comprises use of RAPID software.
159. The method of any one of claims 148-158, wherein the target mismatch profile is defined by: a. a mismatch ratio of at least 1.8;PATENT Genentech Docket No: P38439-WO b. a mismatch volume of at least 15 mL; and c. an ischemic core volume of less than 70 mL.
160. The method of any one of claims 22-24 and 103-159, wherein the subject has: (a) an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion, wherein the occlusion is identified by magnetic resonance angiography (MRA) or computed tomography angiography (CTA); and (b) a target mismatch profile defined by: i. a mismatch ratio of at least 1.8; ii. a mismatch volume of at least 15 mL; and iii. an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of a CTP scan or a MRP scan.
161. The method of any one of claims 22-24 and 103-160, wherein the subject has: (a) a T >6s perfusion deficit consistent with an ICA occlusion, an MCA M1 occlusion, or an MCA M2 occlusion; and (b) a target mismatch profile defined by: i. a mismatch ratio of at least 1.8; ii. a mismatch volume of at least 15 mL; and iii. an ischemic core volume of less than 70 mL; and wherein the target mismatch profile is identified by use of RAPID software.
162. The method of any one of claims 22-24 and 103-161, wherein: a. the subject has an ICA or M1 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a diffusion-weighted imaging (DWI) lesion volume 25 mL or less; or b. the subject has an M2 occlusion and the salvageable brain tissue or salvageable brain pattern is identified by a DWI lesion volume 15 mL or less.
163. The method of any one of claims 22-24 and 103-162, wherein the subject is a human subject.
164. The method of claim 27, wherein each member of the population of subjects and each member of the reference population has an MCA M1 occlusion before administration of tenecteplase or placebo and the distribution of mRS scores at Day 90 in the population of subjects is improved relative to the distribution of mRS scores at Day 90 in the reference population.
165. The method of claim 164, wherein the distribution of mRS scores at Day 90 in the population of subjects is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% relative to the distribution of mRS scores at Day 90 in the reference population.PATENT Genentech Docket No: P38439-WO 166. The method of claim 164, wherein the proportion of subjects having mRS score of 0 at Day 90 in the population is improved by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% relative to the proportion of subjects having mRS score of 0 at Day 90 in the reference population.
167. The method of claim 166, wherein the proportion of subjects having mRS score of 0 at Day 90 in the population is improved by about 2.8% relative to the proportion of subjects having mRS score of 0 at Day 90 in the reference population.
168. The method of claim 164, wherein the proportion of subjects having mRS score of 1 at Day 90 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 1 at Day 90 in the reference population.
169. The method of claim 168, wherein the proportion of subjects having mRS score of 1 at Day 90 in the population is improved by about 11.7% relative to the proportion of subjects having mRS score of 1 at Day 90 in the reference population.
170. The method of claim 164, wherein the proportion of subjects having mRS score of 0 or 1 at Day 90 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 0 or 1 at Day 90 in the reference population.
171. The method of claim 170, wherein the proportion of subjects having mRS score of 0 or 1 at Day 90 in the population is improved by about 14.5% relative to the proportion of subjects having mRS score of 0 or 1 at Day 90 in the reference population.
172. The method of claim 164, wherein the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the population is improved by at least 1%, 5%, 10%, 15%, or 20% relative to the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the reference population.
173. The method of claim 172, wherein the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the population is improved by about 14.5% relative to the proportion of subjects having mRS score of 0, 1, or 2 (mRS 0-2) at Day 90 in the reference population.
174. The method of any one of claims 45-47, wherein each member of the population of subjects has an MCA M1 occlusion.
175. The method of claim 103, wherein the subject has an MCA M1 occlusion before administration of tenecteplase and mRS score of the subject at Day 90 is improved by at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% after the administration.PATENT Genentech Docket No: P38439-WO 176. The method of claim 175, wherein the likelihood of the subject’s mRS score being 0 at Day 90 is increased by at least 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, or 5% after the administration.
177. The method of claim 176, wherein the likelihood of the subject’s mRS score being 0 at Day 90 is increased by about 2.8% after the administration.
178. The method of claim 175, wherein the likelihood of the subject’s mRS score being 1 at Day 90 is increased by at least 1%, 5%, 10%, 15%, or 20% after the administration.
179. The method of claim 178, wherein the likelihood of the subject’s mRS score being 1 at Day 90 is increased by about 11.7% after the administration.
180. The method of claim 175, wherein the likelihood of the subject’s mRS score being 0 or 1 at Day 90 is increased by at least 1%, 5%, 10%, 15%, or 20% after the administration.
181. The method of clam 180, wherein the likelihood of the subject’s mRS score being 0 or 1 at Day 90 is increased by about 14.5% after the administration.
182. The method of claim 175, wherein the likelihood of the subject’s mRS score being 0, 1, or 2 at Day 90 is increased by at least 1%, 5%, 10%, 15%, or 20% after the administration.
183. The method of claim 182, wherein the likelihood of the subject’s mRS score being 0, 1, or 2 at Day 90 is increased by about 14.5% after the administration.
184. The method of any one of claims 118-120, wherein the subject has an MCA M1 occlusion before administration.
185. The method of any one of claims 43-47, wherein each member of the population of subjects has an MCA M2 occlusion.
186. The method of claim 185, wherein the proportion of subjects in the population of subjects having recanalization of one or more occluded vessels is about 21% higher than the proportion of subjects in the reference population having recanalization of one or more occluded vessels.
187. The method of any one of claims 118-120, wherein each member of the population of subjects has an MCA M2 occlusion.
188. A method for treating acute ischemic stroke (AIS) in a subject having salvageable brain tissue or a salvageable brain pattern, the method comprising administering to the subject at a time between 4.5 and 24 hours after onset of said AIS a therapeutically effective amount of tenecteplase,PATENT Genentech Docket No: P38439-WO wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg, wherein said treatment results in recanalization of one or more occluded vessels in the subject.
189. The method of claim 188, wherein the recanalization is complete.
190. The method of claim 188 or 189, wherein recanalization is detected by computed tomography angiography (CTA) or magnetic resonance angiography (MRA).
191. The method of any one of claims 188-190, wherein recanalization is assessed 24 hours after the tenecteplase is administered.
192. A method for treating AIS in a subject having an MCA M1 occlusion, the method comprising administering tenecteplase to the subject, wherein the subject has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject at a time between 4.5 and 24 hours after the onset of AIS; and wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg.
193. The method of claim 192, wherein the tenecteplase treatment prevents an increase in the ordinal modified Rankin scale (mRS) score in the subject.
194. The method of claim 192 or 193, wherein the tenecteplase treatment decreases the mRS score in the subject.
195. A method for treating AIS in a subject having an MCA M2 occlusion, the method comprising administering tenecteplase to the subject, wherein the subject has or has been determined to have salvageable brain tissue or a salvageable brain pattern; wherein the tenecteplase is administered to the subject at a time between 4.5 and 24 hours after the onset of AIS; and wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg.
196. The method of claim 195, wherein the subject is a member of a population of subjects, wherein each member of the population (i) has AIS and salvageable brain tissue or a salvageable brain pattern, and (ii) is administered a therapeutically effective amount of tenecteplase at a time between 4.5 and 24 hours after onset of the AIS, wherein the therapeutically effective amount is 0.25 mg / kg up to a maximum dose of 25 mg;PATENT Genentech Docket No: P38439-WO and wherein the method increases the proportion of subjects having complete recanalization of one or more occluded vessels relative to a reference population of subjects, wherein each member of the reference population (iii) has AIS and salvageable brain tissue or a salvageable brain pattern, and (iv) is administered placebo at a time between 4.5 and 24 hours after onset of AIS.
Citation Information
Patent Citations
Plasminogen activator variant formulations
US20100330083A1
Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US5612029A
